1
Status: Approved ,Date: 4 April 2017Janssen Research & Development *
Clinical Protocol
A Randomized, Double -blind, Multicenter, Active -controlled Study of Intranasal 
Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment -resistant 
Depression
Sustenance of Es ketamine Treatment Response With Repeated Doses a t Intervals D etermined by  
[CONTACT_170455] (SUSTAIN -1)
Protocol ESKETINTRD3003; Phase 3
AMENDMENT 4
JNJ-54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor ”is used throughout the protocol to represent these
various legal entities; the sponsor is identified on the Contact [CONTACT_170456].
This compound is being investigated in Phase 3 clinical studies.
This study  will be conducted under USFood & Drug Administration IND regulations (21 CFR
Part 312).
EudraCT Number :2014 -004586 -24
Status: Approved
Date: 4 April 2017
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number :EDMS- ERI-93094733, 5.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be d isclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These res trictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
2
Status: Approved , Date: [ADDRESS_199338] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 6
PROTOCOL A MENDMENTS ....................................................................................................................... 7
SYNOPSIS .................................................................................................................................................. 35
TIME AND EVENTS SCHE DULE ( Screening/Prospective Observational Phase and Open -
label Induction Phase ).............................................................................................................................. 49
TIME AND EVENTS SCHE DULE ( Optimization Phase )......................................................................... 53
TIME AND EVENTS SCHE DULE ( Maintenance Phase )......................................................................... 57
TIME AND EVENTS SCHE DULE ( Early Withdrawal/End of Maintenance Phase Visit and 
Follow -up Phase )...................................................................................................................................... 61
ABBREVIA TIONS ...................................................................................................................................... 63
1. INTRODUCTION ................................................................................................................................ 65
1.1. Backgroun d.................................................................................................................................... 66
1.1.1. Summary  of Nonclinical Findings ............................................................................................... 66
1.1.2. Clinical Studies ........................................................................................................................... 69
[IP_ADDRESS]. Pharmacokinetics and Product Metabolism ............................................................................ 69
[IP_ADDRESS]. Pharmacodynamics and Efficacy ............................................................................................ 71
[IP_ADDRESS]. Safety and Tolerability ............................................................................................................. 72
1.1.3. Marketing Experience ................................................................................................................. 76
1.2. Active Comparators ........................................................................................................................ 76
1.2.1. Selective Serotonin Reuptake Inhibitors ..................................................................................... 76
[IP_ADDRESS]. Escitalopram ............................................................................................................................ 76
[IP_ADDRESS]. Sertraline ................................................................................................................................ .77
1.2.2. Serotonin and Norepi[INVESTIGATOR_75618] ................................................................... 77
[IP_ADDRESS]. Duloxetine ................................................................................................................................ 77
[IP_ADDRESS]. Venlafaxine Extended -release ................................................................................................ .78
1.3. Overall Rationale for the Study ...................................................................................................... 79
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 80
2.1. Objectives ...................................................................................................................................... 80
2.2. Hypothesis ..................................................................................................................................... 81
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .81
3.1. Overview of Study Design .............................................................................................................. 81
3.1.1. Study Phases .............................................................................................................................. 82
3.1.2. Definitions of Terms .................................................................................................................... 86
3.2. Study Design Rationale .................................................................................................................. 87
3.2.1. Study Population ......................................................................................................................... 87
3.2.2. Study Phases .............................................................................................................................. 89
3.2.3. Blinding and Randomization ....................................................................................................... 90
3.2.4. Treatment Groups and Dose Selection ...................................................................................... 91
[IP_ADDRESS]. Intranasal Study Drug .............................................................................................................. 91
[IP_ADDRESS]. Oral Antidepressant ................................................................................................................. 92
3.2.5. Efficacy  Measures ...................................................................................................................... 93
3.2.6. Safety Evaluations ...................................................................................................................... 94
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
3
Status: Approved , Date: 4 April [ZIP_CODE].2.7. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations .............................. [ADDRESS_199339] -entry Subjects ................................................................................................................ 101
4.2.2. Transferred -entry Subjects ....................................................................................................... 105
4.3. Prohibitions and Restrictions ....................................................................................................... 106
5. TREA TMENT A LLOCA TION AND BLINDING ............................................................................... 107
6. DOSA GE A ND A DMINISTR ATION................................................................................................ 109
6.1. Intranasal Study Drug .................................................................................................................. 109
6.1.1. Open -label Induction Phase ..................................................................................................... 110
6.1.2. Optimization Phase ................................................................................................................... 111
[IP_ADDRESS]. Transferred -entry Subjects .................................................................................................... 111
[IP_ADDRESS]. Direct -entry Subjects ............................................................................................................. 111
[IP_ADDRESS]. Intranasal Treatment Session Frequenc y (All Subjects) ....................................................... 111
6.1.3. Maintenance Phase .................................................................................................................. 113
6.1.4. Follow -up Phase ....................................................................................................................... 114
6.2. Oral Antidepressants .................................................................................................................... 115
6.2.1. Screening/Prospective Observational Phase (Direct- entry Subjects Only) .............................. 115
6.2.2. Open -label Induction Phase (Direct -entry Subjects Only) ........................................................ 115
6.2.3. Optimization and Maintenance Phases (Direct -entry and Transferred -entry Subjects) ........... 116
6.2.4. Follow -up Phase ....................................................................................................................... 116
7. TREA TMENT COMPLIA NCE .......................................................................................................... 117
8. PRESTUDY A ND CONCOMI TANT THERA PY.............................................................................. 117
9. STUDY EVA LUATIONS .................................................................................................................. 119
9.1. Study Procedures ......................................................................................................................... 119
9.1.1. Overview ................................................................................................................................... 119
9.1.2. Screening/Prospective Observational Phase ........................................................................... 121
9.1.3. Open -label Induction Phase ..................................................................................................... 122
9.1.4. Optimization Phase ................................................................................................................... 123
9.1.5. Maintenance Phase .................................................................................................................. 124
9.1.6. Early W ithdrawal/End of Maintenance Phase .......................................................................... 124
9.1.7. Follow -up Phase ....................................................................................................................... 125
9.2. Efficacy ......................................................................................................................................... 126
9.2.1. Evaluations ............................................................................................................................... 126
[IP_ADDRESS]. Primary Efficacy  Evaluation: Montgomery -Asberg Depression Rating Scale (MADRS) ....... 126
[IP_ADDRESS]. Clinical Global Impression - Severity (CGI -S)....................................................................... 126
[IP_ADDRESS]. Patient Health Questionnaire, 9- Item (PHQ -9)...................................................................... 126
[IP_ADDRESS]. Generalized Anxiety Disorder, 7- item (GAD -7)..................................................................... 127
[IP_ADDRESS]. European Quality of Life (EuroQol) Group, 5- Dimension, 5 -Level (EQ -5D-5L).................... 127
[IP_ADDRESS]. Sheehan Disability Scale (SDS) ............................................................................................ 127
9.2.2. Endpoints .................................................................................................................................. 127
9.3. Medical Resource Utilization ........................................................................................................ 128
9.4. Safety Evaluations ....................................................................................................................... 128
9.5. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations ................................ 136
9.6. Other Evaluations ......................................................................................................................... 137
9.7. Sample Collection and Handling .................................................................................................. 139
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
4
Status: Approved , Date: [ADDRESS_199340] COMPLETION/W ITHDRA WAL..................................................................................... [ADDRESS_199341] Information ...................................................................................................................... 142
11.2. Sample Size Determination ......................................................................................................... 142
11.3. Efficacy  Analyses ......................................................................................................................... 143
11.4. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Analyses .................................... [ADDRESS_199342] ................................................. 158
16.2.3. Informed Consent ..................................................................................................................... 160
16.2.4. Privacy of Person al Data .......................................................................................................... 161
16.2.5. Long- term Retention of Samples for Additional Future Research ............................................ 161
16.2.6. Countr y Selection ..................................................................................................................... 162
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 162
17.1. Protocol Amendments .................................................................................................................. 162
17.2. Regulatory Documentation .......................................................................................................... 162
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_199343] Identification, Enrollment, and Screening Logs .............................................................. 163
17.4. Source Documentation ................................................................................................................. 163
17.5. Case Report Form Completion .................................................................................................... 164
17.6. Data Quality Assurance/Quality Control ...................................................................................... 165
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
5
Status: Approved , Date: [ADDRESS_199344] Retention ......................................................................................................................... 165
17.8. Monitoring .................................................................................................................................... 166
17.9. Study Com pletion/Termination ..................................................................................................... [ADDRESS_199345] OF A TTACHMENTS
Attachment 1: Prohibited Concomitant Medications W ith Intranasal Study Medication 
(Esketamine or Placebo) .......................................................................................... 176
Attachment 2: [LOCATION_001] Heart Association Classification of Cardiac Disease ............................... 179
Attachment 3: Oral Antidepressant Titration Schedules for Open- label Induction Phase ............... 180
Attachment 4: Anticipated Events .................................................................................................... 181
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
6
Status: Approved , Date: [ADDRESS_199346] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Intranasal Esketamine Treatment Sessions: Open -label Induction Phase ............................ 111
Table 2: Intranasal Esketamine Treatment Sessions: Optimization Phase (Direct entry 
Subjects) ................................................................................................................................ .112
Table 3: Intranasal Esketamine or Placebo Treatment Sessions: Optimization Phase 
(Transferred -entry Subjects) ................................................................................................... 113
Table 4: Intranasal Esketamine or Placebo Treatment Sessions: Maintenance Phase ....................... 114
Table 5: Volume of Blood to Be Collected From Each Subject ............................................................ 120
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 86
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
7
Status: Approved , Date: [ADDRESS_199347] recent amendment.
Amendment 4(4 April 2017 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: In order to enhance the number of clinically valid subjects proceeding to 
the Maintenance phase as stable remitters , the stable remission criteria have been revised .
Applicable Section(s) Description of Change(s)
Rationale: The justification for allowing a single excursion of the MADRS total score or one missed MADRS 
assessment was made on the basis that it could be due to a life event and not the underlying illness, eg, having a bad 
day, difficulty in a family relationship, a setback at w ork or school, o r a scheduling conflict.
Synopsis: Overvie w of Study Design, 
Definitions of Terms;
3.1.2 .Definitions of Terms:
Optimization PhaseThe definition of stable remission was modified (bold text added ;
strikethrough text deleted ):
 Remission: MADRS total score 12
Stable remission: 
MADRS total score ≤[ADDRESS_199348] 4 w eeks of the optimization 
phase 
MADRS total score ≤[ADDRESS_199349] 4 w eeks of the 
optimization phase, but one excursion of a MADRS total score 
>[ADDRESS_199350] be ≤12.
3.2.2. Study Phases: Optimization 
PhaseFor the primary analysis, a subject must be in stable remission (MADRS 
total score 12 for 4 consecutive weeks) fo r the last 4 w eeks of this phase 
(see full definition, section 3.1.2) to enter the maintenance phase . 
Rationale: The definition of stable response w as modified , as there is no longer a requirement to have a MADRS 
score of >[ADDRESS_199351] 2 w eeks of the Optimization p hase.
Synopsis: Overvie w of Study Design, 
Definitions of Terms;
3.1.2 .Definitions of Terms:
Optimization PhaseThe definitio n of stable response w as modified as follows (bold text 
added; strikethrough text deleted):
Stable response: 50% reduction in the MADRS total score from baseline 
(Day  1 of induction phase; pre -randomization/prior to the first intranasal 
dose) in each of the last [ADDRESS_199352] 1 M ADRS total score of 
>12 in these 2 weeks. Note: For transferred -entry subjects, Day [ADDRESS_199353] in ESKETINTRD3001 or 
ESKETINTRD3002.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
8
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
3.2.2. Study Phases: Optimization 
PhaseSubjects with stable response ( 50% reduct ion in the MADRS total score 
from baseline [Day 1 of induction phase; pre -random ization/prior to the 
first intranasal dose] ) in each of the last 2weeks of the optimization phase 
with at least 1 MADRS total score of >12 in these 2 weeks but who doare 
not meet criteria for instable remissio n,will also enter the maintenance 
phase ,but will not be part of the primary analysis.
Rationale: Missing MADRS asse ssments during Weeks [ADDRESS_199354]’s eligibility to participate in the maintenance phase of the study. This 
modification has been made to reduce the impact of missing MADRS assessments, given the lengthiness of the trial
and need for weekly assessments . The justification for removin g this criterion is made on the basis that, in general, 
rather than indicating poor compliance to study procedure, missing assessments may often be due to a family 
emergency or illness, vacation or travel plans, or change in work or school schedule. In ord er to enhance the number 
of clinically valid subjects proceeding to the Maintenance phase, the criterion has been removed.
Syno psis: Dosage and Administration ,
Optimization phase;
[IP_ADDRESS] .Intranasal Treatment Session 
Frequency :All SubjectsThe follow ingtext was modified (strikethrough text deleted) :
Missed MADRS Assessments:
If [ADDRESS_199355] 8 weeks of the 
optimization phase (Week 5 to Week 12), the subject can complete the 
optimization phase but is not eligible to pa rticipate in the maintenance 
phase.
9.1.4. Optimization Phase; 10.2. 
Withdraw al From  the StudyA subject w ill not be eligible to proceed into the maintenance phase if he 
or she:
Misses 21 days of the oral antidepressant doses (total daily dose) 
Misses [ADDRESS_199356] 8 w eeks (Weeks 5 to 12)
Rationale: Clarification that subjects in the Optimization phase at the time study closes are not required to complete 
the Optimization phase.
Synopsis :Optimization Phase; 3.1.1 .
Study Phases :Optimization PhaseThe follow ing tex t was modified ( bold text added ;strikethrough text 
deleted):
At the time the study is stopped (for efficacy) ,subjects in the optimization 
phase will be able to complete the phase. After completing the phase, 
these subjects will have an Early Withdrawal Visit conducted and proceed 
directly to the follow -up phase.
10.1. Criteria for Completion Subjects in the Screening Prospective Observational phase at the tim e 
of study term ination may be eligible to proceed to the
54135419TRD3008 study.   
Subjects in the induction or optimization phase of the study at the time of 
study termination will be allowed to complete the ir current induction
phase, will complete an Early Withdraw al Visit, and continue into the 
follow  up phas e but will not be considered completers.
These subjects, after com pleting the Early Withdrawal visit, may 
proceed to the 54135419TRD3008 study, but will not be considered 
completers for this study. Subjects in the optimization phase at tim e of 
study termin ation will not need to com plete this phase, and will 
complete an Early Withdrawal Visit, and continue into the follow up 
phase, but they will not be considered completers.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
9
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Clarification for subjects in different phases of the study at the time study is stopped (for efficacy) 
regarding whether they will complete the ircurrent phase.
Synopsis :Overvie w of Study Design ; 
3.1.1 .Study Phases ; 16.1. Study -
specific Design ConsiderationsThe follow ing te xt was modified (bold text added; strikethrough text 
deleted):
The study will be stopped once 84 relapses (in the subjects with stable 
remission) occur during the maintenance phase, or earlier ,based on the 
results of the interim analysis for efficacy or futility . At the time the study 
is stopped (for efficacy) , subjects in the induction phase or optimization 
phase will be able to complete the Induction respective phase. 
Those subjects who are r esponders after com pleting an Early 
Withdrawal Visit may proceed to the 54135419TRD3008 study 
without com pleting the follow up phase. Those who are not 
responders will have an Early Withdrawal Visit and proceed directly 
to the follow -up phase . After completing the respective phase, these 
subjects and Ssubjects who are in the optimization or ma intenance phase 
at the time the study is terminated w ill have an Early Withdrawal
Visit /End of Maintenance Visit conducted and proceed directly to the 
follow -up phase .
Synopsis: Open -label Induction Phase;
3.1.1 .Study Phases :Open -label 
Induction PhaseAt the time the study is stopped (for efficacy) ,subjects in the induction 
phase will be able to complete the phase.
Those who are responders, after completing a n Early Withdrawal 
Visit, may proceed to the 54135419TRD3008 study without 
completing the follow up phase. Those who are not responders After 
completing the phase, these subjects will have an Early Withdraw al Visit 
conducted and proceed directly to the follow -up phase.
Rationale: To allow  earlier access to open label esketamine treatment, subjects who relapse in the Maintenance 
phase and those who are responders at the end of induction at the time the study is stopped, will be allowed to
proceed to the open -label safety extension study, 54135419TRD3008, w ithout completing the follow up phase (if 
clinically indicated) .
Synopsis :Follow -up Phase;
Time and Events Schedule (Early 
Withdraw al/End of Maintenance 
Phase Visit and Follow -up Phase)
footnote a;3.1.1.Study Phases :
Follow -up Phase;
9.1.6. Early Withdrawal/End of 
Maintenance Phase ;9.1.7.Follow -up 
Phase ;The follow ing text was modified (bold text added ; strikethrough text 
deleted ):
This phase will include all subjects w ho have received at least 1 dose of 
intranasal study medication in this study. For those subjects who relapse 
in the Maintenance phase, if clinically indicated based on 
investigator’s judgm ent, after com pleting the end of m aintenance 
visit, the subject m ay proceed to the open -label safety extension study, 
54135419TRD3008, without com pleting t he follow up phase. 
Similarly ,when t he study is stopped , (for efficacy) subjects in the 
Induction phase who are responders, after com pleting the early 
withdrawal visit, if clinically indicated based on the investigator’s 
judgment, may proceed to the 54135419TRD3008 study, without 
completing the follow up phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
10
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Synopsis: Ma intenance Phase ;
3.1.1 .Study Phases :Maintenance 
phaseThe follow ing text was modified (bold text added ;strikethrough text 
deleted):
Subjects who meet the relapse criteria and subjects who remain relapse -
free at study termination will have an End of Maintenance Phase Visit 
conducted and may proceed to the follow -up phase. If clinically 
indicated, subject s who have m et relapse criteria after completing the 
End of Maintenance visit may proceed to the open -label safety 
extension study, 54135419TRD3008, without com pleting the follow up 
phase. Subjects who are participating in the maintenance phase at the time 
the study is stopped (for efficacy) will have an Early Withdraw al Visit 
condu cted and proceed directly to the follow -up phase.
9.1.6. Early Withdrawal/End of 
Maintenance Phase; The follow ing text was modified (bold text added): 
A subject meeting relapse criteria during the maintenance phase is not 
considered an early withdraw al. These subjects, and subjects in the 
maintenance phase who remain relapse -free at study termination, will have 
an End of Maintenance Phase Visit conducted, followed by [CONTACT_170457]. If clinically indicated, subjects who relapse in the Maintenance 
phase may proceed to the open -label safety extension study, 
54135419TRD3008, without com pleting the follow up phase.
10.2. Withdrawal from Study The follow ing text was modified (bold text added; strike through text 
deleted): 
A subject meeting relapse criteria during the maintenance phase is not 
considered an early withdraw al. If clinically indicated, after com pleting 
the End of Maintenance visit, subjects who have m et relapse criteria 
may proceed to the open -label safety exten sion study, 
54135419TRD3008, without com pleting the follow up phase. For these 
subjects, and Subjects who remain relapse -free at study termination, will 
have an End of Maintenance Phase Visit conducted, followed by [CONTACT_170458] -up phase.
Rationale: Early termination of the maintenance phase for futility, based on interim analysis results, is no longer 
applicable, because these results could indicate that once subjects become stable remitters on esketamine, the 
intranasal placebo plus oral antidepressant ar m can be as good or potentially better at maintaining response as 
intranasal esketamine + oral antidepressant arm. This potential outcome is not a negative outcome, but rather may 
inform how to use esketamine in long term. As such, the study would not be c onsidered futile.
Synopsis :Overvie w of Study Design ,
Synopsis :Statistical Methods, Interim 
Analysis; 
3.1.1. Study Phases; 11.3. Efficacy 
Analyses;
11.7.Interim Analysis;
11.8. Independent Data Monitoring 
Committee;
16.1.Study -specific Design 
ConsiderationsClarified that the results of the interim analysis would no longer be used to 
stop the study due to futility; the results could only indicate stoppi[INVESTIGATOR_170404] (ie, futility was deleted).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
11
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Clarification on Dosage and Administration of Intranasal Study Drug . Dose adjustment will be permitted 
on Days 15, 18, and 22 to allow more time for dosing to be optimized based on efficacy and tolerability
Synopsis: Dosage and Administration :
Open -label Induction Phase;
6.1.1 .Open -label Induction PhaseModified the following text (bold text added ;strikethrough text deleted) :
On Day 1, subjects w ill start with a dose of 56 mg. On Day 4, the dose 
may be increased to 84 mg or remain at 56 mg, as determined by [CONTACT_170459]. On Day 8, the dose may be 
increased to 84 mg (if Day 4 dose w as 56 mg), remain the same, or be 
reduced to 56 mg (if Day 4 dose w as 84 m g), as determined by [CONTACT_170460] y and tolerability. Similarly, on Day s11,15, 
18, and 22, the dose may be increased to 84 mg (if Day 8 dose w as 56 
mg), rem ain the same, or be reduced to 56 mg (if Day 8 dose w as 84 mg) , 
if applicable as determined by [CONTACT_170461]. On Day 15, a dose reduction from 84 mg to 56 mg is 
permitted, if required for tolerability; no dose increase is permitted on 
Day 15.On Day s18, 22, and 25, a dose reduction from  84 m g to 56 m g 
is permitted if required for tolerability; no dose increase is permitted .
the dose must remain stable (unchanged). If there is no intranasal 
treatment session on Day 15 (eg, visit is missed), a dose reduction from 84 
mg to 56 mg is permitted on Da y 18 if required for tolerability; no dose 
increase is permitted.
Rationale: Added information about 54135419TRD3008, an open -label safety extension study, that may be 
available for eligible subjects participating in ESKETINTRD3003.
Synopsis: Follow -up Phase; 3.1.1 . 
Study Phases :Follow -up Phase; 9.1.7. 
Follow -up PhaseThe follow ing text was modified (bold text added ;strikethrough text 
deleted ):
An open -label safety extension study, 54135419TRD3008, may be 
available (pending country and site approval) for eligible subjects 
participating in the ESKETINTRD3003 study. Please refer to the 
54135419TRD3008 protocol for full details when available of potential 
pathways for entry .
Rationale: Restrictions for Day 28 of the Induction phase and visit 3.1 of the Optimization phase were relaxed to 
allow  for some flexibility.
Time and Events Schedule 
(Optimization Phase, footnote b) ;
9.1.3 .Open -label Induction Phase ;
9.1.4 .Optimization PhaseThe follow ing text was modified ( bold text added ;strikethrough text 
deleted):
Results for all assessments performed on Day [ADDRESS_199357] -entry subjects (Visit 2.9) and transferred -entry subjects (Visit 
2.10 of Study ESKETINTRD3001 or ESKETINTRD3002) will serve as 
the baseline values for the optimiza tion phase and will not be repeated as 
part of Visit 3.1. The Day [ADDRESS_199358] coincide exactly with Day 
28 (Visit 3.1) for this study. There is no gap allow ed between studies. All 
transferred -entry subjects must meet all of the transferred -entry s ubject -
specific inclusion criteria and none of the exclusion criteria in order to be 
enrolled.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
12
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Clarified the approach forcollection of duplicate assessments during Optimizat ion Phase and 
Maintenance Phase.
Time and Events Schedule
(Optim ization Phase, footnote a) ;The follow ing text was modified (bold text added):
If a subject w ithdraws before the end of the optimization phase for reasons
other than withdraw al of consent, or is not eligible to continue into the 
maintenance phase, an Early Withdraw al Visit ( Refer to Time and Events 
Schedule: Early Withdrawal/End of Maintenance Phase Visit and follow  
up phase ) should be conducted. If the Early Withdrawal Visit is 
conducted on the same day as a scheduled visit, duplicate assessments 
are not r equire d.
Time and Events Schedule 
(Maintenance Phase, footnote b)If a subject w ithdraws before the end of the maintenance phase for reasons 
other than withdraw al of consent, an Early Withdrawal Visit should be 
conducted . A subject meeting relapse criteri a is not considered to be an 
early withdraw al subject; for relapse subjects, and those subjects 
remaining relapse -free at the time of study termination, an End of 
Maintenance Phase Visit should be conducted. If the End of 
Maintenance Visit is conducted on the sam e day as a scheduled visit, 
duplicate assessments are not required. Refer to the Time and Events 
Schedule: Early Withdrawal/End of Maintenance Phase Visit and Follow -
up Phase. 
Rationale: Given the potential to cause increased sedation and potential impact on efficacy, benzodiazepi[INVESTIGATOR_170405] -dose on the dosing day.
3.1.1. Study Phases: Open -label 
Induction Phase; 4.3.Prohibition sand 
Restriction s; 9.1.2. 
Screening/Prospective Observational 
PhaseThe follow ing text was modified (bold text added):
No dose increases beyond the equivalent of 6 mg/day of lorazepam, or 
new benzodiazepi[INVESTIGATOR_154823], 
with the exception of the use of permitted benzodiazepi[INVESTIGATOR_154830] (post -dose on the dosing day only) . 
8. Prestudy and Concomitant Therapy For agitation or anxiety: As required, midazolam (maximum dose 2.5 mg 
orally or IM) or short acting benzodiazepi[INVESTIGATOR_050] (only permitted post -dose 
on the day of dosing).
Rationale: Updated language in Attachment 1 to align with the changes made regarding oral antidepressant 
requirem ents un der INT -3of 3003. Under that am endm ent, the dose of oral antidepressant medications can be 
adjusted in the screening /prospective phase.
Attachment 1 The follow ing text was modified (bold text added ;strikethrough text 
deleted):
Except where specifically noted, the prohibited medications listed in the 
following table are prohibited from 1 week (or 5 half -lives, whichever is 
longer) prior to the first dose of intranasal study medication until after the 
last dose of intranasal study medication. Note: If a medication is part of 
the antidepressant treatment regimen being taken at the time of signing the 
ICF (ie, start of screening/prospective observational phase), per protocol, 
the m edication is continued it must be continued unchanged until the end 
of Week 4 of the screening/prospective observational phase, therefore this 
requirement is not applicable. In such cases the investigator may choose to 
taper the relevant medication during the up to 3 -week taper period based 
on their clinical judgment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
13
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: As clonidine is considered a safe and effective treatment option for blood pressure elevation, it is now  
permitted as a treatment for blood pressure control in the study.
Attachment 1 Epi[INVESTIGATOR_170406] a treatment 
option for blood pressure control.
The follow ing text was deleted (strikethrough text deleted) :
Safety and PD Interaction
The follow ing text was added (bold text added):
Use for blood pressure control is allowed
Epi[INVESTIGATOR_170407] (As Needed) and Continuous Use were changed from No 
(N) to Yes (Y).
Rationale: (brief course of corticosteroids may be permitted to treat conditions including rash, asthma etc. ): The 
Com pany considered that there is no increased risk in terms of safety or efficacy in allowing a brief course of 
corticosteroids, if clinically indicated, to treat an acute medical condition.
Attachment 1 The follow ing text was added (bold text added ):
Intermittent IM/IV/ POcorticosteroids are permitted with sponsor 
approval (chronic use prohibited) .
Rationale: (allow ing brief course of opi[INVESTIGATOR_858]): Company considered that there is no increased risk in terms of safety 
or efficacy in allowing a brief course of opi[INVESTIGATOR_858] ,if clinically indicated ,to treat pain associated w ith recent surgery or 
acute injury.
Attachment 1 The follow ing text was added (bold te xt added):
Note: With Sponsor approval, brief treatm ent with opi[INVESTIGATOR_170408].
Rationale: Modafinil and armodafinil are deleted from the psychostimulants row  of Attachment 1 (they are no 
longer permitted as psychostimulants) because they are potent CYP 3A4 inducers and therefore should be prohibited 
during the study.
Attachment 1 The follow ingtext was modified (strikethrough text deleted):
Psychostimulants 
(eg, amphetamines, methylphenidate, modafinil, armodafinil)
Rationale: Minor grammatical, formatting, and spelling errors w ere noted
Throughout the document Minor erro rs were corrected. Minor formatting changes were made.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
14
Status: Approved , Date: 4 April 2017Amendment 3 (9June 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: Based on feedback received from Investigators involved in the study, the 
subject entry criteria have been revised to improve recruitment.
Applicable Section(s) Description of Change(s)
Rationale: To im prove recruitment, the antidepressant treatment requirements at study entry (ie, time of signing the 
ICF) in inclusion criterion no. 3 .1were changed. In addition, the definition of non-response at the end of the 
screening/prospective observational phase was rev ised.
4.1.1.  Direct -entry 
SubjectsInclusion criterion no. 3 .1was revised as follows (bold text added ; strikethrough text 
deleted ):
At the start of the screening/prospective observational phase, subject must have had non -
response ( ≤25% improvement) to ≥ 12but ≤5 (if current epi[INVESTIGATOR_154806] > [ADDRESS_199359] 2 years) oral antidepressant treatments in the current epi[INVESTIGATOR_154807], assessed using the MGH- ATRQ and confirmed by [CONTACT_154899] (eg, 
medical/pharmacy/pres cription records /or a letter from a treating physician, etc .). In 
addition, the sSubject must be istaking one of the a different oral antidepressant 
treatment (s) with nonresponse that is documented (on the MGH -ATRQ) for at least the 
previous 2 weeks (ie, this oral antidepressant treatment must have been taken for at least 6 
weeks at or above the minim umaltherapeutic dose with a lack of clinically meaningful 
improvement) at the start of the screening/prospective observational phase.
-For specific tricyclic antidepressants which are ongoing and being taken at a 
dose below  the MGH -ATRQ minimum therapeutic dose, a blood level that is 
within the therapeutic (antidepressant) range, is acceptable to establish the 
adequacy of the antidepressa nt treatment.
-Subjects must have been beadherent to the continued oral antidepressant 
treatment medication(s) (w ithout adjustment in dosage) through the 
screening/prospective observational phase, as documented on the PAQ. Missing 
≥4 days of antidepressant medication in the prior 2 -week period w ill be 
considered as inadequate adherence.
-Subjects who are non -responders to their current oral antidepressant 
medication(s) from the screening/prospective observational phase (as assessed by 
[CONTACT_6222], remote rate rs) may  be eligible for randomization if all other entry 
criteria are met. Non -response at the end of the screening/prospective 
observational phase is defined as ≤25% improvement in the MADRS total score 
for 2 consecutive visits from  Week 1 to Week 4 and a MADRS total score of 
≥28 for 2 consecutive visits on Week 2 and Week 4 .  
Synopsis, Overview 
of Study Design ; 
Synopsis, Dosage and 
Administration; 3.1.1. 
Study Phases; 3.2.2. 
Study PhasesDeleted text stating that the antidepressant treatment will contin ue unchanged at the same 
dosage during the screening/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
15
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Synopsis, Subject
Population; Synopsis, 
Dosage and 
Administration; 3.1. 1.
Study Phases ; 3.2.1. 
Study Population; 
6.2.1. 
Screening/Prospective 
Observational Phase; 
9.1.2.
Screening/Prospective 
Observational PhaseText regarding antidepressant treatment during the screening/prospective observational 
phase was revised as follows (bold text added ; strikethrough text deleted ):
In addition, the subject is betaking one of the a different oral antidepressant treatment (s)
with nonresponse ( ≤25% improvement) that will be documented (on the MGH ATRQ) for 
at least the previous 2 weeks (ie, this oral antidepressant treatment must have been taken
for at least 6 w eeks at or above the min imum  therapeutic dose with a lack of clinically 
meaningful improvement) . This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will 
continue unchanged, at the same d osage, from the start of Week 1 through the end of 
Week 4 of the screening/prospective observational phase to confirm non -response 
prospectively. Dose adjustment is permitted per clinical judgment, but the oral 
antidepressant treatment is to rem ain at or a bove the m inimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4.
Synopsis, Subject 
Population; 3.1.1; 
Study Phases; 3.2.1. 
Study Population; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for the minimum number of oral antidepres sant treatments in the current epi[INVESTIGATOR_154808] -response at the start of the screening/prospective observational 
phase was revised from ≥2 to ≥1.
Synopsis, Overview 
of Study Design; 
Synopsis, Subject 
Population; 3.1. 
Overvie w of Study 
Design ; 3.2.1. Study 
Population; 3.2.2. 
Study Phases; 6. 2.1. 
Screening/Prospective 
Observational Phase; 
9.1.2. 
Screening/Prospective 
Observational PhaseCriteria for non -response at the end of the screening/prospective observational phase was 
revised as follows (bold text added ; strikethrough text deleted ):
Non-response at the end of the screening/prospective observational phase is defined as 
≤25% improvement in the MADRS total score for 2 consecutive visits from Week 1 to 
Week 4 and a MADRS total score of ≥ 28 for 2 consecutive visits on Week 2 and Week 4 .
16.1. Study -specific 
Design 
ConsiderationsText w as revised as follows (bold text added ; strikethrough text deleted ):
For eligibility, subjects must have had non -response to at least [ADDRESS_199360] and be currently taking non-responders to their current an
antidepressant treatment with non -response being observed with at the start of the 
screening/prospective observational phase th at will be continued as prospective 
treatment in the screening/prospective observational phase. Only subjects w ith non -
response to their current antidepressant treatment after 4 weeks of prospectively observed 
treatment (for a total duration of antidepress ant treatment of at least 10 6weeks by [CONTACT_154900]/prospective observational phase), will be eligible to proceed to the double -
blind induction phase, whe nreall subject swill receive a new oral antidepressant in 
addition to intranasal esketam ine or placebo.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
16
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Inclusion criterion no. [ADDRESS_199361] -entry 
SubjectsThe text of inclusion criterion no. 11.1has been changed as follow s (bold text added ; 
strikethrough text deleted ):
During the study (ie, from Day 1 of the double -blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately 
90 days) after receiving the last dose of intranasal study medication, in addition to the user 
independent highly effective method of contraception, a man who is sexually active with 
a wom an of childbearing potential
-must be practicing a highly effective m ethod of contraception with his fem ale 
partner from  those listed above (see exam ples of highly effective m ethods of 
contraception provided for female subjects). who is sexually active with a 
woman of childbearing potential must agree to use a double -barrier method of 
contraception (eg, diaphragm or cervical/vault caps plus condom with spermicidal 
foam/gel/film/cream/suppository) .
-who is sexually active with a woman who is pregnant must use a condom if his 
partner is pregnant .
-must agree not to donate sperm.
12.Alternatively female partners of childbearing potential may be practicing a highly 
effective method of birth control, eg, established use of oral, injected, or implanted 
horm onal methods of contraception; placement of an intrauterine device (IUD) or 
intrauteri ne system (IUS); or male partner sterilization. Note: If the childbearing potential 
changes after start of the study, a female partner of a male study subject, must begin a 
highly effective method of birth control, as described above.
Rationale: Exclusion criterion no. [ADDRESS_199362] degree atrioventricular (AV) 
block ,as the analyses of PR intervals from subjects in Phase [ADDRESS_199363] -entry 
SubjectsExclusion criterion no. 11 .1revised as follows (bold text added ; strikethrough text 
deleted ):
Subject has clinically significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the open -label induction phase 
prior to randomization, defined as:
-During screening, a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec; if the QTcF is prolonged on the initial ECG, the average 
QTcF of three ECG ’s, recorded [ADDRESS_199364] not be ≥450 msec.
-On Day 1 (predose), a QT interval corrected according to Fridericia’s formula 
(QTcF): ≥450 msec based on the site -evaluated ECG; if the QTcF is prolonged on 
the initial ECG, the average QTcF of three ECG ’s, recorded [ADDRESS_199365] 
not be ≥[ADDRESS_199366] degree AV block with PR interval 
>200 msec (may repeat ECG once, and use average of both readings, if the initial 
PR interval is <240 msec), complete left bundle branch block (LBBB), or 
complete right bundle branch block (RBBB). 
-Features of new ischemia.
Arrhythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs]).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
17
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Exclusion criterion no. [ADDRESS_199367] -entry 
SubjectsText in exclusion cr iterion no. 14 .1revised as follows (bold text added ; strikethrough text 
deleted ):
Subject has positive test result(s) for drugs of abuse (including barbiturates, methadone, 
opi[INVESTIGATOR_858], cocaine, phencyclidine, and amphetamine/methamphetamine) at the start of the 
screening/prospective observational phase or Day [ADDRESS_199368] result at screening due to prescribed 
psychostimulants (eg, am phetam ine, methylphenidate, etc.) taken for an 
indication other than MDD are perm itted to continue to take this medication 
during the study in accordance with  Attachm ent 1.
-Otherwise, Subjects subjects who have a positive test result at screening due to 
prescribed/over -the-counter opi[INVESTIGATOR_858] ,or barbiturates , or amphetamines may be 
permitted to continue in the screening/prospective observational phase if the 
medication is discontinued at least 1 w eek or 5 half -lives, whichever is longer, 
before Day 1 of the double -blind induction phase (prior to randomization) in 
accordance w ith Attachment 1 restrictions. The result of the Day 1 (prior to 
randomization) test for drugs of abuse must be negative for the subject to be 
randomized.
oRetesting is not permitted for positive test result(s), except fo r reasons stated 
above.
Rationale: Clarifications made regarding the usage of antidepressant treatments for indications other than 
depression during the screening/prospective observational phase, and the use of corticosteroids, psychostimulants, 
and ADHD medications.
8. Prestudy and 
Concomitant TherapyThe follow ing text was added:
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for an indication other than depression (eg, 
insomnia) should be continued during the screening/prospective observational phase but 
must be discontinued before the start of the double -blind induction phase.
Attachment 1 For antidepressants, changed 3rdbullet to read “Even if used for indications other than 
MDD (eg, trazodone primarily for sleep ), trazodone the use of any m edication listed on 
the ATRQ is not permitted during the treatment phase” 
For corticosteroids, changed “oral” to “systemic”; allowed epi[INVESTIGATOR_81532] (previously 
prohibited); added that intermittent IM/IV corticosteroids are permitted (chronic use 
prohibited). 
For pseudoephedrine, clarified that is an orally administered agent (not intranasal).
For psychostimulants, allowed continuous use (previously prohibited); added that 
prescr ibed psychostimulants taken for indications other than MDD can be continued but 
must not be taken within 12 hours prior to the intranasal treatment session or for 2 hours 
after the intranasal treatment session. 
For ADHD medications, allowed continuous us e (previously prohibited); added that these 
medications can be continued but must not be taken within 12 hours prior to the intranasal 
treatment session or for 2 hours after the intranasal treatment session.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
18
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: In Amendment 2, inclusion of subject s who have thyroid -stimulating hormone (TSH) outside the normal 
ranges was permitted; however, the text indicating that a subject must have a normal TSH at screening was not 
removed from Amendment 2. This has been corrected in Amendment 3.
4.1.1. Direct -entry 
SubjectsThe bullets in inclusion criterion no. 7 w ere revised as follows (bold text added; 
strikethrough text deleted) :
-Subjects with a pre- existing history of thyroid disease/disorder w ho are treated 
with thyroid hormones must be on a stabl e dosage for 3 months prior to the start 
of the screening/prospective observational phase and must have thyroid -
stimulating hormone (TSH) within normal range in the screening/prospective 
observational phase.
-For any subject (regardless of thyroid history), if the thyroid -stimulating 
horm one ( TSH )value is out of range, a free thyroxine (FT4) w ill be conducted. 
If the FT4 is normal, the subject can be enrolled. If the FT4 value is abnormal 
and considered to be clinically significant (after discussion with th e medical 
monitor) out of range , the subject is not eligible.
Rationale: Based on feedback from the sites to allow subjects to proceed to the end of the optimization phase 
unless not clinically appropriate, the criteri on specifying withdraw al of subjects w ith MADRS total score ≥22 for 
2consecutive assessments during the optimization phase has been removed .
Synopsis, Dosage and 
Administration;
[IP_ADDRESS]. Intranasal 
Treatment Session 
Frequency (All 
Subjects) ; 9.1.4. 
Optimization Phase; 
10.2. Withdra wal 
From  the StudyThe follow ing withdrawal criterion for the optimization phase and any text referring to this 
criterion h avebeen deleted:
Any subject who has a MADRS total score ≥22 for 2 consecutive assessments separated 
by 5 to 15 days will be discon tinued from the optimization phase.
Rationale: Definition of stable response during the optimization phase adjusted to be less rigid as this subgroup is 
an exploratory patient population in the maintenance phase .The duration of the response has been changed from the 
last [ADDRESS_199369] 2 weeks of optimization.
Synopsis, Overview 
of Study Design; 
3.1.2. Definitions of 
Term sStable response redefined as ≥50% reduction in the MADRS to tal score from basel ine in 
each of the last [ADDRESS_199370] 1 MADRS total score of 
>12 in these 2 weeks.
Rationale: Provide clarification regarding missed MADRS assessments. With the revision of the definition of 
stable response, stable responders are no longer required not to have missed the MADRS in all of the last 4 weeks of 
optimization.
Synopsis, Dosage and 
Administration; 
[IP_ADDRESS].Intranasal 
Treatment Session 
Frequency (All 
Subjects)The follow ing text regarding missed MADRS assessments was deleted :
A subject that misses a MADRS assessment during the last 4 w eeks of this phase (Week 
13 to Week 16) is not eligible to participate in the maintenance phase because eligibili ty 
criteria for stable remission or stable response cannot be confirmed. These subjects w ill be 
permitted to complete the optimization phase, if desired.
9.1.4. Optimization 
PhaseThe follow ing bullet was deleted from the list of  criteria for why a subject w ould not be 
eligible to proceed into the maintenance phase:
Misses a MADRS assessment in Weeks 13 to 16
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
19
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
10.2. Withdraw al 
From  the StudyText regarding missed MADRS assessments was revised as follow s(strikethrough text 
deleted) :
Missed MADRS as sessments: Subject misses ≥[ADDRESS_199371] 8 w eeks (Weeks 5 
to 12) or misses a MADRS assessment in Weeks 13 to 16 .
11.2. Sample Size 
DeterminationText w as revised as follows (bold text added; strikethough text deleted) :
The actual number of subjects randomized ( which includes both those in stable remission 
and those with stable response [but who are not in stable remission] )will depend on the 
time it takes to obtain the necessary number of relapses.
Rationale: Provide clarification regarding when follow -up visits will be performed .
Synopsis, Overview 
of Study Design; 
Time and Events 
Schedule, Follow -up 
Phase ; 3.1.1. Study 
Phases; 9.1.7. Follow -
up PhaseSpecified that follow -up visits w ill be performed at [ADDRESS_199372] clinic visit 
(instead of after the last dose of intranasal study drug).
Rationale: Provide clarification regarding when the PWC -20 assessment will be administered.
9.4. Safety 
EvaluationsText w as revised as follows (bold text added; strikethough text deleted):
For those subjects who proceed to the optimization and maintenance phases, the PWC -[ADDRESS_199373] day of intranasal dosing atthe End of Study Visit. If subjects 
withdraw early from  the study during any phase, the PWC- 20 will be cond ucted at 
the Early Withdrawal Visit.
Rationale: Provide clarification in the footnotes regarding antidepressant treatment in the screening/prospective 
observational phase and guidance on repetition of the MADRS assessment.
Time and Events 
Schedule, Screening 
and Induction PhaseText w as revised as follows (bold text added; strikethough text deleted):
Footnote “a” revised to state: Subjects who do not require a taper and are thus eligible to 
immediately proceed to the open -label induction phase canwillhave Visit 1.3 and Visit 2.1 
occur ringon the same day or within 1 week of each other (if not occurring the sam e 
day, the antidepressant treatment regimen should be continued and discontinued 
prior to Visit 2.1) .
Deleted “only” from footnote “k”.
Footnote “q” revised to state: The MADRS should be administered no more than [ADDRESS_199374]’s scheduled targeted (not actual) clinic visit date (except Visit 2.9, 
which is within 1 day prior) . If performed on the day of the scheduled clinic visit for an 
intranasal treatment session, the MADRS must be performed prior to the intranasal 
treatment session.
Rationale: Revise the visit window  for Day 28 of the open -label induction phase to allow more flexibility for 
conducting the visit.
Time and Events 
Schedule, Open -label 
Induction PhaseFor Visit 2.9 during the induction phase, the visit window  was revised to ±1 day (rather 
than -1 day ). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
20
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: To obtain AE and concomitant therapy data in between clinic visits.
Time and Events 
Schedule, Follow -up 
PhaseThe follow ing statement was added as footnote “f” to the remote assessment during the 
follow -up phase:
At the “Remote Assessment ” visit, site staff will contact [CONTACT_170462][INVESTIGATOR_154809]: To add drug accountability for the intranasal study medication to the list of procedures during the 
Optimization Phase.
Time and Events 
Schedule, 
Optimization PhaseAdded a row  in the Time and Events Schedule (under the subheading Study Drug) 
showing drug accountability for the intranasal study medication.
Added a footnote “r” stating:  Drug accountability for intranasal study medication should 
be performed weekly during Weeks 5 through 8 (inclusive) and then weekly or every other 
week from Weeks 9 through 15 (inclusive).
Rationale: Add information about 54135419TRD3008, an open -label safety extension study, thatmay be available 
for eligible subjects participating in ESKETINTRD3003.
Synopsis, Overview 
of Study Design; 
3.1.1. Study Phases; 
9.1.7. Follow -up 
PhaseThe follow ing text was added:
An open -label safety extension study, 54135419TRD3008, may be available (pending 
country and site approval) for eligible subjects participating in the ESKETINTRD3003 
study. Please refer to the 54135419TRD3008 protocol for full details when available.
Rationale: Removal of requirement to report arterial oxygen saturation <93% and any treatment -emergent change 
in the nasal examination as adverse events because adverse event reporting in these instances should be at the 
discretion of the PI.
9.4. Safety 
EvaluationsText w as revised as follows (bold text added; strikethough text deleted):
Any arterial oxygen saturation (SpO 2) <93% should be and lasting for more than 
2minutes, and confirmed by [CONTACT_170463] , will 
be reported as an adverse event .
The follow ing statement was deleted from the description of nasal examinations: Any 
treatment -emergent change or worsening from the baseli ne examination will be recorded 
as an adverse event.
Rationale: The maximum sertraline dose w as changed from 150 mg/day to 200 mg/day as the maximum dose 
allow ed by  [CONTACT_154903] 200 mg/day.
[IP_ADDRESS]. Sertraline; 
Attachment 3 Maximum dose of sertraline changed from 150 mg/day to 200 mg/day. Titration schedule 
adjusted accordingly. 
Rationale: Revise text regarding uptitration of duloxetine dose, which referred to an incorrect phase of the study.
[IP_ADDRESS]. Duloxetine Text revised to state that certain subjects may be started on a 30 mg dose of duloxetine and 
up-titrated to the therapeutic range of 60 mg by [CONTACT_154904] 2 of the open -label 
induction phase (not the screening/prospective observational phase).
Rationale: Removal of LSD and MDMA from urine drug screen results that will lead to discontinuation as LSD is 
not measured in the current urine drug screen and prescribed psychostimulants are now  permitted.
4.3. Prohibitions and 
RestrictionsLysergic acid diethylamide (LSD) and MDMA were deleted from the list of drugs that will 
lead to discontinuation if detected in the urine drug screen during the study.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
21
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Clarification of procedure to follow  if subjects wish to withdraw from the study.
10.2 Wit hdraw al from 
the StudyUnder “Withdraw al of Consent”, the following text was revised to state (bold text added): 
Subjects who wish to withdraw from the study should be asked if they are agreeable to 
continue to an Early Withdrawal Visit (if withdrawing from  the induction , 
optimization or m aintenance phase) and the follow up phase, or to be contact[CONTACT_170464] -up information.
Rationale: Added definition of treatment -resistant depression (TRD) to the synopsis.
Synopsis, Subject 
PopulationThe fol lowing d efinition of TRD from Section 3.2.[ADDRESS_199375] Population :
Treatment- resistant depression is defined as a lack of clinically meaningful improvement 
after treatment with at least 2 different antidepressant agents prescribed in adequate doses 
for adequate duration.
Rationale: Clarification of adverse event reporting procedures in the instance of pregnancy. In addition, 
clarification that all SAEs must be reported using the SAE form.
12.3.1. All Adverse 
EventsText revised as follows (bold text added ; strikethrough text deleted ):
All adverse events and special reporting situations, whether serious or non -serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's 
last study -related procedure (which may include contact [CONTACT_20687] -up of safety), with the 
exception of pregnancy which will be reported up to [ADDRESS_199376] dose of 
study medication (fem ales) or [ADDRESS_199377] dose of study m edication 
(partners of m ale participants) .  Serious adverse events, including those spontaneously 
reported to the investigator, within [ADDRESS_199378] be 
reported using the Serious Adverse Event Form. The sponsor w ill evaluate any safety 
information that is spontaneously reported by [CONTACT_41029].
Rationale: Minor changes were made throughout the p rotocol for compliance with updated protocol template text.
Cover page Updated Sponsor Statement to remove Janssen Infectious Diseases BVBA. 
4.1.1.  Direct -entry 
SubjectsThe follow ing text was added to inclusion criterion no. 9.1:
Contraceptive use by [CONTACT_170465].
17.5 Case Report 
Form  Com pletionDeleted text stating “All data relating to the study must be recorded in CRF.”
References Removed edition number and date from reference 60. 
Attachment 3 Added the following text for footnote “a” as this was inadvertently omitted from the table 
in Amendment 1:
Subjects should be initiated with 60 mg/day. Subjects that have in the past shown 
increased sensitivity towards serotonin reuptake inhibitors (SSRI) /norepi[INVESTIGATOR_170409] (SNRI) can, at the discretion of the treating physician, be started on a 
30mg dose and up -titrated into the therapeutic range of 60 mg by [CONTACT_154904] 2.
Investigator 
Agreement PageRemoved the “LAST PAGE” designation.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
22
Status: Approved , Date: 4 April 2017Amendment 2 (13 January 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: This amendm ent update s and clarifies the protocol based on ongoing 
feedback received during study initiation activities.
Applicable Section(s) Description of Change(s)
Rationale: Clarification was needed that criteria are the same for transferred -entry subjects as for direct -entry 
subjects at the beginning of the optimization p hase.
4.1.2 . Inclusion 
Criteria, Transferred -
entry Subjects;
4.1.[ADDRESS_199379] -entry 
Subjects and 
Transferred -entry 
Subjects;
4.2.[ADDRESS_199380]-entry subjects at the same time point (ie,beginning of optimization phase).
Rationale: The effect of impaired renal clearance on the pharm acokinetic profile of intranasal esketamine is not 
fully known , and subjects with renal impairment may be more vulnerable to blood pressure increases ; therefore, as 
an added safety precaution, subjects with severe renal impairment will be excluded from the study.
4.2.[ADDRESS_199381] -entry 
Subjects ;
4.2.2 . Exclusion 
Criteria, Transferred -
entry SubjectsThe new  Exclusion Criterion 31 was added, to exclude subjects with s evere renal 
impairment (creatinine clearance < 30 m L/min) .
9.4. Safety 
EvaluationsCalculation of creatinine clearance was added.
Rationale: Eligibility criteria and definitions related to previous oral antidepressants (and nonresponse to them) 
needed to be expanded and clarified.
Synopsis, Overview of 
Study Design, Subject 
Population , Dosage 
and Administration ;
3.2.1 . Study
Population ;
4.1.[ADDRESS_199382] -entry 
Subjects ;
6.2.1 . Screening/
Prospective 
Observational Phase 
(Direct -entry Subjects 
Only) ;
9.1.2 . Screening/
Prospective 
Observational PhaseDefinitions for nonresponse in the screening/prospective observational phase were 
clarified, as follows :
-For nonresponse at the beginning of the phase (for eligibility to enter into the 
study), Inclusion Criterion 3 and corresponding text (where relevant) now define
nonresponse as≤25% improvement per Massachuse tts General Hospi[INVESTIGATOR_307] -
Antidepressant Treatm ent Response Questionnaire (MGH -ATRQ), which specifies 
at least 6 w eeks of treatment at a minimum therapeutic dose.
-For no nresponse at the end of the phase (for eligibility to continue into the 
optimization phase), the definition is no longer blinded to investigators and is now 
stated as ≤25% improvement in the Montgomery -Asberg Depression Rating Scale
(MADRS )total score for 2 consecutive visi ts and a MADRS total score of ≥28 for 
2 consecutive visits .
For the ≥2 but ≤5oral antidepressant treatments relevant to Inclusion Criterion 3 and 
associated descriptions, text was added to specify that the upper limit of 
≤5antidepressants was only applicable to the past 2 years of a current epi[INVESTIGATOR_170410] > 2 years.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
23
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
For the documentation to confirm nonresponse for Inclusion Criterion [ADDRESS_199383]'s treating physician , etc.
In Inclusion Criterion [ADDRESS_199384] to be taking one of the aforem entioned oral antidepressant 
treatment(s) with nonresponse that is documented on the MGH -ATRQ (ie, this oral 
antidepressant treatment must have been taken for at least 6 weeks at the minimal 
therapeutic dose with a lack of clinically meaningful improvement) at the start of the 
screening/prospective observational phase .
4.1.[ADDRESS_199385] -entry 
Subjects;
9.1.1 . OverviewInclusion Criterion 3 and related assessments were modified as follows:
Eligibility was modified for tricyclic antidepressant dose ingested versus therapeutic 
blood level attained (ie, if a subject is taking a specific tricyclic anti depressant at a 
dose below  the MGH -ATRQminimum therapeutic dose, then a blood level that is 
within the therapeutic [antidepressant ]range is acceptable to establish the adequacy of 
the antidepressant treatment ).
The t able describing the v olume of blood to be collected from eachsubject was 
updated to reflect this change.
Rationale: The scope of the Site Independent Qu alification Assessment needed clarification .
Synopsis, Subject 
Population;
3.2.1 . Study 
Population ;
4.1.[ADDRESS_199386] -entry
Subjects;
9.1.2 . Screening/
Prospective 
Observational Phase ;
9.6. Other EvaluationsInclusion Criterion [ADDRESS_199387]'s 
current major depressive epi[INVESTIGATOR_170411], but also the severity of depression ( required at Week 1 to be MADRS 
total score ≥28).
Rationale: Assessments and eligibility relevant to th yroid health needed to be expanded and clarified.
4.1.[ADDRESS_199388] -entry 
SubjectsIn Inclusion Criterion 7, new parameters were added for all subjects (regardless of thyroid 
history). If the thyroid-stimulating hormone (TSH) value is outside the normal reference 
range, then the free thyroxine (FT4) level will be assessed. If the FT4 level is normal, then 
thesubject can be enrolled. If the FT4 level is outside the normal reference range, then the 
subject is not eligible.
9.1.1 . Overview;
9.4. Safety 
AssessmentsThe analysis of FT4 w as added for cases where the TSH is outside of the normal reference 
range.
Attachment 1 Comments about t hyroid hormone supplement s were deleted, to harmonize this 
attachment with the associated Inclusion Criter ion 7.
Rationale: Eligibility parameters and assessments related to childbearing potential and contraception needed to be 
clarified and strengthened. Many of these issues were related to changes in the sponsor's protocol template (ie, some 
of these issues may be generally applicable to all similar studies and may not be specific to this study). 
4.1.[ADDRESS_199389] -entry 
SubjectsInclusion Criterion 9 w as strengthened in its definitions of women who are n ot of 
childbearing potent ialand in its requirements for highly effective methods of 
contraception.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
24
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
4.1.[ADDRESS_199390] -entry 
Subjects;
9.1.[ADDRESS_199391] for β-human chorionic 
gonadotropin (β-hCG) must be highly sensitive, and to clarify the serum versus urine tests. 
The t able that describes the v olume of blood to be collected from each subject now  
specifies the highly sensitive nature of the β-hCG test.
4.1.[ADDRESS_199392] with a woman via sexual activity or donation ; requirements are 
specified both for male study subjects and for their female partners . 
Time andEvent s 
Schedule s(All 
Phases) ;
9.6. Other EvaluationsFootnotes and text were added to clarify menstrual cycle tracking (the start date of the last 
menstrual period prior to the study visit ). This tracking is captured as part of Module I of 
the [LOCATION_005] Ge neral Hospi[INVESTIGATOR_307] -Female Reproductive Lifecycle and Hormones 
Questionnaire (MGH- FRLHQ )at Week 1 of the screening/ prospective observational 
phase, and then is tracked separately thereafter only for women with a menstrual cycle.
The redundant tracking was removed at Week 1 in the Time and Events Schedule of the 
screening/prospective observational phase , leaving only the MGH -FRLHQ at that first 
time point .
Rationale: The description of the studies that could precede this study needed to be corrected.
4.1.[ADDRESS_199393] double -blind description.
Rationale: Eligibility criteria and definitions related to previous procedural interventions for depression needed to 
be expanded and clarified.
Synopsis, Subject
Population;
4.2.[ADDRESS_199394] -entry 
SubjectsIn the exclusion criteria about antidepressant procedures and the related synopsis section,
Exclusion Criterion 1 was modified so it is clearer that nonresponse to 
electroconvulsive therapy (ECT) may be either unilateral or bilateral ECT.
Exclusion Criterion 2 was modified to emphasize the stimulation of the vagal nerve 
rather than themethod of stimulation ; ie, the mention of the implant was deleted.
Rationale: The exclusionary features associated with (comorbid to) major depressive disor der (MDD) needed to be 
clarified and expanded.
Synopsis, Subject
Population;
4.2.[ADDRESS_199395] -entry 
SubjectsIn Exclusion Criterion 3 and in the corresponding synopsis text.
Obsessive -compulsive disorder w as clarified as being exclusionary only when current, 
not when prior.
The diagnostic codes for the exclusion related to intellectual disability were broadened 
from the previous 319 only to also include 317, 318.0, 318.1, 318.2, 315.8, or 319 .
Autism spectrum disorder w as added as exclusionary.
The terminology of "MDD with psychosis" w as harmonized w ith terminology that 
already appeared elsewhere in the protocol, to read "MDD with psychotic features."
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
25
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: The exclusions and prohibitions related to cardiovascular health and medications needed clarification 
and modification.
4.2.[ADDRESS_199396] -entry 
SubjectsExclusion Criterion 8 was modified to allow  entry of patients who had 
revascularization procedures performed >1 2 months prior to screening and are now  
clinically stable and symptom -freein the investigator's clinical judgment .
In Exclusion Criterion 9, the term "antihypertensive medication regimen" w as changed 
to "antihypertensive medication(s)."
In Exclusion Criterion 11,
-For QT interval corrected (QTc) according to Fridericia 's formula (QTcF) , text 
was clarified that the exclusionary abnormal result of ≥450 msec during screening 
or on Day 1 should be based on a repeated demonstration (ie, average of 
3electrocardi ograms [ECGs] with QTcF of ≥450msec, recorded 4minutes apart) .
-For left or right bundle branch blocks, text was clarified that only "complete" 
block w as exclusionary.
-For exclusionary first-degree atrioventricular block with PR interval >200 msec , 
text w as modified to state that retesting was permitted if the initial PR interval wa s 
<240 msec , and that the average of both readings should then be used .
In Exclusion Criterion 12, the use of concomitant medications that prolong the 
QT/QTc interval was deleted (no longer excluding such subject sfrom study 
enrollment).
Rationale: Flexibility was needed for retesting of potentially transient abnormal alanine aminotransferase (ALT) or 
aspartate aminotransferase (AST) values , in case of collection/lab oratory errors or other transient factors .
4.2.[ADDRESS_199397] during the screening period, per investigator discretion and provided there 
is an alternative explanation for the out of range value.
Rationale: Testing time points versus exclusion for cannabinoids needed clarification and harmonization.
4.2.[ADDRESS_199398] -entry 
Subjects;
9.4. Safety 
EvaluationsExclusion Criterion 14 and related text were modified to clarify that testing for 
cannabinoids is to be conducted both during screening and at predose on Day 1; however, 
a positive result is not exclusionary during screening ( as long as the subject does not meet 
the criteria for substance use disorder ) but is exclusionary at predose on Day 1. 
Rationale: Exclusions related to diabetes needed clarification.
4.2.[ADDRESS_199399] -entry 
SubjectsIn Exclusion Criterion 15, the redundant term " secondary diabetes "was removed , since
the criterion had already stated that any uncontrolled diabetes mellitus wa s exclusionary.
Rationale: Exclusions due to anatomical or medical condition sthatcould impede delivery or absorption of 
intranasal study drug needed modification.
4.2.[ADDRESS_199400] -entry 
SubjectsIn Exclusion Criterion 17, text was added to clarify that the exclusion would be 
deter mined by [CONTACT_093]'s clinical judgment based on assessment. Examples of such 
conditions (eg, significant structural or functional abnormalities of the nose) were deleted.
The now-redundant Exclusion Criterion 18, w hich had described exclusionary con ditions 
related to nasal septa, w as similarly deleted.
Rationale: Eligibility related to sleep apnea needed to be clarified.
4.2.[ADDRESS_199401] -entry 
SubjectsIn Exclusion Criterion 23, the parameter for effective treatment was clarified as reaching 
thepreviously stated apnea -hypopnea index (AHI) threshold of <30 (events per hour of 
sleep). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
26
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: Exclusions relevant to current or previous participation in other studies needed clarification .
4.2.[ADDRESS_199402] be interventional to be 
exclusionary. 
Rationale: Details about limitations on prior and concomitant therapi[INVESTIGATOR_170412].
4.3. Prohibitions and 
RestrictionsLysergic acid diethylamide (LSD) w as added to the lis t of positive urine drug screen 
results that would lead to discontinuation during any treatment phase ( open -label 
induction, optimization, or maintenance phases ).
4.3. Prohibitions and 
RestrictionsThe restriction w as rem oved about ingest inggrapefruit juice, Seville oranges, or quinine 
for 24 hours before an intranasal dose of study medication.
4.3. Prohibitions and 
Restrictions ;
8. Prestudy and 
Concomitant TherapyCognitive behavioral therapy (CBT): Where the protocol previously had stated that 
subjects receiving CBT must have had it stable in terms of frequency for the last 
6months, this parameter was made less stringent, to now  read that CBT must have 
been ongoing for the last 3 months. The protoc ol now  clarifies that new CBT is 
prohibited.
Non-CBT psychotherapy: Wher e the protocol previously had stated that subjects 
receiving psychotherapy must have had it stable in terms of frequency for the last 
6months, this parameter was made less stringent, rem oving the time restriction and 
stating that s ubjects receiving psychotherapy can continue receiving psychotherapy , 
and that new non-CBT psychotherapy is allowed during the study.
For any kind of therapy: The protocol now  clarifies that a ny change in exi sting therapy 
or any new therapy must be documented on the concomitant therapi[INVESTIGATOR_77235].
6.2.1 . Screening/
Prospective 
Observational Phase
(Direct -entry Subjects 
Only) ;
4.3. Prohibitions and 
Restrictions;
8. Prestudy and 
Concomitant TherapyRestrictions on the use of benzodiazepi[INVESTIGATOR_92650] -benzodiazepi[INVESTIGATOR_170413], to state the follow ing:
Subjects who were taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the 
equivalent of 6 mg/day of lorazepam) and/or permitted non -benzodiazepi[INVESTIGATOR_170414] (eg, zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational 
phase can cont inue these medications. 
No dose increases beyond the equivalent of 6 mg/day of lorazepam or new 
benzodiazepi[INVESTIGATOR_154823], with the 
exception of the use of permitted benzodiazepi[INVESTIGATOR_154824].
Benzodiazepin es and non -benzodiazepi[INVESTIGATOR_154825] (eg, zolpi[INVESTIGATOR_6730], zaleplon, 
eszopi[INVESTIGATOR_11123], and ramelteon) are prohibited within [ADDRESS_199403] routinely 
takes his or her oral antihypertensive medication (s)in the morning, then the usual morning 
dose(s) should be taken prior to intranasal dosing .
8. Prestudy and 
Concomitant TherapyA sentence was added to clarify that even a ntidepressant treatments which are not listed 
on the MGH -ATRQ but were used, or are currently being used, as antidepressant 
treatment in the current depressive epi[INVESTIGATOR_170415]/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
27
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Attachment 1 Additional examples were provided for existing classes of medications.
Prohibitions were deleted forcytochrome P450 subtype 3A4 ( CYP3A4 )inhibitors.
Prohibitions were added for p seudoeph edrine-conta ining products in the 12 hours prior 
to an intranasal treatment session, for nonstimulant attention -deficit/hyperactivity 
disorder medications, and for n on-vitamin K antagonist oral anticoagulation agents .
Prohibitions were clarified. Inthe section about antidepressants, clarification was 
added that trazodone is not permitted during study phase s that include intranasal 
treatment, e ven if used primarily for sleep . In the section about b enzodiazepi[INVESTIGATOR_170416] , the allowable dosage was clarified ( equal to 
or less than the equivalent of 6 mg/day lorazepam) and comments were consolidated.
Comments about t hyroid hormone supplement s were deleted, to harmonize this 
attachment with the associated inclusion criterion, as described above.
Rationale: Clarification was needed about how  a subject's medications for depression must be maintained 
unchanged and then fully discontinued at the end of the screening/prospective observational phase for subjects 
eligible to enter the open -label induction phase.
Synopsis, Overview of 
Study Design and 
Dosage and 
Administration;
3.1.1 . Study Phases;
3.2.2 . Study Phases;
6.2.1 . Screening/
Prospective 
Observational Phase
(Direct -entry Subjects 
Only) ;
9.1.2 . Screening/
Prospective 
Observational PhaseText w as added and harmonized to clarify that all medication (s) being used for depression , 
including adjunctive/augmentation therapi[INVESTIGATOR_170417] , will be discontinued at the end of the screening/prospective observational 
phase for subjects eligible to enter the open -label induction phase. 
Attachment 1 The follow ing details were added: If a medication is part of the antidepressant treatment 
regimen being taken at t he time of signing the informed consent form (ie , start of 
screening/p rospective o bservational phase), then it must be continued unchanged until the 
end of Week 4 of the screening/p rospective observational phase; therefore ,the prohibition 
terms are not applicable to those medications during that period . In such case s the 
investigator may choose to taper the relevant medication during the optional taper period 
of up to 3 w eeks that may follow  the screening/prospective observational phase, based on 
clinical judgment.
Rationale: The titration schedule wit h the oral antidepressant medication in the open -label induction phase needed 
to be clarified for all antidepressants and modified for duloxetine.
Synopsis, Dosage and 
Administration; 
[IP_ADDRESS] . Oral 
Antidepressant;
6.2.2 . Open -label 
Induction Phase 
(Direct -entry Subjects 
Only)For the low er limit, the time point for the minimum therapeutic dose w as specified as the 
end of the induction phase. For the upper limit, the text was clarified that doses are not to 
exceed the maximum dose defined in the titration schedule. Statements were added to 
clarify that use of the titration schedule in Attachment 3 is mandatory.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
28
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
[IP_ADDRESS] . Duloxetine; 
Attachment 3For t heduloxetine starting dose of 60 mg/day ,this amendment adds flexibility for subjects 
who have in the past shown increased sensitivity towards selective serotonin reuptake 
inhibitors ( SSRI s) or serotonin -norepi[INVESTIGATOR_5608] ( SNRIs ). Those 
subjects can, at the discretion of the treating physician, now be started on a 30-mg dose 
and then up-titrated into the therapeutic range of 60 mg by [CONTACT_154904] 2 of the open -
label induction phase.
Rationale: The oral antidepressant was not scheduled to be dispensed frequently enough to ensure continuous 
coverage. (One dispensation had been omitted in error.)
Time and Events 
Schedule 
(Maintenance Phase)In the row  entitled "D ispensing oral antidepressant (open -label)," an X w as added to the 
column at Week 16.
Rationale: Clarification was needed about the order of administering intranasal devices.
[IP_ADDRESS] . [Optimization 
Phase], Intranasal 
Treatment Session 
Frequency (All 
Subjects)
6.1.3 .Maintenance 
Phase Footnotes were added to the tables that describe i ntranasal treatm ent sessions , clarifying 
that t he intranas al devices for each intranasal treatment session should be administered in 
the medication kit order provided by [CONTACT_80356] (IWRS).
Rationale: The guidance for discontinuing any subjects who may develop ulcerative cystitis needed to be 
strengthened.
3.2.6 . Safety 
EvaluationsThe previous text stating that "i f cystitis is considered to be associated with esketamine, 
subjects will be discontinued " was strengthened to state that if a subject is determined to 
have a diagnosis of ulcer ative cystitis, the subject must be discontinued .
9.4. Safety 
EvaluationsUnder the subheading for Bladder Pain/Interstitial Cystitis Symptom Score (BPIC -SS), a 
new criterion for discontinuation w as added: i f a subject is determined to have a diagnosis 
of ulcerative cystitis, then the subject must be discontinued from the study and followed 
up with appropriate medical care.
Rationale: A guidance for discontinuing subjects who may develop abnormal ECG reading sneeded to be added.
9.4. Safety 
Evaluations;
10.2. Withdraw al 
From the StudyText w as added to specify that a subject must be discontinued at any time point afte r 
baseline (Day 1, predose), if either of the following criteria are met:
QTcF change from baseline is ≥60 msec and QTcF >480 msec, or 
QTcF > 500 msec.
Rationale: Clarification was needed regarding training requirements for site staff who will be present w ith the 
subject during t he intranasal treatment session and the postdose observation period .
Synopsis, Dosage and 
Administration; 
6.1. Intranasal Study 
DrugPrevious text that stated a physician, nurse, or other appropriate member of the site staff 
with recent (ie, w ithin 1 year) training for cardiopulmonary resuscitation now states a site 
staff member with training incardiopulmonary resuscitation ( eg, a basic life support 
course or equivalent course) that is up to date per local regulations.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
29
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: The g uidance for blood pressure monitoring on intranasal treatment session daysneeded to be more 
conservative, comprehensive, and clear.
6.1. Intranasal Study 
DrugRegarding predose monitoring,
-Values that should prompt retesting (for a single observation), or postponing the 
dose (for same -day values ), or referral for consultation (if persistent to the next 
visit) w ere made more conservative. The s ystolic blood pressure (SBP) alert 
parameter was low ered from ≥160to >140mmHgand the diastolic blood pressure 
(DBP) alert parameter w as lowered from ≥100 to>[ADDRESS_199404] between retesting was changed from a 10 -minute period to an 
open -ended period.
Regarding both predose and postdose monitoring, "other specialist" w as added as an 
option (along with cardiologist and primary care physician) to w hom subjects shoul d 
be referred if alert parameters were met.
Regarding postdose monitoring, 
-For subjects w ith SBP ≥160 mm Hg and/or DBP ≥100 mm Hg at 1.5 hours 
postdose, the handling options for the 30 -minute assessments thereafter w ere 
updated.
-For subjects w ith SBP ≥180mmHg and/or DBP ≥[ADDRESS_199405] sshould be referred 
for immediate medical treatment.
-For subjects w ith SBP ≥180 but <200 mm Hg and/or DBP ≥110 but <120 mm Hg , 
conditions for contin uing with intranasal dosing (after referral for assessment) 
were changed from "given approval" to if recommended by [CONTACT_170466] .
-For subjects w ith SBP ≥200 mmHg and/or DBP ≥120mmHg at any postdose 
time point, the handling was strengthened from should discontinue from further 
dosing to must discontinue from further dosing.
Rationale: Flexibility was needed for methods to measure blood pressure and pulse/heart rate.
9.4. Safety 
EvaluationsThe emphasis on the completely automated device was decreased and the allowance for 
manual techniques wasmade broader.
Rationale: Cognition testing needed clarification.
Time and Events 
Schedule 
(Screening/Prospective 
Observational Phase);
9.4. Safety 
Evaluations The table and text w ere clarified to state that a practice session will be conducted only for 
the computerized cognitive battery , while the Hopkins Verbal Learning Test -Revised
(HVLT -R)has no practice session.
9.4. Safety 
EvaluationsThe description of the HVLT -R was clarified and was revised to describe administration 
by a person rather than a computer.
Rationale: The University of Pennsylvania Smell Identification Test (UPSIT) and the Smell Threshold Test needed 
to be ad ministered more frequently and more flexibly.
Time and Events 
Schedule (All Phases);
9.4. Safety 
EvaluationsFootnotes and text were added to indicate that i f asubject has significant nasal congestion 
on the day of a scheduled assessment of sense of smell, then the site should consider 
postponing the UPSIT, Smell Threshold Test, or both (as applicable) to the next scheduled 
clinic visit.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
30
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Time and Events 
Schedul e 
(Maintenance Phase)An additional UPSIT assessment was added to Week 20 (Visit 4.5).
Rationale: Flexibility was needed for decongestants versus delay for a subject w ith congestion on an intranasal 
dosing day.
6.1. Intranasal Study 
DrugFor subjects with nasal congestion on a dosing day, the text was changed from "it is 
recommended that the dosing day be delayed" to " an intranasal decongestant can be used 
to reduce congestion or the dosing day can be delayed. "This section had already stated 
thatif an intranasal decongestant is used to reduce congestion, it cannot be used within 
1hour prior to intranasal study drug dosing.
Rationale: Clarification was needed about repetition of safety assessments if a subject start s a scheduled clinic visit 
in which an intranasal treatment session is planned, but then a predose observation prom pts the site staff to postpone 
the intranasal treatment session within the visit window.
Time and Event 
Schedules (Open -label 
Induction Phase, 
Optimization Phase, 
Maintenance Phase); 
9.4. Safety 
EvaluationsA paragraph and footnotes were added to describe w hich assessments must be repeated on 
the actual intranasal treatment session day after a postponement .
Rationale: The volume of blood to be collected needed to be updated.
9.1.1 . Overview;
16.1. Study -specific 
Design ConsiderationsAfter adding conditional assessments as already described above in this section (for FT4 
and for tricyclic antidepressant level), and then reducing the volume of blood to be 
collected for biomark ers, the total volume of blood to be collected needed to be updated. It 
previously was stated as up to 210 or 231 mL, but now is stated as up to 189 mL.
Rationale: During the open -label induction phase, the Sheehan Disability Scale ( SDS) was administered too 
infrequently to track the time course of improvement.
Time and Events 
Schedule, Open -label 
Induction PhaseAn additional SDS assessment w as added to Study Day 15.
Rationale: The w indows and methods for remote MADRS assessment needed modification and clarification .
Time and Events 
Schedule s 
(Screening/Prospective 
Observational Phase 
and Open -label 
Induction Phase)The guidance about the window for remote MADRS monitoring was moved out of a table 
header row  and into a footnote (associated w ith the MADRS row ) providing similar 
guidance .
[IP_ADDRESS] . Primary 
Efficacy Evaluation: 
Montgomery -Asberg 
Depression Rating 
Scale ( MADRS) ;
ReferencesInformation was added to clarify that the independent remote raters will be using the 
Structured Interview Guide for the MADRS. A reference was added to describe this guide.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
31
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: The definition of relapse updated to include completed suicide .
Synopsis, Overview of 
Study Design ;
3.1.[ADDRESS_199406] is not hospi[INVESTIGATOR_057].
Rationale: Some template -based text that can be applicable to all of the sponsor's studies needed to be made more 
specific to the latest details about this study.
9.3. Medical Resource 
UtilizationThe description of data to be collected was simplified and reduced.
12.3.[ADDRESS_199407] of hospi[INVESTIGATOR_170418], 
hospi[INVESTIGATOR_69014] "for the duration of the treatment period" w ere edited to 
read "at times during the treatment period."
15. Study -Specific 
MaterialsThe list of materials supplied to the investigator was updated to include the MGH -ATRQ 
guidance document .
17.4. Source 
Documentatio nText w asdeleted about parameters that would be recorded directly and considered to be 
source data .
Rationale: The protocol needed to be updated for better alignment with recent changes to one or more of the 
sponsor's general practices for all studies: an initiative to prevent missing data, the template for protocols, or other 
policies and procedures. (The underlying issues may be applicable to all of the sponsor's studies and are not 
necessarily specific to this study.)
4. Subject Population The previous statement about "should consult the appropriate sponsor representative " was 
strengthened to " must consult ,"and the qualifier "and resolve any issues" w as added. A 
statement was added that w aivers are not allow ed.
10.2. Withdraw al 
From the StudyThis section was updated to include methods to prevent loss to follow -up and withdraw al 
of consent, and for documentation and notification of withdrawn consent.  
10.3. Withdraw al 
From  the Use of 
Samplesin Future 
Research ;
16.2.5 .Long -term 
Retention of Samples 
for Additional Future 
ResearchThe section that was previously a subheading (" Withdraw al From the Use of Samples for 
Future Research") under Section 10.2 w as promoted to its own section . A cross- reference 
to this section from elsewhere in the proto col (ie, from Section 16.2.5) w as updated.
12.3.1 . All Adverse 
EventsThis section was updated to describe how  the sponsor w ill report suspected unexpected 
serious adverse reactions (S[LOCATION_003]Rs) .
14.5. Drug 
AccountabilityThe "drug return form" w as replaced with the "i nvestigational p roduct destruction form."
16.2.2 . Independent 
Ethics Committee or 
Institutional Review 
BoardFor the statement about annual review and reapproval of this study , the qualifier "w here 
required" w as added.
17.4. Source 
DocumentationThe information was reorganized and expanded to include review of methods for source 
data collection with the investigator .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
32
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
17.5. Case Report 
Form  Com pletionRoles and options were updated for handling corrections to a nelectronic case report form 
(eCRF )after the initial entry into the eCRF , and other clarifications were made .
Rationale: Minor errors w ere noted and clarifications were needed .
Time and Events 
Schedule s 
(Screening/Prospective 
Observational Phase 
and Open -label 
Induction Phase)For ECGs, the footnote was revised from expressing a range of visits ("Visits 2.3 to 2.8," 
which could have been incorrectly interpreted as intending every visit within that range) to 
instead match the specific visits already marked in the table: " Visits 2.3, 2.5, and 2.8."
Time and Events 
Schedule
(Screening/Prospective 
Observational Phase)A footnote was added to Visit 2.1 C -SSRS (Since Last Visit) assessment, to indicate that it 
is only performed for subjects who do not have Visit 1.3 and 2.1 occur on the same day.
Time and Events 
Schedule s 
(Maintenance Phase)In the header and associated footnote, " From Week 21 " was changed to "From Week 20."
1.1.1 . Summary of 
Nonclinical FindingsRegarding the studies in dogs, one of the duplicative but inconsistent sections was 
modified . Both sections now state that the results are about ECGs, where previously one 
section indicated that the results were about EEGs (electroencephalograms).
2.1. Objectives Medical resource utilization had previously been stated as an exploratory objective in the 
protocol synopsis but a secondary objective in the protocol body. The protocol body now 
has been updated to correctly state the exploratory nature. 
9.4. Safety 
EvaluationsIn the section about pulse oximetry, one instance of " ≤93%" w as changed to "<93%" in 
the description of arterial oxygen saturation, and the section w as revised for better clarity. 
(Another instance in this section had already stated the c orrect <93%.)
16.1. Study -specific 
Design ConsiderationsA sentence was revised from previous internal inconsistency ("had response . . . lack of 
response ") to be internally consistent ("had nonresponse . . . lack of response").
Attachment 3 Country -specific titration schedules were removed for countries where no sites are 
participating in the study.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
33
Status: Approved , Date: 4 April 2017Amendment INT -1(21April 2015 )
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union , inthat it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor the scientific value of the study .  
The overall reason for the amendment: The overall reason for the amendment is to c orrect an error in the Time 
and Events S chedule that is required for the Interactive Web Response System (IWRS )setup . 
Applicable Section(s) Description of Change(s)
Rationale: Corrections made to the Time and Events Schedule to specify assessments for the Week 20 visit, and to 
clarify dosing instructions in case of a missed dose during the induction p hase. 
Synopsis , 
Maintenance Phase ; 
Time and Events 
Schedule 
(Optimization Phase, 
Maintenance Phase) ;
6.1.3. Maintenance 
Phase ;
Table 5.Collection of biomarkers was deleted at Visit 3.1 (Week 4 , Day 28 ) of the o ptimization 
phase as it wouldhave been collected twice at the same visit (is still b eing collected at 
Day 28 but as part of the induction phase Visit 2.9 ).Blood volume table (Table 5) w as 
adjusted to reflect the low er volum e of blood collected due to deletion of the duplicate 
collection.
During maintenance phase, a column which was missing in the table was added for 
Week 20,Visit 4.5 (Day 137) . Timing of various procedures and assessments were revised 
accordingly to be performed at Week 20 visit. Subsequent visits now  start with Visit 4.6 
(Week 21).
Text w as adjusted where applicable. 
Synopsis, Dosage and 
Administration;
6.1.1. Open -label 
Induction PhaseSentence was added to clarify in case of a missed dose during the induction p hase: If there 
is no intranasal treatment session on Day 15 (eg, visit is missed), a dose reduction from 
84mg to 56 mg is permitted on Day 18 if required for tolerability; no dose increase is 
permitted .
Rationale: Changes were made to simplify the algorithm and facilitate implementation by [CONTACT_170467].
Synopsis, 
Optimization Phase; 
[IP_ADDRESS]. Intranasal 
Treatment Session 
FrequencyClarified that the 2 fixed time points where adjustments to dosing frequency can be made 
are Week 8 and 12. The algori thms used to determine whether a frequency adjustment 
could be made (based on MADRS total score at Week 8 and Week 12) w ere clarified. 
Added guidance on how  to determ ine if a change in dosing frequency is indicated in case 
of a missing MADRS assessment.
Synopsis, 
Maintenance Phase ; 
Time and Events 
Schedule
(Maintenance Phase ); 
6.1.3 Maintenance 
PhaseClarified the guidance for dosing frequency adjustments at Week 16 and Week 20 and 
every 4 weeks until the end of the phase. Added guidance on how  to determi ne if a change 
in dosing frequency is indicated in case of a missing MADRS assessment. 
Rationale: For consistency with other Phase [ADDRESS_199408] entry subjects 
requiring lower doses of the oral antidepressant thanthose prescribed in the protocol are allow ed to complete the 
induction phase but not eligible to participate in the optimization phase. 
Synopsis, Oral 
Antidepressants ; 
[IP_ADDRESS]. Oral 
Antidepressant;
6.2.2. Open -label 
Induction PhaseAdded the sentence “While subjects requiring lower doses can continue in the study and 
complete the induction phase, such subjects w ill not be eligible to participate in the 
optimization phase and will proceed to the follow -up phase after completion of the 
induction phase.” 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
34
Status: Approved , Date: 4 April 2017Applicable Section(s) Description of Change(s)
Rationale: To add / revise information for dispensing, review, and collection of subject diaries for oral 
antidepressant 
Time and Events 
Schedule, all phases; 
6.2 Oral 
Antidepressants ;
7. Treatment 
Com pliance ;
15. Study -Specific 
MaterialsRows / timepoints / text added for subject diaries for oral antidepressants . 
Rationale: To revise the amount of oral antidepressant dispensed at the End of Study visit from a [ADDRESS_199409] be performed for all 
dispensed study medication.
Synopsis, Follow Up
Phase, Oral 
Antidepressant;
Time and Events 
Schedule (Induction, 
Optimization and 
Maintenance Phases); 
3.1.1. Study Phases; 
6.2.4. Follow -up 
Phase; 
9.1.7 Follow -up 
Phase;
16.1 Study Specific 
Design 
Considerations. Revised (or added where it wasn 't present) text to indicate that subjects will be provided 
with an additional 2 -week supply (rather than 4 -week supply) of the oral antidepressant 
medication to ensure that there is no interruption of oral antidepressant therapy during the 
transition to fu rther clinical/standard of care. 
Rationale: To clarify scoring of the PAQ assessment
9.6. Other 
EvaluationsText describing scoring of the PAQ was revised to indicate it is based on Question 1 (not 
1c through 1f).
Rationale: Correction smade to the diagram of the study design ,Safety Analyses section, and reference list.
Figure 1 . Relapse prevention phase replaced w ith maintenance phase for consistency with protocol 
text terminology.
11.6. Safety Analyses. Deletion of sentences that defined baseline values for subsections on clinical laboratory 
tests, electrocardiograms, vital signs, nasal examination and nasal symptom questionnaire, 
and o ther safety and tolerability questionnaires and assessments . Details about relevant 
baseline will be provided w ithin the Statistical Analysis Plan (SAP).
References . Reference number 139 corrected (for PHQ -9).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
35
Status: Approved , Date: [ADDRESS_199410] Number: 2014 -004586 -24
INTRODUCTION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness, is the second 
leading cause of years lost to disability worldwide ,and isassociated with excess mortality (with years of 
potential life lost).About 30% of patients fail to achieve remission despi[INVESTIGATOR_154826], and are considered to have treatment -resistant depression (TRD) .There is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways underlying 
MDD for the rapid relief of symptoms of depression, especially in patients with TRD .
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) areapproved and widely used for 
the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. 
The desired analgesic -anesthetic effects of ketamine and esketamine are attributed to the blockade of 
ionotropic N -methyl -D-aspartate (NMDA) glutamate receptors. The mechanism of action of ketamine and 
esketamine is distinct from conventional monoaminergic antidepressant treatments and ketamine 
profoundly affects fast excitatory glutamate transmission, increases brain -derived neurotrophic factor 
(BDNF) release, and stimulates synaptogenesis.
Janssen Research & Development (JRD) is developi[INVESTIGATOR_170419] . The higher 
NMDA receptor affinity of esketamine versus ketamine allows a lower volume of medication to be 
administered via thenoninvasive and rapi[INVESTIGATOR_154828] .
This study will investigate whether repeated use of intranasal esketamine plus an oral antidepressant can 
sustain the antidepressant effects of an induction course of intranasal esketamine plus an oral 
antidepressant in subjects with TRD , or whether the oral antidepressant alone is sufficient to maintain the 
antidepressant effect .
OBJECTIVES AND HYPOTHESIS
Primary Objective
The primary objective of this study is to assess the efficacy of intranasal esketamine plus an oral 
antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in 
delaying relapse of depressive symptoms in subjects with TRD who are in stable remission (see 
Defini tions of Term s below) after an induction and optimization course ofintranasal esketamine plus an 
oral antidepressant .
Secondary Objectives
 To assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral 
antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive 
symptoms in subjects with TRD with stable response (but who are not in stable remission) (see 
Definitions of Terms below) after an induction and optimization course of intranasal esketamine plus 
an oral antidepressant
 To assess the effect of intranasal esketamine plus an oral antidepressant compared with an oral 
antidep ressant (active comparator) plus intranasal placebo on:
 Depressive symptoms
 Overall severity of depressive illness
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
36
Status: Approved , Date: 4 April 2017 Functional impairment and associated disability 
 Anxiety symptoms
 Health- related quality of life and health status
 To investigate the safety and tolerability of intranasal esketamine plus an oral antidepressant 
compared with an oral antidepressant (active comparator) plus intranasal placebo in subjects with 
TRD, with special attention to the following:
 Treatment -emergent adverse e vents (TEAEs) ,including AEs of special interest
 Local nasal tolerability
 Effects on heart rate, blood pressure, respi[INVESTIGATOR_697], and blood oxygen saturation
 Effects on alertness and sedation
 Potential psychosis -like symptoms
 Dissociative symptoms
 Potential effects on cognitive function
 Potential effects on suicidal ideation/behavior
 Potential t reatment -emergent symptoms of cystitis and/or lower urinary tract symptoms
 Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine
treatment
 Potential effects on sense of smell
Exploratory Objectives
 To assess the potential relationship of biomarkers with response/non -response to intranasal 
esketamine plus an oral antidepressant or to an oral antidepressant plus intranasal placebo in adult 
subjec ts with TRD
 To assess m edical resource utilization
Hypothesis
The hypothesis for this study is that intranasal esketamine plus an oral antidepressant is more effective
than treatment with an oral antidepressant plus intranasal placebo in delaying relapse of depressive 
symptoms in subjects with TRD in stable remission. 
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, parallel -group, active -controlled, multicenter study to evaluate the 
efficacy ,safety , and tolerability of intranasal esketamine plus an oral antidepressant compared with an 
oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive 
symptoms in adult men and women with TRD who are in stable remission after an induction and 
optimization course with intranasal esketamine plus an oral antidepressant. 
Approximately 211 subjects in stable remission (see Definition of Term sbelow) at the end of the 
optimization phase will be randomized in a 1:1 ratio to either continue intranasal esketamine (same dose) 
or be switched to intranasal placebo ; all subjects willcontinue the same oral antidepressant at the same 
dose.
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
37
Status: Approved , Date: 4 April 2017Subjects will enter the study either directly (referred to as direct -entry subjects) or after completing the 
double -blind induction phase of a short -term study (ESKETINTRD3001 or ESKETINTRD3002)
(referred to as transferred -entry subjects) . 
The study has 5 phases:
 A 4-week screening/pr ospective observational phase, with an optional taper of up to 3 weeks for oral 
antidepressant medication(s) (direct -entry subjects only)
 A 4-week open -label induction phase (direct -entry subjects only)
 A 12-week optimization p hase (open -label for direct -entry subjects and double -blind for transferred -
entry subjects)
 A maintenance phase (variable duration) 
 A 2-week follow -up phase
The maximum duration of a subject 's participation will be variable, depending on whether he or she enters 
the study directly or is transferred from one of the double -blind short -term studies, and whether he or she 
meets phase -specific criteria (eg, meets criteria for response at the end of the induction phase, is in stable 
remission/ response at the end ofthe optimization phase, and when and if he or sherelapse sin the 
maintenance phase). Direct -entry subjects may participate in up to 5 phases and transferred-entry subjects 
may participate in up to 3 phases.
The study will be stopped once 84 relapses (inthe subjects with stable remission) occur during the 
maintenance phase, or earlier based on the results of the interim analysis for efficacy . At the time the 
study is stopped, subjects in the induction phase will be able to complete the Induction phase. Those 
subjects who are responders , after completing an Early Withdrawal Visit may proceed to the 
54135419TRD3008 study without completing the follow -up phase. Those who are not responders will 
have an Early Withdrawal Visit and proceed directly to the follow -up phase. Subjects who are in the 
optimization or maintenance phase at the time the study is terminated will have an Early Withdrawal
Visit /End of Maintenance Visit conducted andproceed directly to the follow -up phase . 
Definitions of Terms :
 Open -label Induction Phase
 Response: 50% reduction in the MADRS total score from baseline (Day [ADDRESS_199411] 
intranasal dose) to the end of the 4 -week open -label induction phase.
 Optimization Phase
 Stable remission: 
oMADRS total score ≤[ADDRESS_199412] 4 weeks of the optimization phase, 
but one excursion of a MADRS total score > [ADDRESS_199413] be ≤ 12.
 Stable response: 50% reduction in the MADRS total score from baseline (Day 1 of induction 
phase; pre-randomization/prior to the first intranasal dose) in each of the last 2 weeks of the 
optimization phase ,but does not meet criteria for stable remission. Note: Fortransferred-entry 
subjects, Day [ADDRESS_199414] in ESKETINTRD3001 or 
ESKETINTRD3002.
 Maintenance Phase :Relapse is defined as any of the following:
 MADRS total score 22 for 2 consecutive assessments separated by 5 to 15days. The date of 
the second MADRS assessment will be used for the date of relapse .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
38
Status: Approved , Date: 4 April 2017 Hospi[INVESTIGATOR_170420] a relapse of depressive illness such as suicide attempt, 
completed suicide, or hospi[INVESTIGATOR_170421]. If hospi[INVESTIGATOR_170422], the start date of hospi[INVESTIGATOR_170423] . Otherwise the date of 
the event will be used if the subject is not hospi[INVESTIGATOR_057].
 In case both relapse criteria are met, the earlier date will be defined as the date of relapse for 
this subject .
Screening/Prospective Observational Phase :
Direct -entry subjects will participate in this 4-week phase to prospectively assess treatment response to 
the subject’s current oral antidepressant treatment regim en. After 4 weeks of continuing the same 
treatment regimen , subjects who are non-responders to their current oral antidepressant treatment (as 
assessed by [CONTACT_6222], remote raters) may be eligible to proceed to the open -label induction phase if 
they have ≤25% improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of ≥28 on Week 2 and Week 4 .
Eligible subjects who are entering the open -label induction phase will discontinue their current oral 
antidepressant medication (s). If clinically indicated, a subject’s current antidepressant medication(s) may 
be tapered over an additional , optional period of up to 3 weeks per the local prescribing information or 
clinical judgment .
As a new oral antidepressant will be initiated on Day 1 of the open -label induction phase, e ligible s ubjects 
who do not require a taper ed discontinuation of their antidepressant medication(s) can immediately 
proceed into the open- label induction phase.
Open -label Induction Phase :
Eligible direct -entry subjects will receive intranasal esketamine (flexible dose: 56 mg or 84 mg) treatment 
sessions twice weekly for 4weeks. In addition, all subjects will initiate a new, open -label oral 
antidepressant on D ay 1thatwill be taken daily for the duration of the induction phase. The assigned oral 
antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or 
venlafaxine extended release [XR]), that the subject has not previously had a non-response to in the 
current depressive epi[INVESTIGATOR_1865], has not been previously intolerant to (lifetime), and is available in the 
participating country .
At the end of the induction phase, subjects who are responders (defined as 50% reduction in the 
MADRS total score from baseline [Day [ADDRESS_199415] intranasal dose] to the end of the 4 -week ope n-
label induction phase ) may beeligible to proceed to the optimization phase. All subjects who do not 
proceed to the optimization phase will have an Early Withdrawal Visit conducted and proceed to the 
follow -up phase .
At the time the study is stopped ,subjects in the induction phase will be able to complete the phase. Those 
who are responders , after completing an Early Withdrawal Visit, may proceed to the 54135419TRD3008 
study without completing the follow -up phase. Those who are not responders will have an Early 
Withdrawal Visit conducted and proceed directly to the follow -up phase .
Optimization Phase :
Eligible direct -entry subjects from the open -label induction phase and transferred -entry subjects from the 
2 double -blind short -term studies (ESKETIN TRD3001 and ESKETINTRD3002) will participate in this 
12-week phase.
The intranasal treatment session frequency will be reduced from that in the induction phase (twice 
weekly) to weekly for the first [ADDRESS_199416] 4 weeks, the frequency of intranasal 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
39
Status: Approved , Date: 4 April 2017treatment sessions will be individualized to either once weekly or once every other week based on the 
severity of depressive symptoms, as assessed by [CONTACT_170468]. The dose of intranasal 
esketamine will remain unchanged from thedose at the end of the induction phase. All subjects will 
continue taking the same oral antidepressant treatment (at the same dosage) that was initiated during the 
induction phase.
At the end of the optimization phase , subjects in stable remission and tho se with stable response (but who 
are not in stable remission) may be eligible to continue into the maintenance phase ; all other subjects will 
have an Early Withdrawal Visit conducted and proceed to the follow -up phase .
For subjects in stable remission and those with stable response at the end of this phase, the last visit of the 
optimization phase (Visit 3.13; Week 16) also serves as the baseline visit (Visit 4.1; Week 16) of the 
maintenance phase. Subjects eligible for the maintenance phase will be randomi zed and receive their first 
double -blind intranasal treatment session of the maintenance phase at this visit.
At the time the study is stopped, subjects in the optimization phase will have an Early Withdrawal Visit 
conducted and proceed directly to the fol low-up phase .
Maintenance Phase :
On Day 1 of this phase:
 Approximately 211 s ubjects in stable remission at the end of the optimization phase (after treatment 
with intranasal esketamine plus an oral antidepressant )will be randomized in a 1:1 ratio to either 
continue with intranasal esketamine (same dose) and the same oral antidepressant or to continue with 
the same oral antidepressant (active comparator) but switch to intranasal placebo .The primary 
efficacy analys is will be performed for these subjects only . 
 Additionally, subjects with stable response (but who are not in stable remission) at the end of the 
optimization phase (after treatment with intranasal esketamine plus an oral antidepressant )will be 
randomize d in a 1:1 ratio (using a separate randomization list) to either continue with intranasal 
esketamine (same dose) and the same oral antidepressant or to continue with the same oral 
antidepressant (active comparator) but switch to intranasal placebo (for a secondary efficacy analysis
only). 
 Transferred-entry subjects who achieve stable remission or stable response at the end of the 
optimization phase after treatment with an oral antidepressant plus intranasal placebo will continue 
to receive the same treatme nt in order to maintain the blinding for the ongoing short -term studies. 
These subjects will not be included in the efficacy analyses, but will be included in safety analyses.
The frequency of intranasal treatment sessions will befurther individualized during the maintenance 
phase to once weekly or once every other week based on the severity of depressi ve symptoms , as assessed 
by [CONTACT_170468]. Subjects will only be permitted to switch from weekly to every other weekly 
dosing a total of 3times. After this time, if a given subject is unable to sustain improvement on every 
other week dosing they will remain on a weekly dosing regimen for the duration of this phase .
This phase will have a variable duration, continuing until [ADDRESS_199417] 
an Early Withdrawal Visit conducted and proceed directly to the follow -up phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
40
Status: Approved , Date: 4 April 2017Follow -up Phase :
This phase will include all subjects who have received at least 1 dose of intranasal study medication in 
this study . For those subjects who relapse in the Maintenance phase, if clinically indicated based on 
investigator’s judgment, after completing the end of maintenance visit, the subject may proceed to the 
open -label safety extension study, 54135419TRD3008, without completing the follow -up phase. 
Similarly ,when the study is stopped, subjects in the Induction phase who are responders, after completi ng 
the early withdrawal visit, may proceed to the 54135419TRD3008 study, without completing the follow 
up phase .
Follow -up visits will be performed at [ADDRESS_199418] clinic visit .
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression willbe 
arranged by [CONTACT_63789]/or the subject’s treating physician. There will be no intranasal 
treatment administered during this phase. Subjects will be provided with an additional 2-week supply of 
the oral antidepressant medication to ensure that there is no interruption of oral antidepressant therapy  
during the transition to further clinical/standard of care. The decision to continue the oral antidepressant 
in this phase will be at the discretion of the investigator, however, in order to better assess potential 
withdrawal symptoms from intranasal study drug, the oral antidepressant should be continued during the 
2-week follow -up phase unless determined as not clinically appropriate .
An open -label safety extension study, 54135419TRD3008, may beavailable (pending country and site 
approval) for eligible subjects participating in the ESKETINTRD3003 study. Please refer to the 
54135419TRD3008 protocol for full details of potential pathways for entry .
SUBJECT POPULATION
Direct -entry Subjects
The study population will include adult men and women, 18 (or older if the minimum legal age of consent 
in the country in which the study is taking place is >18) to 64 years of age (inclusive), who meet the 
Diagnostic and Statistical Manual of Mental Disorders (5th Edition; DSM -5) diagnostic criteria for 
recurrent MDD or single -epi[INVESTIGATOR_154831] (if a single epi[INVESTIGATOR_1865], the duration of epi[INVESTIGATOR_154832] 2 years), 
without psychotic features, based upon clinical assessment, and confirmed by [CONTACT_170469]. The subject must have an Inventory of Depressive Symptomatology-
Clinician rated, 30-item (IDS -C30) total score of 34, which corresponds to moderate to severe 
depression.
At the start of the screening/prospective observational phase , subjects must have had non-response (ie, 
lack of clinically meaningful improvement, defined as ≤25% improvement) to1but 5(if current 
epi[INVESTIGATOR_154806] >[ADDRESS_199419] 2 years) different oral antidepressant 
treatments taken at adequate dosage and for adequate duration, as assessed on the [LOCATION_005] General 
Hospi[INVESTIGATOR_307] –Antidepressant Treatment Response Questionnaire (MGH -ATRQ) and documented by
[CONTACT_115645]/pharmacy/prescription records or a letter from a treating physician, etc.for the current epi[INVESTIGATOR_154807]. In addition, the subject is taking a different oral antidepressant treatment (on the MGH -
ATRQ ) for at least the previous [ADDRESS_199420]’s current major depressive epi[INVESTIGATOR_170424] (retrospectively assessed) must be deemed valid for participation in a clinical study 
based on the Site Independent Qualification Assessment. The Site Independent Qualification Assessment 
is a tool to facilitate subject selection for MDD clinical studies, with a goal to ensure enrollment of 
subjects who have symptoms that reflect the current state of illness, that these symptoms can be reliably 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
41
Status: Approved , Date: 4 April 2017measured with appropriate measurement tools, and that the severity of depressio n is appropriate (required 
at Week 1 to be MADRS total score ≥28).
Potential subjects will be excluded from participating in the study if they have previously demonstrated 
non-response of depressive symptoms to any of the following: esketamine or ketamine in the current 
major depressive epi[INVESTIGATOR_1865] , all of the oral antidepressant treatment options available in the respective 
country for the open -label induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine XR) 
in the current major depressive epi[INVESTIGATOR_1865] (based on MGH -ATRQ), or an adequate course of treatment with 
electroconvulsive therapy (ECT) in the current major depressive epi[INVESTIGATOR_1865], defined as at least [ADDRESS_199421] 
a current or prior DSM -5 diagnosis of a psychotic disorder or MDD with psycho tic features , bipolar or 
related disorders (confirmed by [CONTACT_42145]), intellectual disability (DSM -5 diagnostic code s 317, 318.0, 
318.1, 318.2, 315.8, or 319), autism spectrum disorder, borderline personality disorder, antisocial 
personality disorder, histrionic personality disorder, or narcissistic personalit y disorder; if they have 
current obsessive -compulsive disorder; if they have homicidal ideation/intent or suicidal ideation with 
some intent to act within 6 months prior to the start of the screening/prospective observational phase per 
the investigator’s clinical judgment and/or based on the Columbia Suicide Severity Rating Scale (C-
SSRS); or if they have a history of moderate or sev ere substance or alcohol use disorder according to 
DSM -5 criteria.
Transferred -entry Subjects
Subjects who enter this study after participation in 1of the short -term studies (ESKETINTRD3001 or 
ESKETINTRD3002) must have completed the double -blind induction phase in the short -term study and 
must have demonstrated response at the end of that phase (50% reduction in the MADRS total score 
from baseline [Day 1 pre -randomization] at the end of the 4 -week double -blind induction phase).
DOSAGE AND ADMINISTRATION
Intranasal Study Drug
On all intranasal treatment session days, a site staff member with traini ng incardiopulmonary 
resuscitation (eg, basic life support course or equivalent course) that is up to date per local regulations
must be present with the subject during the intranasal treatment session and the postdose observation 
period. In addition, equ ipment for supportive ventilation and resuscitation needs to be present.
All subjects will self -administer the intranasal study drug at treatm ent sessions at the study site.
Intranasal treatment sessions should not take place on consecutive days.
On all in tranasal dosing days, subjects must remain at the site until study procedures have been completed 
and the subject is ready for discharge .Subjects should be accompanied by a responsible adult when 
released from the clinical site. Subjects must not drive a car or work with machines for [ADDRESS_199422] -entry subjects will 
practice spraying (into the air, not intranasally) a demonstration intranasal device that is filled with a 
placebo solution.
Open -label Induction Phase
This phase is for direct -entry subjects only. All subjects will self -administer intranasal esketamine twice a 
week for [ADDRESS_199423] treatment session will be on Day 1.
On Day 1, subjects will start with a dose of 56 mg. On Day 4, the dose may be increased to 84 mg or 
remain at 56 mg, as determ ined by [CONTACT_170470]. On Day 8, the dose 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
42
Status: Approved , Date: 4 April 2017may be increased to 84 m g (if Day 4 dose was 56 mg), remain the same, or be reduced to 56 mg (if Day 4 
dose was 84 mg), as determined by [CONTACT_170470]. Similarly, on 
Days 11, 15, 18, and 22, the dose may be increased to 84 mg, remai n the same, or be reduced to 56 mg,if 
applicable as determined by [CONTACT_170470]. On Day 25,a dose 
reduction from 84 mg to 56 mg is permitted if required for tolerability; no dose increase is permitted.
Optimization Phase
Transferred -entry subjects : In thisphase , subjects will continue the same double -blind intranasal study 
drug (same dose) from the double -blind induction phase of ESKETINTRD3001 or ESKETINTRD3002.
Direct -entry subjects: In the optimization phase , subjects will continue the same open -label intranasal 
esketamine treatment (same dose) from the open -label induction phase.
All subjects will continue their oral antidepressant medication (at the same dosage) during this phase.
Intranasal Treatment Sessi on Frequency:
During this phase, the MADRS will be performed weekly by [CONTACT_10981], remote rater , and changes to 
the intranasal treatment session frequency will be based on theMADRS total score, ifapplicable
(seebelow ).
For all subjects, the frequenc y of intranasal treatment sessions will be reduced from the twice -weekly 
frequency used in the induction phase to weekly for the first 4weeks of the optimization phase (Week 5 
to Week 8).
During this phase, there are twofixed time points (Week 8and Week 12) in which anadjustment to the 
frequency will be made if applicable.
Week 8:
 Subjects with a MADRS total score >12 at Week 8 visit will continue to receive weekly intranasal 
treatment sessions for the remainder of the optimization phase. No further change to the treatment 
session frequency is permitted for the remainder of the optimization phase (through Week 16).
 If the MADRS total score is [ADDRESS_199424] will reduce the frequency to receive 
intranasal treatment sessions every other week for the next 4 weeks (ie, next treatment sessions will 
be at Week s 10 and 12 ).
 This is the only time during the optimization phase that a subject will be permitted to change to 
a frequency of every other week.
 If the MADRS assessment is missed at Week 8, the last MADRS total score available prior to Week 
8 will be used to determine if a change in treatment session frequency is indicated at Week 8. In this 
case:
 If the MADRS total score is≤ 12, the subject will reduce the frequency to receive intranasal 
treatment sessions every other week for the next 4 weeks (ie, next treatment sessions will be at 
Weeks 10 and 12).
 If the MADRS total score is >12, the subject will continue to receive weekly intranasal 
treatment sessions for the remainder of the optimizatio n phase. No further change to the 
treatment session frequency is permitted for the remainder of the optimization phase (through 
Week 16).
Week 12 ( only for those on an every other week treatment session frequency):
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
43
Status: Approved , Date: 4 April 2017 Ifthe MADRS total score is >12 at Week 12, the frequency of intranasal treatment sessions will be 
increased to weekly for the remainder of the optimization phase ; no further change to the treatment 
session frequency is permitted for the remainder of the optimization phase (through Week 16).
 If the MADRS total score is ≤[ADDRESS_199425] will remain on the treatment session 
frequency of every other week for the next 4 weeks ( ie,through to Week 16).
 If the MADRS is m issed at Week 12, the last MADRS total score available prior to Week 12 will be 
used to determine if a change in treatment session frequency is indicated at Week 12. In this case:
 If MADRS total score is 12, the subject will remain on the treatment session frequency of 
every other week for the next 4 weeks (ie,through to Week 16).
 If the MADRS total score >12 at that week, the frequency of intranasal treatment sessions will 
be increased to weekly for the remainder of the optimization phase; no further change to the 
treatment session frequency is permitted for the remainde r of the optimization phase (through 
Week 16).
Maintenance Phase
All subjects will receive double -blind intranasal study medication in this phase, as described above 
(seeOverview of Study Design, M aintenance P hase).
During this phase, the MADRS will conti nue to be assessed weekly by [CONTACT_10981], remote rater, and
changes to the intranasal treatment session frequency will occur at 4-week intervals, if applicable, andbe 
based on the MADRS total score (see below) . 
At the start of this phase (Visit 4.1; Week 1 6): 
 Subjects who currently receive intranasal treatment sessions on a weekly basis will stay at the same 
weekly intranasal treatment session frequency for the first 4 weeks o f this phase. 
 For those on an every other week frequency:
 Ifthe MADRS to tal score is >12 at Week 16, the frequency of intranasal treatme nt sessions will 
be increased to weekly for the next 4 weeks .
 If the MADRS total score is ≤[ADDRESS_199426] 4 weeks of this phase (ie, starting from Week 20), the intranasal treatment session 
frequency willbe adjusted (if applicable) at fixed, 4- week intervals (eg, Week 20, 24, 28, 32, 36, 40, 44 
and every 4 weeks unt il the end of the phase), based on the guidance below:
 If the MADRS total score is 12at that week :
 If the frequency is weekly , the frequency will be changed to every other week.
 If the frequency is every other week, there will be no change in frequency.
 If the MADRS total score >12 at that week :
 If frequency is weekly , there will be no change in frequency.
 If frequency is every other week , the frequency will be changed to weekly
 If the MADRS is missed at that week, the last MADRS total score available prior to that week will 
be used to determine if a change in treatment session frequency is indicated at that week. In this case:
 If the MADRS total score is≤12, and the frequency is every other week, there will be no change 
in frequency.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
44
Status: Approved , Date: 4 April 2017 If the MADRS total s core is≤12, and the frequency is weekly, the frequency will be changed to 
every other week.
 If the MADRS total score is >12, and the frequency is weekly, there will be no change in 
frequency.
 If the MADRS total score is >12, and the frequency is every other week, the frequency will be 
changed to weekly. 
A maximum of [ADDRESS_199427] 3 hours after the treatment session .
Screening/Prospective Observational Pha se(Direct-entry S ubjects Only)
During this phase , direct -entry subjects will continue taking their current oral antidepressant treatment
regimen for the duration of the 4-week phase for prospective observation of response or non-response . 
The regimen must include a different oral antidepressant treatment (on the MGH -ATRQ ) for at least the 
previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, as well as any  
other medication (s) being used for depression (including adjunctive/augmentation therapi [INVESTIGATOR_014]), will 
continue from the start of Week 1 through the end of Week 4 of this phase. Dose adjustment is permitted 
per clinical judgment, but the oral antidepressant treatment is to remain at or above the minimum 
therapeutic d ose (per the MGH -ATRQ) through the end of Week 4.
The sponsor will not supply these oral antidepressant s. Antidepressant treatment adherence will be 
assessed during this phase using the Patient Adherence Questionnaire (PAQ). For subjects who are 
eligible to enter the open -label induction phase, after the completion of 4 weeks of prospective 
antidepressant treatment and confirmation of the antidepressant treatment non-response, all medication(s) 
being used for depression will be discontinued, including adjunctive/augmentation therapi[INVESTIGATOR_014]. I f clinically  
indicated (e g, antidepressant treatments with short half -lives, such as paroxetin eand venlafaxine XR), the 
medication(s ) being used for depression may be tapered off and discontinued over a period of up to 3
weeks per the local prescribing information or clinical judgment. Eligible subjects who do not require a 
taper of their medication(s) being used for depression can immediately proceed into the open -label 
induction phase.
Open -label Induction Phase (Direct-entry S ubjects Only)
Starting on Day [ADDRESS_199428] -entry subjects. The oral antidepressant will be 1 of 4 oral antidepressant medications 
(duloxetine, escitalopra m, sertraline, or venlafaxine XR). The antidepressant medication will be assigned 
by [CONTACT_170471] -ATRQ and relevant prior antidepressant medication 
information ,and will be one that the subject has not previously had a non-response to in the current 
epi[INVESTIGATOR_1865] (based on MGH -ATRQ) , has not been previously intolerant to (lifetime), and is available in the 
participating country.
Dosing of the oral antidepressant will begin on Day 1. A mandatory titration schedule is provided in the 
protocol. Doses are not to exceed the maximum dose defined in the titration schedule. If higher doses are 
not tolerated, a down -titration is permitted based on clinical judgment. However, the subject’s dose 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
45
Status: Approved , Date: 4 April 2017should not be lower than the following minimum therapeutic doses at the end of the induction phase : 
sertraline (50 mg/day), venlafaxine XR (150 mg/day), escitalopram (10 mg/day), and duloxetine 
(60mg/day). While subjects requiring lower doses can continue in the study and complete the induction 
phase, such subjects will not be eligible to participate in the optimization phase and will proceed to the 
follow -up phase after completion of the induction phase .
Optimization and Maintenance Phases (Direct -entry and Transferred -entry Subjects)
For all subjects, the same oral antidepressant treatment (duloxetine, escitalopram, sertraline, or 
venlafaxine XR) started on Day 1 of the induction phase will be continued through the optimization and 
maintenance phases. The oral antidepressant dosage at the end of the induction phase will remain 
unchanged through the maintenance phase.
Subjects who miss21 days of the oral antidepressant doses (total daily dose) inthe optimi zation phase 
will not be eligible to continue into the maintenance phase .
Follow -up Phase
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by [CONTACT_63789]/or t he subject’s treating physician.
No intranasal study medication will be administered during this phase. 
The decision to continue the oral antidepressant medication in this phase will be at the discretion of the 
investigator ;however, in order to better assess potential withdrawal symptoms from the intranasal study 
medication, the oral antidepressant medication should be continued during the 2-week follow -up phase , 
unless determined as not clinically appropriate.
All subjects will be provided with an additional 2-week supply of the oral antidepressant medication at 
the last clinic visit prior to entering the follow -up phase ,to ensure there is no interruption of 
antidepressant therapy during the transition to further clinical/standard of care.
EFFICACY EVALUATIONS/ENDPOINTS
Primary Efficacy Evaluation/Endpoint
The primary efficacy evaluation will include the MADRS total sc ore as it pertains to relapses.
The primary efficacy endpoint includes only subjects who are instable remission at theend ofthe 
optimization phase after treatment with intranasal esketamine plus an oral antidepressant, and is defined 
as the time between subject randomization and the first documentation (earliest date) of a relapse in the 
maintenance phase .
Secondary Eff icacy Evaluations/Endpoints
Secondary efficacy evaluations /endpoints include the following:
 The time between subject randomization and the first documentation (earliest date) of a relapse in the 
maintenance phase for subjects with stable response (not in r emission) at the end of the optim ization 
phase after treatment with intranasal esketamine plus an oral antidepressant .
 The change from baseline (of maintenance phase )to endpoint in:
o Depressive symptoms, using the MADRS and the self-reported Patie nt Health 
Questionnaire 9-item (PHQ -9) scale 
o Overall severity of illness, using the Clinical Global Impre ssion -Severity (CGI -S)
o Symptoms of anxiety, using the Generalized Anxiety Disorder, 7 -item (GAD -7) scale
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
46
Status: Approved , Date: 4 April 2017o Health -related quality of life and health status, using the European Quality of Life 
(EuroQol) Group, 5- Dimension, 5- Level (EQ -5D-5L) questionnaire
o Function ingand associated disability, using the Sheehan Disability Scale (SDS)
BIOMARKER ,PHARMACOGENOMIC (DNA) , AND EXPRESSION (RNA) EVALUATIONS
Assessment of biomarkers (protein and RNA) and their potential relationship to the different treatment 
groups and to maintenance/stabilization of response, non-response, and relapse will be explored. Blood 
samples will be collected to measure genetic and epi[INVESTIGATOR_27787] (including but not limited to brain 
derived neurotrophic factor [BDNF] allelic variants) and protein markers (including but not limited to 
growth factors, inflammation, endocrine, or metabolic markers). Samples of DNA and biomarkers may be 
used to help address emerging issues and to enable the development of safer, more effective, and 
ultimately individualized therapi[INVESTIGATOR_014] .
MEDICAL RESOURCE UTILIZATION
Medical resource utilization data, associated with healthcare encounters, will be collected using the 
Healthcare Resource Use Questionnaire (HRUQ) during the optimization, maintenance, and follow -up 
phases. The HRUQ includes information regarding utilization of healthcare services (including the 
duration and type of services), enabling changes in level and quantity of services to be considered as a 
variable in economic models.
SAFETY EVALUATIONS
Safety evaluations will include :
 Monitoring of TEAEs, including TEAEs of special interest; clinical laboratory tests (including 
hematology, serum chemistry , and urinalysis), pregnancy testing (for women of childbearing 
potential), urine drug screen, 12- lead electrocardiogram, vital signs, pulse oximetry, physical 
examination, and body weight measurements
 Nasal examinations and nasal symptom questionnaire
 Columbia Suicide Severity Rating Scale (C -SSRS), to assess potential suicidal ideation and behavior
 Clinician Administered Dissociative States Scale (CADSS), to assess treatment -emergent 
dissociative symptoms
 Four -item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+), to assess 
potential treatment -emergent psychotic symptoms
 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S), to measure treatment -emergent 
sedation
 Clinical Global Assessment of Discharge Readiness (CGADR), to document the subject’s current 
clinical status and is the clinician 's assessment of the readiness to be discharged from the study site
 Physician Withdrawal Checklist (PWC -20) includes 20 items to assess potential withdrawal 
symptoms following cessation of intranasal esketamine treatment
 Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC -SS), to monitor subjects for potential 
symptoms of cystitis, bladder pain, and interstitial cystitis
 Computerized cognitive battery and Hopkins Verbal Learning Test-Revi sed (HVLT -R), to assess the 
effect of intranasal esketamine on cognition
 University of Pennsylvania Smell Identification Test (UPSIT) and Smell Threshold Test, to assess 
any potential treatment -emergent effects on the sense of smell
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
47
Status: Approved , Date: [ADDRESS_199429] Information
The full analysis sets for the primary efficacy evaluation are defined as follows:
 At Interim Analysis: All subjects who are in stable remission at the end of the optimization phase
and who receive at least 1 dose of intranasal study drug and 1 dose of oral antidepressant during the 
maintenance phase at the time of t he interim analysis data cutoff
 At Final Analysis: All subjects who are in stable remission at the end of the optimizat ion phase and 
who receive at least [ADDRESS_199430] 1 dose of intranasal 
study drug or 1 dose of oral antidepressant during that phase.
Transferred-entry subjects who continue to receive an oral antidepressant plus intranasal placebo will be 
summarized separately in both optimization and maintenance phases.
Sample Size Determination
The maximum number of relapses (in the subjects with stable remission) required by [CONTACT_170472]84, 
which provides 90% power to detect a hazard ratio of 0.[ADDRESS_199431] relapse follows an exponential distribution, with a median time of 
6months for oral antidepressant alone and 12.17 months for intranasal esketamine plus oral 
antidepressant (hazard ratio =0.493). The corresponding 6-month relapse rates are 50% for oral 
antidepressant alone and 28.95% for oral antidepressant plus intr anasal esketamine .
Assumptions were made for accrual period and rate, maximum study duration, and dropout rate. Based on 
such assumptions, calculations indicated that a total of approximately 211 subjects in stable remission 
need to be randomized (in a 1:1 ratio) in order to obtain 84 relapses.
Interim Analysis
To evaluate the assumptions used in sample size calculation, relapse rates will be monitored sequentially 
during the maintenance phase. In particular, a 2-stage group -sequential design will be adopte d, with 
1interim analysis to be performed when a total of 30 relapses are observed. Early termination of the 
maintenance phase for efficacy will be based on interim analysis results. If the interim analysis results 
show that the study should proceed to the second stage (ie, continue to record more relapses after the 
interim cutoff), sample size re-estimation will be performed based on the interim analysis results to 
determine how many additional relapses shou ld be obtained .The study team will not know the 
adjustments that will be made to the sample size; however, the clinical supplies group will be informed of 
the decision made at the interim analysis so that only the required amount of study medication will be 
packaged.
Efficacy Analyses
Theprimary efficacy endpoint will be the time between subject randomization into the maintenance phase
and the first documentation of a relapse event. Subjectswith stable remission who meet at least [ADDRESS_199432] had a relapse. All other randomized subjects with stable 
remission who had entered the maintenance phase but do not havea relapse by [CONTACT_170473].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
48
Status: Approved , Date: 4 April 2017The cumulative distribution function of the time to relapse will be estimated by [CONTACT_8761] -Meier method. 
Time to relapse will be summarized (number of relapses, number of censored subjects, median, 25th and 
75th percentile of time to relapse , if estimable )by [CONTACT_1570] . Treatment differences will be 
compared using a 2-sided log-rank testasthe primary analysis .The estimate of the hazards ratio and its 
95% confidence interval will be based on the Cox proportional hazards model with treatment as a factor .
Treatment comparison between intranasal esketamine plus oral antidepressant and oral antidepressant 
(active comparator) plus intranasal placebo in the changes from baseline to endpoint of MADRS total 
score, PHQ -9, CGI-S, SDS, and GAD -7during the maintenance phase will be performed using an 
analysis of covariance model with treatment and country as factors and baseline (maintenance phase ) 
value as a covaria te. Least -squares estimates of the treatment differences and 95% confidence intervals 
will be presented. Dimension scores of EQ-5D-5L data, health status index, and the overall health status 
score will be summarized over time. These analyses will be provided separately for stable remitters and 
stable responders (not in remission).
Additionally, the time between the randomization of a subject with stable response (but who are not in 
stable remission) and the first documentation of a relapse for that subject in the maintenance phase will be 
analyzed using the log -rank test as described above for the primary efficacy endpoint.
Biomarker, Pharmacogenomic (DNA), and Expression (RNA) Analyses
Baseline biomarker values and changes from baseline biomarker values to the time points specified in the 
Time and Events Schedule will be summarized. Exploratory analyses may include comparison of 
biomarker measures between the treatment groups and correlation with baseline and change from baseline 
biomarker values in the efficacy and other measures. Additional exploratory analyses may also include 
relationship of baseline and change from baseline in biomarker measures to clinical response, 
maintenance/stabilization of response, relapse, and non -response.
Pharmacogenomic analyses may include candidate gene analyses or genome -wide association analyses in 
relation to treatment response, maintenance/stabilization of response, relapse, and non-response and 
MDD/TRD. Expression analyses may include testing of known mRNA/miRNA transcripts or 
transcriptome -wide analysis in relation to antidepressant treatment and MDD/TRD.
Medical Resource Utilization Analysis
Medical resource utilization data (including HRUQ results) will be analyzed descriptively .
Safety Analyses
All safety data will be analyzed separately for each phase.
For each adverse event, the percentage of subjects who experience at least 1 occurrence of any given 
adverse event will be summarized by [CONTACT_1570]. Data from clinical laboratory tests, 
electrocardiograms, and vital signs will be provided as descriptive statistics and frequency tabulations. 
Nasal examination results will be provided as a shift table for changes from baseline, while nasal 
tolerability questionnaire results will be summarized descriptively. The C-SSRS results will be 
summarized in incidence and shift tables. The BPIC -SS, BPRS+, CADSS, CGADR, compu terized 
cognitive battery, HVLT -R, MOAA/S, Smell Threshold Test, PWC -20, and UPSIT results will be 
provided as descriptive statistics of scores and their changes (and/or percent changes) from predose or 
baseline, as appropriate per assessment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
49
Status: Approved , Date: 4 Apri l 2017TIME A ND EVENTS SCHE DULE (Screening/Prospective Observational Phase and Open- label Induction Phase )
Screening/Prospective 
Observational Phase Open -label Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4
Study day — — —1
(baseline) 4 8 11 15 18 22 25 28
Clinic visit window (in days) — ±2 ±2 — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1
Clinic visit (C) or remote MADRS interview 
only (RM) C C C C C C C C C C C C
Screening/Administrative
Informed consent (ICF) X
Medical history, psychiatric history, 
demographics, employment statusX
MINI X
MGH -ATRQ X
Site Independent Qualification Assessment X
Height X
Inclusion/exclusion criteria X X
Prestudy therapy X
Preplanned surgery/procedures X
STOP -Bang questionnaire (inc luding 
assessment of BMI and neck circumference)X
MGH -Female RLHQ: Module I X
IDS-C30 X
Study Drug
Dispensing of new oral antidepressant 
(duloxetine, escitalopram, sertraline, or 
venlafaxine XR)X Xm
Practice session for use of intranasal device Xc
Intranasal esketamine X X X X X X X X
Drug accountability
(intranasal study medication)X X X X X X X X
Drug accountability (oral antidepressant 
study medication)X X
Dispense subject diary for oral antidepressant X
Review subject diary and update (if 
applicable)X X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
50
Status: Approved , Date: 4 Apri l 2017Screening/Prospective 
Observational Phase Open -label Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4
Study day — — —1
(baseline) 4 8 11 15 18 22 25 28
Clinic visit window (in days) — ±2 ±2 — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1
Clinic visit (C) or remote MADRS interview 
only (RM) C C C C C C C C C C C C
Oral antidepressant compliance check X X X X
Collect/return of subject diary X
Safety Assessments (Site -completed )
Physical examination X X X
Nasal examinationcX X X
Vital signs: blood pressure, pulse, respi[INVESTIGATOR_862], temperaturec,p X X X X X X X X X
Vital signs (postdose): blood pressure, pulse, 
respi[INVESTIGATOR_170425] X X X X X X X X
Weight X X X
12-lead ECGe,pX X X X X
C-SSRS: Baseline/Screening version X
C-SSRS: Since last visit versionpX X XrX X X X X X X X
MOAA/S and pulse oximetryf,pX X X X X X X X X
BPRS+g,pX X X X X X X X
CADSSg,pX X X X X X X X
CGADRhX X X X X X X X
PWC-20iX
Safety Assessments (Subject -com pleted)
Nasal symptom questionnaire jX X X X X
BPIC -SScX X X
Assess ment of Sense of Smell
UPSITc,oX X X
Smell Threshold Test c,oX X
Efficacy Assessments (Clinician)
MADRS (7 -day recall; performed by 
[CONTACT_6222], remote raters)X XqXqXk,qXc,qXc,qXc,qXc,q
CGI-ScX X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
51
Status: Approved , Date: 4 Apri l 2017Screening/Prospective 
Observational Phase Open -label Induction Phase
Visit number 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 b
Week Week 1End of 
Week 2End of 
Week 4 1 2 3 4
Study day — — —1
(baseline) 4 8 11 15 18 22 25 28
Clinic visit window (in days) — ±2 ±2 — ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1
Clinic visit (C) or remote MADRS interview 
only (RM) C C C C C C C C C C C C
Subject -com pleted Assessments
PAQ X X X
PHQ -9cX X X X
SDScX X X X
GAD-7cX X X
EQ-5D-5LcX X X X
Cognition Testing
Practice session for computerized cognitive
batteryX
Computerized cognitive battery and HVLT -R X X
Clinical Laboratory Assessments
TSH, HbA1c X
Lipid panel (fasting) X
Hematology, chemistrycX X X
Urine drug screencX X X X
Alcohol breath test X X
UrinalysiscX X X X
Serum pregnancy test X
Urine pregnancy testcX X X
Biom arkers
Blood sample collection (protein)c,lX X X X
Blood sample collection ( RNA)c,lX X X X
Blood sample collection (DNA) c,lX X
Ongoing Subject Review
Concomitant therapy Ongoing
Adverse events Ongoing
Other
Menstrual cycle tracking (start date of last 
menstrual period prior to study visit)n X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
52
Status: Approved , Date: 4 Apri l 2017Footnotes:
Abbreviations: BMI =body mass index; BPIC -SS=Bladder Pain/Interstitial Cystitis Symptom Score; BPRS + = 4- item positive symptom subscale of the Brief Psychiatric Rating Scale; C =clinic 
visit; CADSS =Clinician Administered Dissociative States Scale; CGADR =Clinical Global Assessment of Discharge Readiness; CGI -S = Clinical Global Impression –Severity; C -SSRS =
Columbia Suicide Severity Rating Scale; DNA =deoxyribonucleic acid; ECG =electrocardiogram ;.EQ-5D-5L=EuroQol -5 dimension =5-level; EW =early withdrawal; GAD -7 = Generalized 
Anxiety Di sorder =7-item scale; HbA1c =glycated hemoglobin test; HRUQ =Healthcare Resource Use Questionnaire ;;HVLT -R = Hopkins Verbal Learning Test -Revised; IDS -C30=Inventory of 
Depressive Symptomatology Clinician -rated ,30-item scale ; MADRS =Montgomery -Asbe rg Depression Rating Scale; MGH -ATRQ =[LOCATION_005] General Hospi[INVESTIGATOR_170426]; MGH Female RLHQ =[LOCATION_005] General Hospi[INVESTIGATOR_170427]; MINI =Mini International Neuro psychiatric 
Interview; MOAA /S = Modified Observer 's Assessment of Alertness/Sedation; PAQ =Patient Adherence Questionnaire; PHQ -9 = Patient Health Questionnaire –9; PWC -20=Physician 
Withdrawal Checklist ,20 item scale; RNA =ribonucleic acid; SDS =Sheehan Disability Scale; STOP -Bang = Snoring , Tired, Observed Apnea , High Blood Pressure , Body mass index , Age, N eck 
Size, Gender (a questionnaire); TSH =thyroid -stimulating hormone ;UPSIT =University of Pennsylvania Smell Identification Test .
Note: On intranasal dosing days, time [ADDRESS_199433] intranasal spray. Therefore, postdose time points are refe renced from this.
a) An additional, optional period of up to 3 weeks is permitted to taper and discontinue all current medication(s) b eing used for depression after completion of the Week 4 (Visit 1.3) assessments, 
per the local prescribing information or clinical judgment. Subjects who do not require a taper and are thus eligible to imme diately proceed to the open -label induction phase can have Visit 1.3 
and Visit 2.1 occur on the same day or within 1 week of each other (if not occurring the same day, the antidepressant treatment regimen should be continued and d iscontinued prior to Visit 2.1) .
b) If a subject withdraws before the end of t he open -label induction pha se (ie, before completing Visit 2.9/Day 28) for reasons other than withdrawal of consent, an Early Withdrawal Visit (refer to
Time and Events Schedule: Early Withdrawal/End of Maintenance Phase Visit and Follow -up Phase) should be conducted , followed by [CONTACT_6591] -up phase. If the Early Withdrawal Visit is 
conducted on the same day as a scheduled visit, duplicate assessments are not required .
c) Predose (if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -related procedures during a clinic visit.
d) Postdose vital signs will be performed at 40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.1for guidance for blood pressure monitoring on intranasal dosing days.
e) Twelve -lead ECG will be performed predose and at t =1 hour postdose at Visit 2.1. Thereafter ,12-lead ECG will be performed at t = 1 hour postdose only (ie, no predose ECG is required) at 
Visits 2.3, 2.5, and 2.8. A time window of ±15 minutes will be permitted .
f) The MOAA/S will not be performed at Visit 1.1 (pulse oximetry only). The MOAA/S will be performed every 15 minutes from predose to t = +1.5 hours postdose (please refer to Section 9.4
for further guidance on MOAA/S assessments). Pulse oxim etry will be performed every 15 minutes from predose to t =1.5 hours postdose (please refer to Section 9.4 for further guidance on 
timing of pulse oximetry assessments).
g) The BPRS+ and CADSS willbe performed predose and at 40 minutes and 1.5 hours postdose. 
h) CGADR willbe performed at 1 hour and 1.5 hours postdose; if the response is not “Yes” at 1.5 hour postdose, the assessment will be repeated every 15 minutes until a “Yes” r esponse is 
achieved or until the subject is referred for appropriate medical care if clinically indicated. A subject should not be discharged prior to the 1.5 hour time point.
i) PWC -[ADDRESS_199434] is not continuing into the optimization phase.
j) Nasal symptom questionnaire will be performed predose and at 1 hour postdose.
k) Performed for subjects requiring a taper period during the screening/prospective observational phase; the result will be cons idered as the subject’s baseline MADRS for the open -label induction 
phase. For all other subjects, the baseline MADRS for the open -label induction phase will be the MADRS performed at the end of Week 4 of the screening/prospective observational phase.
l) Blood samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet on the day of sample collection .
m) Additional 2-week supply of the oral antidepressant medication only for subjects entering the follow -up phase .
n) At Week 1 of the screening/ prospective observational phase, the start date of the last menstrual period prior to study visit is captured as part of the MGH -FRLHQ: Module I. Thereafter, 
menstrual cycle tracking is only applicable to women with a menstrual cycle and is documented separately.
o) If the subject has signific ant nasal congestion on the day of a scheduled assessment of sense of smell, then the site should consider postponing the UPSIT, Smell Threshold Test, or both (as 
applicable) to the next scheduled clinic visit.
p) If a subject has started a scheduled clinic visit in which an intranasal treatment session is planned, but then a predose obs ervation (eg, blood pressure results) prompts the site staff to postpone 
the intranasal treatment session within the visit window, then all time points (including predose) of the footnoted assessments must be repeated on the actual intranasal treatment ses sion day, as 
follows: vital signs (ie, blood pressure, pulse, respi[INVESTIGATOR_697], and temperature), 12 -lead ECG, C -SSRS (since last v isit), MOAA/S, pulse oximetry, BPRS+, and CADSS.
q) The MADRS should be administered no more than [ADDRESS_199435]’s targeted (not actual) clinic visit date (except Visit 2.9 , which is within 1 day prior) . If performed on the day of the 
scheduled c linic visit for an intranasal treatment session, the MADRS must be performed prior to the intranasal treatment session.
r) Performed only if Visit 1.3 and Visit 2.1 do not occur on the same day.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
53
Status: Approved , Date: 4 April 2017TIME A ND EVENTS SCHE DULE ( Optimization Phase )
Phase Optimization Phase a
Visit Number 3.1b3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13c
Week 4 5 6 7 8 9 10 11 12 13 14 15 16
Day 28 32 39 46 53 60 67 74 81 88 95 102 109
Clinic (C) or remote MADRS only (RM) visit dC C C C CC or 
RM CC or 
RM CC or 
RM CC or 
RM C
Study Procedures
Administrative
ICF (transferred -entry subjects only) X
Inclusion/ exclusion criteria (transferred -entry 
subjects only)X
Efficacy Assessments (Clinician)
MADRS (7 -day recall): independent remote rater 
Permitted window: -[ADDRESS_199436] -completed Assessments
PHQ -9 fX X X X X X
SDS fX X X
GAD-7 fX X X X
EQ-5D-5LfX X X X X X
Study Drug
Intranasal treatment session X X X X XeX XeX XeX Xe
Adjustment of intranasal treatment session 
frequency (if applicable)X X
Dispensing oral antidepressant (open -label) X X X Xn
Dispense subject diary for oral antidepressant X
Oral antidepressant compliance check , including 
review of subject diaryX X X X X X X X
Collect/return of subject diary X
Drug accou ntability (intranasal study medication)rX X X X X X X X X X X
Drug accou ntability (oral antidepressant) X X X
Safety Assessments (S ite-completed )
Physical examination, nasal examination, weight X X X
Vital sign s (predose): blood pressure, pulse, 
respi[INVESTIGATOR_697], and temperaturef,q X X X X XeX XeX XeX XeX
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
54
Status: Approved , Date: 4 April 2017Phase Optimization Phase a
Visit Number 3.1b3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13c
Week 4 5 6 7 8 9 10 11 12 13 14 15 16
Day 28 32 39 46 53 60 67 74 81 88 95 102 109
Clinic (C) or remote MADRS only (RM) visit dC C C C CC or 
RM CC or 
RM CC or 
RM CC or 
RM C
Study Procedures
Vital signs (postdose): blood pressure, pulse, and 
respi[INVESTIGATOR_170428] g X X X X XeX XeX XeX Xe
12-lead ECGh,qX X XeXeX XeXe
C-SSRS (since last visit version)qX X X X XeX XeX XeX Xe
MOAA/S and pulse oximetryi,qX X X X XeX XeX XeX Xe
BPRS+ and CADSS j,qX X X X XeX XeX XeX Xe
CGADRkX X X X XeX XeX XeX Xe
PWC-20 (only for subjects not entering 
maintenance phase)X
Safety Assessments (Subject)
Nasal symptom questionnairelX X X X XeX XeX XeX Xc
BPIC -SS X X X X
Assess ment of Sense of Smell
UPSITf,pX
Smell Thre shold TestpX
Cognitive Testing
Computerized cognitive battery and HVLT -RfX
Clinical Laboratory Testsf
Hematology and chemistry X X X
Urinalysis X X X
Urine drug screen X X X
Alcohol breath test X X X
Urine pregnancy test X X X
Medical Re source Utilization
HRUQ X X X X X X
Biom arker s
Blood sample col lection (protein)f,mX X
Blood samp le collection (RNA)f,mX X
Blood samp le collection (DNA)f,mX X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
55
Status: Approved , Date: 4 April 2017Phase Optimization Phase a
Visit Number 3.1b3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13c
Week 4 5 6 7 8 9 10 11 12 13 14 15 16
Day 28 32 39 46 53 60 67 74 81 88 95 102 109
Clinic (C) or remote MADRS only (RM) visit dC C C C CC or 
RM CC or 
RM CC or 
RM CC or 
RM C
Study Procedures
Ongoing Su bject Review and Other
Menstrual cycle tracking (start date of last 
menstrual period prior to study visit)o X X X
Concomitant therapy Ongoing
Adverse events Ongoing
Footnotes:
Abbreviations : BPIC -SS = Bladder Pain/Interstitial Cystitis Symptom Score; BPRS+ = Four -item Positive Symptom s ubscale of the Brief Psychiatric Rating Scale; C = clinic visit;
CADSS = Clinician -Administered Dissociative States Scale; CGADR = Clinical Global Assessment of Discharge Readiness; CGI-S = Clinical Global Impression -Severity; C -SSRS = 
Columbia Suicide Severity Rating Scale; ECG = elect rocardiogram EQ -5D-5L =European Quality of Life (EuroQol) Group, 5 -Dimension, 5 -Level; GAD -7 = Generalized Anxiety 
Disorder, 7-item; HRUQ=Healthcare Resource Use Questionnaire; HVLT -R = Hopkins Verbal Learning Test -Revised; MADRS = Montgomery -Asberg Depression Rating Scale; 
MOAA/S = Modified Observer' s Assessment of Alertness/Sedation; PHQ -9 = Patient Health Questionnaire, 9-item; PWC -20 = Physician Withdrawal Checklist, 20-item; RM =Remote 
MADRS; SDS = Sheehan Disability Scale; UPSIT = University of Pennsylvania Smell Identification Test.
Note: On intranasal dosing days, time [ADDRESS_199437] intranasal spray.
a) If a subject withdraws before the end of the optimization phase for reasons other than withdrawal of consent, or is not eligible to continue into the maintenance phase , an Early 
Withdrawal Visit (Refer to Time and Events Schedule: Early Withdrawal/End of Maintenance Phase Visit and follow u p phase) should be conducted. If the Early Withdrawal Visit is 
conducted on the same day as a scheduled visit, duplicate assessments are not required.
b) Results for all assessments performed on Day [ADDRESS_199438] -entry subjects (Visit 2. 9) and transferred -entry subjects (Visit 2.10 of Study ESKETINTRD3001 or 
ESKETINTRD3002) will serve as the baseline values for the optimization phase and will not be repeated as part of Visit 3.1 . The Day 28 visit should coincide with Day 28 (Visit 3.1) 
for this study. All transferred -entry subjects must meet all of the transferred -entry subject -specific inclusion criteria and none of the exclusion criteria in order to be enrolled.
c) Visit 3.13 (Wee k 16) serves as the last visit for the optimization phase and will also be the first visit (Visit 4.1; Week 16) of the maintenance phase for subjects who qualify to 
continue. Results for all assessments preformed at this visit will also serve as baseline for the maintenance phase and will be completed before randomization to double-blind 
intranasal study drug.
d) Clinic visits (visit window ±3 days) will be conducted for all intranasal treatment sessions (weekly or every other week); otherwise only a remote MADRS (vi sit window: -3 days) 
will be conducted. 
e) Performed only at clinic visits for intranasal treatment sessions (omitted if remote MADR S only).
f) Predose (if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -related procedures during a clinic 
visit.
g) Postdose vit al signs will be performed at t = +40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.1for guidance for blood pressure monitoring on intranasal dosing 
days.
h) The 1 2-lead electrocardiogram will be performed at 1 hour postdose. A time window of ±15 minutes is permitted.
i) The MOAA/S will be performed every 15 minutes from predose to t = 1.5 hours postdose (please refer to Section 9.4for further guidance on MOAA/S assessments). Pulse oximetry 
will be performed every 15 minutes from predose to t = 1.5 hours postdose (please refer to Section 9.4for further guidance on timing of pulse oximetry assessments).
j) The BPRS+ and CADSS will be performed predose and at 40 minutes and 1.5 hours postdose.
k) The CGADR willbe performed at 1 hour and 1.5 hours postdose; if the response is not “Yes” at 1.5 hours postdose, the assessment will be rep eated every 15 minutes until a “Yes” 
response is achieved or until the subject is referred for appropriate medical care if clinica lly indicated. A subject should not be discharged prior to the 1.5 hour time point.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
56
Status: Approved , Date: 4 April 2017l) The nasal symptom questionnaire will be performed predose and at 1 hour postdose.
m) Blood samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet on the day of sample collection.
n) Additional 2-week supply of the oral antidepressant medication only for subjects entering the follow-up phase.
o) Only applicable to women with a menstrual cycle.
p) If the subject has significant nasal congestion on the day of a scheduled assessment of sense of smell, then the site should consider postponing the UPSIT or Smell Threshold Test (as 
applicable) to the next scheduled clinic visit.
q) If a subject has started a scheduled clinic visit in which an intranasal treatment session is planned, but then a predose observation (eg, blood pressure results) prompts the site staff to 
postpone the intranasal treatment session within the visit window, then all time points (including predose) of the footnoted assessments mu st be repeated on the actual intranasal 
treatment session day, as follows: vital signs (ie, blood pressure, pulse, respi[INVESTIGATOR_697], and temperature), 12 -lead ECG, C -SSRS (since last visit), MOAA/S, pulse oximetry, BPRS+, 
and CADSS.
r) Drug accountability for intranasal study medication should be performed weekly during Weeks 5 through 8 (inclusive) and then weekly or every other we ek from Weeks 9 through 15 
(inclusive) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
57
Status: Approved , Date: 4 April 2017TIME A ND EVENTS SCHE DULE ( Maintenance Phase )
Phase Maintenance Phase
Visit Number a,b4.1 c4.2 4.3 4.4 4.5 4.6 to 4.X
Study Procedure Frequency From Week 2 0Through End of Phase
Week 16 17 18 19 20Every 
weekEvery 
2weeksEvery 
4weeksEvery 
8weeksEvery 
12weeks
Day 109 116 123 130 137Every 
7daysEvery 
14daysEvery 
28daysEvery 
56daysEvery 
84days
Clinic (C) or Remote MADRS only (RM) 
visitaC C/RM C C/RM C C/RM C C C C
Study Procedures
Study Drug d
Randomization: Primary (subjects in stable 
remission after treatment with intranasal 
esketamine and an oral antidepressant) Xe
Randomization: Secondary (subjects with 
stable response after treatment with intranasal 
esketamine and an oral antidepressant)Xe
Intranasal treatment session (esketamine or 
placebo) X XfX XfX XfXf
Adjustment of intranasal treatment session 
frequency (if applicable)X X X
Dispensing oral antidepressant (open -label) X X X
Dispense subject diary for oral antidepressant X
Oral antidepressant compliance check , 
including review of subject diaryX X X X
Drug accountability for intranasal study 
medicationX XfX XfX Xf
Drug accountability for oral antidepressant X X
Efficacy Assessments (Clinician)
MADRS (7 -day recall)h–
independent, remote rater X X X X X
CGI-S X X Xf
Subject -com pleted Assessments
PHQ -9 iX X X
SDS iX X
GAD-7 iX X
EQ-5D-5L iX X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
58
Status: Approved , Date: 4 April 2017Phase Maintenance Phase
Visit Number a,b4.1 c4.2 4.3 4.4 4.5 4.6 to 4.X
Study Procedure Frequency From Week 2 0Through End of Phase
Week 16 17 18 19 20Every 
weekEvery 
2weeksEvery 
4weeksEvery 
8weeksEvery 
12weeks
Day 109 116 123 130 137Every 
7daysEvery 
14daysEvery 
28daysEvery 
56daysEvery 
84days
Clinic (C) or Remote MADRS only (RM) 
visitaC C/RM C C/RM C C/RM C C C C
Safety Assessments (S ite-completed)
Physical examination, nasal examination, and 
weightX X
Vital signs (predose): blood pressure, pulse, 
respi[INVESTIGATOR_697], and temperatures XfX XfX Xf
Vital signs (postdose): blood pressure, pulse, 
and respi[INVESTIGATOR_170428] j X XfX XfX Xf
12-lead ECG k,sX X X
C-SSRS (since last visit version)sXfX XfX Xf
MOAA/S and pulse oximetryl,sX XfX XfX Xf
BPRS+ and CADSS m,sX XfX XfX Xf
CGADR nX XfX XfX Xf
PWC-20 (performed at last clinic visit of this 
phase)
Safety Assessments (Subject)
Nasal symptom questionnaire oX X X X
BPIC -SS X X
Clinical Laboratory Testsi
Hematology and chemistry X X
Urinalysis (to be performed at same visit as 
BPIC -SS)X X
Urine drug screen X X
Alcohol breath test X X
Urine pregnancy test X X
Assess ment of Sense of Smell
UPSIT rX X
Smell Threshold Test rX
Cognition Testinge
Computerized cognitive battery and HVLT -R X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
59
Status: Approved , Date: 4 April 2017Phase Maintenance Phase
Visit Number a,b4.1 c4.2 4.3 4.4 4.5 4.6 to 4.X
Study Procedure Frequency From Week 2 0Through End of Phase
Week 16 17 18 19 20Every 
weekEvery 
2weeksEvery 
4weeksEvery 
8weeksEvery 
12weeks
Day 109 116 123 130 137Every 
7daysEvery 
14daysEvery 
28daysEvery 
56daysEvery 
84days
Clinic (C) or Remote MADRS only (RM) 
visitaC C/RM C C/RM C C/RM C C C C
Medical Resource Utilization
HRUQ X X X
Biom arker s
Blood sample collection (protein )i,pX
Blood sample collection (RNA) i,pX
Blood sample collection (DNA) i,pX
Ongoing Subject Review and Other
Menstrual cycle tracking (start date of last 
menstrual period prior to study visit)q X X
Concomitant therapy Ongoing
Adverse events Ongoing
Footnotes:
Abbreviations : BPIC -SS = Bladder Pain/Interstitial Cystitis Symptom Score. BPRS+ = Brief Psychiatric Rating Scale, positive symptom subscale; CAD SS = Clinician -Administered 
Dissociative States Scale; CGADR = Clinical Global Assessment of Discharge Readiness; CGI -S = Cl inical Global Impression -Severity; C -SSRS = Columbia Suicide Severity Rating 
Scale; EQ -5D-5L =European Quality of Life (EuroQol) Group, 5 -Dimension, 5 -Level; GAD -7 = Generalized Anxiety Disorder, 7 -item; HRUQ= Healthcare Resource Use Questionnaire ; 
HVLT -R = Hopkins Verbal Learning Test -Revised; MADRS = Montgomery -Asberg Depression Rating Scale; MOAA/S = Modified Observer 's Assessment of Alertness/Sedation; 
PHQ -9 = Patient Health Questionnaire, 9-item; PWC -20 = Physician Withdrawal Checklist, 20-item; S DS = Sheehan Disability Scale; UPSIT = University of Pennsylvania Smell 
Identification Test.
Note: On intranasal dosing days, time [ADDRESS_199439] intranasal spray.
a) Visits (clinic or remote contacts) will be conducted weekly during the maintenance phase . Clinic visits (visit window: ± 3 days) will be conducted for all intranasal treatment sessions 
(weekly or every other week) ; otherwise only a remote visit for MADRS (visit window: -3 days) will be conducted. Due to the variable durati onof this phase, following Visit 4.5visit 
numbers will continue sequentially (eg, 4. 6, 4.7 , etc) until the subject completes the phase. The frequency of study procedures from Week 20to the end of the phase is provided 
within the respective column (ie, every week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks). 
b) If a subject withdraws before the end of the maintenance phase for reasons other than withdrawal of consent, an Early Withdrawal Visit should be conducted . A subject meeting 
relapse criteria is not considered to be an early withdrawal subject ; for relapse subjects, and those subjects remaining rela pse-free at the time of study termination, an End of 
Maintenance Phase Visit should be conducte d. If the End of Maintenance Visit is conducted on the same day  as a scheduled visit, duplicate assessments are not required. Refer to the 
Time and Events Schedule: Early Withdrawal/End of Maintenance Phase Visit and F ollow -up Phase .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
60
Status: Approved , Date: 4 April 2017c) Visit 3.13 (Week 16) serves as the last visit for the optimization phase and will also be the first visit (Visit 4.1; Week 16) of the maintenance phase for subjects who qualify to 
continue. Results for all assessme nts performed at this Visit 3.13 of the optimization phase will also serve as baseline for the maintenance phase and will be completed before 
randomization to double -blind intranasal study drug. Duplicate assessments are not required.
d) Transferred -entry subjects who achieve stable remission or stable response in the optimization phase after treatment with an oral antide pressant plus intranasal placebo will continue 
to receive the same treatment in order to maintain the blinding for the ongoing short -term studies.
e) Performed prior to intranasal dose administration.
f) Performed only at clinic visits for intranasal treatment sessions (omit if remote contact [CONTACT_765]).
g) At the last clinic visit of this phase, an additional 2-week supply of the oral antidepressant medication is provided only for subjects entering the follow -up phase.
h) The last MADRS assessment performed prior to the first intranasal treatment session of the maintenance phase will be the baseline value for this phase. 
i) Predose (if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -relate d procedures during a clinic 
visit.
j) Postdose vital signs will be performed at t = +40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.1for guidance for blood pressure monitoring on intranasal dosing 
days.
k) At clinic visits for intranasal treatment sessions, the 12 -lead electrocardiogram will be performed at 1 hour postdose. A time window of ±15 minutes is permitted.
l) The MOAA/S will be performed every 15 minutes from predose to t = 1.5 hours postdose (please refer to Section 9.4for fur ther guidance on MOAA/S assessments). Pulse oximetry 
will be performed every 15 minutes from predose to t=1.5 hours postdose (please refer to Section 9.4for furth er guidance on timing of pulse oximetry assessments).
m) The BPRS+ and CADSS will be performed predose and at 40 minutes and 1.5 hours postdose.
n) The CGADR will be performed at 1 hour and 1.5 hours postdose; if the response is not “Yes” at 1.5 hours postdose, the assessment will be repeated every 15 minutes until a “Yes” 
response is achieved or until the subject is referred for appropriate medical care if clinically indicated.
o) At clinic visits for intranasal treatment sessions, the nasal symptom questionnaire w ill be performed predose and at 1 hour postdose.
p) Blood samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet on the day of sampl e collection.
q) Only applicable to women with a menstrual cycle.
r) If the subject has significant nasal congestion on the day of a scheduled assessment of sense of smell, then the site should consider postponing the UPSIT or Smell Threshold Test (as 
applicable) to the next scheduled clinic visit.
s) If a subject has started a scheduled clinic visit in which an intranasal treatment session is planned, but then a predose observation (eg, blood pressure results) prompt s the site staff to 
postpone the intranasal treatment session within the visit window, then all time points (including predose) of the footnoted assessments must be repeated on the actual intranasal 
treatment session day, as follows: vital signs (ie, blood pressure, pulse, respi[INVESTIGATOR_697], and temperature), 12 -lead ECG, C -SSRS (since last visit), MOAA/S, pulse oximetry, BPRS+, 
and CA DSS.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
61
Status: Approved , Date: 4 April 2017TIME A ND EVENTS SCHE DULE ( Early  Withdrawal/End of Maintenance Phase Visit and Follow -up Phase )
PhaseEarly Withdrawal//End of 
Maintenance P haseaFollow -up Phaseb
Visit Number EW/EMP 5.[ADDRESS_199440] Clinic Visit - 1 2
Clinic (C) or Remote Assessments Only (RA) Visit C RAfC
Study Procedures
Study Drug
Drug accountability (oral antidepressant study medication) X X
Dispensing of additional supply of new oral antidepressant (duloxetine, 
escitalopram, sertraline, or venlafaxine XR)X
Oral antidepressant compliance check X X
Collect/return of subject diary X
Safety Assessments (Site -Completed)
Physical examination X X
Nasal examination X X
Vital signs: blood pressure, pulse, respi[INVESTIGATOR_697], temperature X X
12-lead electrocardiogram X X
C-SSRS: Since last visit version X X
PWC-20 X X X
Safety Assessments (Subject -Com pleted)c
BPIC -SS X X
Efficacy Assess ments (Clinician -Completed)
MADRS (independent, remote blinded rater) X X X
CGI-S X X
Efficacy Assessments (Subject -Completed)c
PHQ -9 X X
SDS X X
GAD-7 X X
EQ-5D-5L X X
Assess ment of Sense of Smell
UPSITeX
Smell Threshold TesteX
Cognition testing
Computerized cognitive battery and HVLT -R X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
62
Status: Approved , Date: 4 April 2017PhaseEarly Withdrawal//End of 
Maintenance P haseaFollow -up Phaseb
Visit Number EW/EMP 5.[ADDRESS_199441] Clinic Visit - 1 2
Clinic (C) or Remote Assessments Only (RA) Visit C RAfC
Medical Resource Utilization
HRUQ X X
Clinical Laboratory Assessments
Hematology and chemistry X X
Urinalysis X X
Serum pregnancy test X X
Biom arker s
Blood sample collection (protein) X X
Blood sample collection (RNA) X X
Blood sample collection (DNA) X
Other Assessments
Menstrual cycle tracking (start date of last menstrual period prior to study visit)dX
Concomitant therapy X Ongoing
Adverse events X Ongoing
Footnotes:
Abbreviations : BPIC -SS = Bladder Pain/Interstitial Cystitis Symptom Score; CGI -S = Clinical Global Impression -Severity; C -SSRS = Columbia Suicide Severity Rating Scale; 
EQ-5D-5L= European Quality of Life (EuroQol) Group, 5 -Dimension, 5 -Level; GAD -7 = Generalized Anxiety Disorder, 7 -item; HRUQ= Healthcare Resource Use Questionnaire ; 
HVLT -R = Hopkins Verbal Learning Test -Revised; MADRS = Montgomery -Asberg Depression Rating Scale; PHQ-9 = Patient Health Questionnaire , 9-item; PWC -20=Physician 
Withdrawal Checklist, 20-item; RA=remote assessment only; SDS = Sheehan Disability Scale.
a) If a subject withdraws before the end of the induction, optimization, or maintenance phase for reasons other than withdrawal of consent, or has completed the induction or 
optimization phase but is not eligible to continue to the next treatment phase, an Early Withdrawal Visit should be conducted followed by [CONTACT_6591]-up phase. If the Early 
Withdrawal Visit is conducted on the same day as a scheduled visit, duplicate assessments are not required. A subject meeting relapse cri teria is not considered to be an early 
withdrawal subject ; for these subjects, and subjects currently in the maintenance p hase at the time the study is terminated, will conduct an End of Maintenance Phase V isit.For those 
subjects who relapse in the Maintenance phase, if clinically indicated based on investigator’s judgment, after completing the end of maintenance visit, the subject may proceed to the 
open -label safety extension study, 54135419TRD3008, without completing the follow up phase.  Similarly ,when the study is stopped, subjects in the Induction phase who are 
responders, after completing the early withdrawal visit, if clinically indicated based on the investigator’s judgment, may pr oceed to the 54135419TRD3008 study, without completing 
the foll ow up phase.
b) Visit window will be ±3 days.
c) Subject-reported outcome assessments should be administered before all other study -related procedures during a clinic visit.
d) Only applicable to women with a menstrual cycle.
e) If the subject has significant nasal congestion on the day of a scheduled assessment of sense of smell, then the site should consider postponing the UPSIT andSmell Threshold Test to 
the next scheduled clinic visit.
f) At the“Remote Assessment” visit, site staff will contact [CONTACT_170474][INVESTIGATOR_014].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
63
Status: Approved , Date: 4 April 2017ABBREVIA TIONS
AHI apnea -hypopnea index
ASA American Society of Anesthesiologists
AUC area under the plasma concentration -time curve
BDNF brain -derived neurotrophic factor
BPIC -SS Bladder Pain/Interstitial Cystitis Symptom Score 
BPRS (the full 18 -item) Brief Psychiatric Rating Scale
BPRS+ (the 4 -item) Brief Psychiatric Rating Scale, positive -symptom subscale
CADSS Clinician -Administered Dissociative States Scale
CGADR Clinical Global Assessment of Discharge Readiness
CGI-S Clinical Global Impression -Severity
Cmax maximum plasma concentration
CRF case report form
C-SSRS Columbia Suicide Severity Rating Scale
CYP cytochrome P450, with any appended letters (2B6, 3A4, etc) indicating subtypes
DSM -IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition
DSM -[ADDRESS_199442] electroconvulsive therapy
eDC electronic data capture
EQ-5D-5L European Quality of Life (EuroQol) Group, 5 -Dimension, 5 -Level (questionnaire)
EQ-VAS EuroQol Group: visual analogue scale
EU European Union
FT4 free thyroxine
GAD -7 Generalized Anxiety Disorder, 7 -item (scale)
GCP Good Clinical Practice
HIV human immunodeficiency virus
HRUQ Healthcare Resource Use Questionnaire 
HVLT -R Hopkins Verbal Learning Test - Revised
ICF informed consent form
ICH International Conference on Harmonisation 
IDMC Independent Data Monitoring Committee
IDS-C30 Inventory of Depressive Symptomatology -Clinician -rated, [ADDRESS_199443]
ITT intent -to-treat
IV intravenous
IWRS interactive web response system
MADRS Montgomery -Asberg Depression Rating Scale
MAOI monoamine oxidase inhibitor
MedDRA Medical Dictionary for Regulatory Activities
MINI Mini International Neuropsychiatric Interview
MMRM mixed -effects model for repeated measures
MOAA/S Modified Observer 's Assessment of Alertness/Sedation
MDD major depressive disorder
MGH- ATRQ [LOCATION_005] General Hospi[INVESTIGATOR_307] -Antidepressant Treatm ent Response Questionnaire
MGH- FRLHQ [LOCATION_005] General Hospi[INVESTIGATOR_307] -Female Reproductive Lifecycle and Hormones Questionnaire
NMDA N-methyl -D-aspartate
PAQ Patient Adherence (to Antidepressant Medication) Questionnaire
PCP phencyclidine
PHQ -[ADDRESS_199444], 20 -item
QTc QT interval corrected
QTcB QT interval corrected according to Bazett 's formula
QTcF QT interval corrected according to Fridericia 's formula
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
64
Status: Approved , Date: [ADDRESS_199445] Characteristics
SNRI serotonin -norepi[INVESTIGATOR_170429] 2 saturation of peripheral blood oxygen
SSRI selective serotonin reuptake inhibitor s
STOP -Bang Snoring, Tiredness, Observed Apnea, High Blood Pressure, Body Mass Index, Age, Neck Size, 
Gender (questionnaire)
S[LOCATION_003]R suspected unexpected serious adverse reaction
TEAE s t reatment -emergent adverse event s
TRD treatment -resistant depression
UPSIT University of Pennsylvania Smell Identification Test
US [LOCATION_002]
XR extended -release
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
65
Status: Approved , Date: 4 April [ZIP_CODE]. INTRODUCTION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness; is the 
second leading cause of years lost todisability  worldwide ;and is associated with excess 
mortality (the estimated median years of potential life lost is 10 years).134,135,140About 30% of 
patients fail to achieve remission despi[INVESTIGATOR_154841], and 
are considered to have treatment -resistant depression (TRD).44,113In patients who respond to 
antidepressants, the time to onset of effect is typi[INVESTIGATOR_897]  [ADDRESS_199446].26,33
Ketamine and esketamine (S-ketamine, the S enantiomer of ketamine) are approved and widel y 
used for the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration.65The desired analgesic -anesthetic effects of ketamine and esketamine are 
attributed to the blockade of ionotropic N-methy l-D-aspartate (NMDA) glutamate 
receptors.82,101,145
Monoamines (serotonin, norepi[INVESTIGATOR_238], and/or dopamine) are only modulatory  transmitters; 
therefore, conventional monoaminergic antidepressants would not be expected to robustly  affect 
synaptic transmission, activity -dependent release of brain -derived neurotrophic factor (BDNF), 
or synaptogenesis.33In contrast, the mechanism of action of ketamine and esketamine is distinct 
from conventional antidepressants because both ketamine and esketamine profoundly  affect fast 
excitatory  glutamate transmission, increase BDNF release, and stimulate s ynaptogenesis.[ADDRESS_199447] literature reports of the antidepressant effects of ketamine describe studies using IV 
administration of the racemate, with a few exceptions.71Janssen Research & Development (JRD) 
is developi[INVESTIGATOR_170430] ,which allows a lower volume tobe administered via the intranasal route .80,95,[ADDRESS_199448] comprehensive nonclinical and clinical information regarding esketamine
(JNJ-54135419), please refer to the latest edition of the Investigator 's Brochure .60
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
66
Status: Approved , Date: 4 April [ZIP_CODE].1. Backgroun d
1.1.1. Summary  of Nonclin ical Findings
Safety Pharmacology
The following text is quoted from the [LOCATION_002] (US) prescribing information for anesthetic 
Ketalar®(ketamine hy drochloride injection)65:
Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey and a rise in 
arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect observed 
in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is accompanied by a 
tachycardia, rise in cardiac output and a fall in total peripheral resistance. The pressor response to 
Ketalar is reduced or blocked by [CONTACT_154929] (central depressant andperipheral α-adrenergic 
blockade), by β -adrenergic blockade, and by [CONTACT_154930].
Findings from animal studies suggest that the increase in blood pressure produced by 
[CONTACT_113883]/esketamine is due to selective activation of central cardiac stimulating mechanisms 
leading to an increase in cardiac output.
In a 3-month repeat -dose toxicity  study with intranasall y administered esketamine in dogs, no 
relevant electrocardiogram (ECG) changes were noted up to the highest dose tested, 
ie,72mg/day . Heart ratewas slightl y increased. The cardiovascular safety  of racemic ketamine 
and esketamine in humans and animals is summarized in the Investigator’s Brochure .60
Toxicology
Repeat -dose Toxicity Studies
In repeat -dose toxicity  studies with intranasally  administered esketamine in rats up to 9 mg/day  
for 6 months, and dogs up to 72 mg/day for 3 months of duration, the clinical observations 
mainly  related to the central nervous sy stem (eg, changes in activity  and gait). No adverse effects 
were noted up to the highest dose tested, ie, 9 mg/day  in rats and 72 mg/day  in dogs. These 
observations reflected the (exaggerated) pharmacology  of the test compound. Minor histologic 
findings were noted in the nasal cavity . These tissue changes were not considered adverse.
In 3-and 9 -month repeat -dose toxicity  studies with intranasall y administered esketamine in dogs, 
no relevant ECG changes were noted up 72 mg/day . Heart r ate was slightl y increased. 
Further details can be found in the Investigator’s Brochure .60
Genetic Toxicity
A series of in vitro and in vivo genot oxicity  studies was conducted with ketamine and 
esketamine. The weight of evidence indicates that esketamine poses no genotoxic risk to 
humans.60
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
67
Status: Approved , Date: 4 April 2017Neurotoxicity
Racemic ketamine has been reported to induce neurotoxicity  in animal fetuses, and in juvenile, 
adolescent, and adult animals, as evidenced by [CONTACT_154931]. The precise thresholds for dose and duration of exposure causing neurotoxicity  in 
animals remain to be established. The relevance to humans of ketamine’s neurotoxic action in 
animals is unknown.
In studies exploring neurotoxic effects of ketamine on juvenile and prenatal monkey s, 
neuroapoptosis was observed to be more widespread in fetal brains than in neonatal brains, after 
administration of ketamine anesthesia IV for [ADDRESS_199449] severel y affected. In neonatal brains, the 
cerebellum was not affected; the strongest neuroapoptotic response was noted in the basal 
ganglia and several thalamic areas.
In juvenile rodents, ketamine induced apoptotic neurodegeneration was observed that was more 
widespread than in adult rodents, with the developi[INVESTIGATOR_154843]. 
Neuronal cell death was induced in the dorsolateral thalamus at blood levels of ketamine of 
14µg/mL  (7 times the human anesthetic blood level of approximately  2 µg/mL ).
No significant neuro toxic effects occurred in juvenile Rhesus monkey s if the anesthesia was 
administered as IM induction followed by [CONTACT_154932] 3 hours. Ketamine 
infusion for 9 or 24 hours increased neuronal cell death in the frontal cortex, but no significan t 
changes were noted in the hippocampus, thalamus, striatum, or amygdala. Cognitive 
impairments were observed beginning around 10 months of age, and persisted at 3.5 years of 
age.
The clinical studies will exclude neonates, infants, children, pregnant women, and breastfeeding 
women. Therefore, ketamine’s neurotoxicity  in juvenile animals does not represent a safet y risk 
to eligible adult subjects. Moreover, the large dosages and prolonged treatment durations 
associated with neurotoxicity  in juvenile animals do not suggest a concern.
Chronic treatment with ketamine at high dose levels affected the brain of adolescent monkey s, as 
evidenced b y histopathologic lesions and functional impairment. 
The neurotoxicity  of ketamine in adult animals is also associated with high dose levels, in 
contrast to the relatively  low dose levels of esketamine associated with antidepressant efficacy  in 
humans. In single -dose and 14-day repeated -neurotoxicity  studies with intranasall y administered 
esketamine in rats, no histopatholo gic brain lesions were noted even upon high exposures, as 
achieved at 54 mg/day  in the 14-day study. In the 6-month rat and 9-month dog repeat -dose 
toxicology  studies with intranasall y administered esketamine, where the animals were of 
adolescent age at initiation of trea tment, and in the pre-and post-natal developmental toxicit y 
study  in rats, no evidence of neurotoxicity  was found. Consequentl y, the risk of neurotoxicity  
associated with intranasal administration of esketamine to adult and adolescent patients is 
considered low.60
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
68
Status: Approved , Date: [ADDRESS_199450] current.39The inhibitory action on membrane 
currents may  partl y explain the species and tissue differences in inotropic responses to ketamine.
Blood pressure responses to ketamine also vary with the laboratory  species and with 
experimental conditions. Blood pressure is increased in normotensive and renal hy pertensive rats 
with and without adrenalectom y and under pentobarbital anesthesia. The US prescribing 
information for the anesthetic Ketalar®(ketamine hy drochloride [HCl] for injection) provides the 
following guidance. 
Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey  and a 
rise in arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular 
effect observed in man. The pressor response to Ketalar injected into intact, unanesthetized 
dogs is accompanied by a tachycardia, rise in cardiac output and a fall in total peripheral 
resistance. It causes a fall in perfusion pressure following a large dose . The tachycardia and 
increase in myocardial contractile force seen in intact animals does not appear in isolated 
hearts . These observations support the hypothesis that the hypertension produced by [CONTACT_170475] l cardiac stimulating mechanisms leading to an 
increase in cardiac output. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
69
Status: Approved , Date: [ADDRESS_199451] predictive species in terms of ketamine’s cardiovascular 
effects in humans, but the antidepressant effects of ketamine were studied only in rod ent models. 
The myocardial contractility  effects and blood pressure responses to ketamine vary between 
species.60Consequently , a margin of safety  could not be reliably  derived from the available 
animal data.
Overall Conclusion
The currentl y available nonclinical safety  studies support chronic intranasal administration of 
esketamine in human subjects up to a dosage of 84 mg/day .
Further details can b e found in the Investigator’s Brochure .60
1.1.2. Clinical Studies
[IP_ADDRESS]. Pharmacokinetics and Product Metabolism
Metabolism
Excretion
Intravenous Esketamine 
 
  
 
 
 
 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
70
Status: Approved , Date: 4 April 2017Intranasal Esketamine
, 
 
 
 
 
 
 
 
 
 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
71
Status: Approved , Date: 4 April [ZIP_CODE].1.2.2. Pharmac odynamics and Efficacy
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
72
Status: Approved , Date: 4 April 2017





[IP_ADDRESS]. Safety  and Tolerability
Ketamine is a rapi[INVESTIGATOR_2478] y acting general a nesthetic that is approved and widel y used intravenousl y or 
intramuscularl y for the induction and maintenance of anesthesia in children and adults at a dose 
of 1 to 3 mg/kg given as a bolus. Ketamine is marketed as a racemic mixture and in Europe also 
as the S-enantiomer, esketamine. Ketamine was first introduced as an anesthetic in [ADDRESS_199452] an ex cellent medical safet y profile.51,66,108,125
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
73
Status: Approved , Date: 4 April 2017Adverse Events Associated With Short -term Use of Intranasal Esketamine in Patients with 
MDD
According to the SmPC for esketamine ,66the following are reported as common adverse effects: 
transient tach ycardia, vivid dreams (including nightmares), nausea and vomiting, increased blood 
pressure, increased salivation, blurred vision, dizziness, motor unrest, increase in vascular 
resistance in pulmonary  circulation and increase in mucus secretion, increased oxygen 
consumption, laryngospasms, and temporary  respi[INVESTIGATOR_2477]. It is reported that the risk of 
respi[INVESTIGATOR_170431] t ypi[INVESTIGATOR_154848] .64
Administration of esketamine is associated with a number of adverse events, which are transient 
in nature and typi[INVESTIGATOR_1306] y resolve in 2 hours or less from the start of drug administration. The 
Phase 1 study  ESKETINTRD1003 evaluated the pharmacokinetics and safet y of a single 
intranasal esketamine 28 mg in 14 healthy  elderly  subjects (65 years of age, with 3 subjects 
75years of age) and 20 healthy  younger adult subjects (18 to 55 years of age, inclusive).15The 
incidences of the treatment -emergent adverse events (TEAEs) were slightly  higher in young 
subjects (100% [20 subjects]) as compar ed with elderly  subjects (85.7% [12 subjects]). The most 
commonly  reported TEAEs by [CONTACT_11702] (>20%) in elderl y subjects were dysgeusia and 
vertigo (9 [64%], of 14 subjects each).
In Panel A of the Phase 2 study  with intranasal esketamine (ESKETINTRD2 003), the most 
common TEAEs (>10% of subjects in the pooled esketamine treatment groups) during the 
double -blind phase were : dizziness, headache, dissociation, dysgeusia (metallic taste), nausea, 
dissociative disorder, and oral hypoesthesia.116Dissociative symptoms were the most typi[INVESTIGATOR_170432]. Transient 
perceptual changes (dissociation), dizziness, and nausea were typi[INVESTIGATOR_154850] y after 
drug admini stration, resolving b y [ADDRESS_199453] experienced a serious adverse event of esophagitis in Panel A (double -blind phase, 
placebo/placebo treatment group). A total of [ADDRESS_199454] in the placebo/esketamine [ADDRESS_199455] in the esketamine group 
(84mg/esketamine 84mg) experienced a TEAE of dissociative disorder (verbatim term: 
dissociative syndrome) of moderate intensity  on Day 8 of Period 2 (day of the third esketamine 
84mg dose in the study ). The subject discontinued from the study due to the event of 
dissociative disorder, which resolved on the same day. The investigator considered the event to 
be very  likel y related to the study agent.116
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
74
Status: Approved , Date: 4 April 2017Dissociative symptoms measured on the Clinician -Administered Dissociative States Scale 
(CADSS) were dose-dependent and were observed to reduce significantly  with multiple doses 
over 2 weeks. No psychotic symptoms were seen. Transient increases in mean blood pressure 
(systolic and diastolic) were observed post dose following the intranasal esketamine 
administration.
Themean (SD) peak sy stolic blood pressure after the first administration in e ach dose group
was:
Placebo: 124.2 (11.51 )mm Hg (mean [SD] increase of 5.4 [7.84 ]mm Hg)
28 mg: 131.8 (15.49 )mm Hg (mean [SD] increase of 10.4 [10.44 ]mm Hg)
56 mg: 130.4 (18.64 mm Hg (mean [SD] increase of 11.2 [15.01 ]mm Hg)
84 mg: 146.1 (19.9 )mmHg (mean [SD] increase of 17.1 [15.5 ]mm Hg)
Mean (SD) peak diastolic blood pressure after the first administration in each dose group 
was: 
Placebo: 81.2 (8.36 )mm Hg (mean [SD] increase of 3.8 [7.99 ]mm Hg)
28 mg: 85.7 (9.16 )mm Hg (mean [SD] increase of 6.5 [7.00 ]mm Hg)
56 mg: 86.5 (11.34 )mm Hg (mean [SD] increase of 7.2 [9.67 ]mm Hg)
84 mg: 87.8 (10.62 )mmHg (mea n [SD] increase of 8.1 [9.12 ]mm Hg)
The blood pressure increase ty pi[INVESTIGATOR_1306] y resolved within 2 hours. Unlike dissociative sy mptoms, the 
blood pressure changes observed do not appear to attenuate over time with multiple doses. 
Transient increases in heart rate were also observed in parallel with blood pressure change. There 
was no clinicall y meaningful change in blood ox ygen level.
Adverse Events Associated With Chronic Use of Ketamine
There are no controlled studies of long-term use with esketamine/ketamine in patients with 
MDD. Much of the literature on chronic use of ketamine comes from data gathered from 
street/illegal use of the drug, rather than sy stematically  conducted clinical studies. Data therefore 
should be interpreted with caution, as in many  cases, no baseline pre-drug data are available and 
drug exposure is poorly  documented.
In a 1-year longitudinal study , 150 subjects were divided into 5 groups of 30 subjects each: 
frequent ketamine users (more than 4 times per week), infrequent ketamine users (at least once a 
month), abstinent users (abstinent for at least 1 month), polydrug controls, and non- users of illicit 
drugs.88Eighty  percent of the participants were retested at the end of 1 year. Cognitive deficits 
(including impairment in spatial working memory , pattern recognition memory ,and category 
fluency ) were mainl y observed in frequent users and not with the infrequent users. Short -lasting, 
dose-dependent effects of psychosis were associated with ketamine users. There was no increase 
in symptoms over time, and symptoms were completely  reversible upon stoppi[INVESTIGATOR_154851]. As noted, these data should be interpreted with caution, as baseline data predating 
drug use were not available. Furthermore, in their recent review, Morgan and Curran report that 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
75
Status: Approved , Date: [ADDRESS_199456] findings are that frequent ketamine users (more than 5 times a week) exhibit impairments 
in both short -and long-term memory .87Although dosages have varied, dosages reported by 
[CONTACT_170476]. Memory  impairments may be reversible when 
individuals stop using the drug, as they were not found in a group of [ADDRESS_199457] common 
symptoms are frequency and urgency  of urination, dysuria, urge incontinence, and occasionall y 
painful hematuria (blood in urine). Computerized tomograph y scans of these subjects revealed a 
marked thickening of the bladder wall, a small bladder capacit y, and perivesicular stranding 
consistent with severe inflammation. At cystoscopy , allpatients had severe ulcerative cystitis. 
Biopsies in [ADDRESS_199458] remaining static.
Abuse Liability, Dependence, and Withdrawal
There are a number of reports of ketamine dependence in the literature ,56,61,84,99but no large -
scale studies, and so the incidence of ketamine dependence is largely  unknown.86An interview 
study  of 90 ketamine users found that 57% of frequent users, 43% of infrequent users, and 60% 
of ex -users expressed con cerns about ketamine addiction .89The majority  of frequent users in that 
study  reported using the drug without stoppi[INVESTIGATOR_154853], so compulsive patterns of 
behavior are also a concern. Oral ketamine has also been evaluated as a positive control in
human abuse potential studies, with dosages of 65 mg and 110 mg reported as appropriate for 
use as positive controls for future abuse potential studies of compounds with a similar 
mechanism of action or with possible perception -altering effects.123There is conflicting evidence 
of the existence of a "withdrawal syndrome "after cessation of ketamine use.86Cravings seem to 
be a key problem in frequent users: 28 of the 30 daily  users in 1 study  reported having tried to 
stop taking the drug but failed; all reported ketamine cravings as the reason for failure .86The 
same study  found that 12 of the 30 daily  users reported withdrawal symptoms characterized by 
[CONTACT_112344] , shaking, sweating, and palpi[INVESTIGATOR_154854]. A few published case 
studies also show craving and somatic and psychological aspects of anxiety  as withdrawal 
symptoms .20,76However, a specific ketamine withdrawal s yndrome has not y et been described.86
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
76
Status: Approved , Date: 4 April 2017Please refer to the Investigator’s Brochure for a summary  of the adverse events reported in 
ketamine and esketamine studies.60
1.1.3. Marketing Experience
No intranasal formulation of esketamine is currently  marketed.
1.2. Active Comparators
Subjects will be assigned to receive 1 of 4 commerciall y available oral antidepressant 
medications from 2 different classes of antidepressant medications, selective serotonin reuptake 
inhibitors (SSRI s: escitalopram or sertraline), or serotonin and norepi[INVESTIGATOR_59446] (SNRI s: duloxetine or venlafaxine extended release [XR]). The oral antidepressant 
medication will be started on Day 1  of the open -label induction phase and continued in the 
optimization , maintenance , and follow -up (if clinically  indicated) phases.
The indications and safety information provided below for each oral antidepressant are from the 
[LOCATION_002] (US) prescribing information .32,32,75,132For further information, please refer to the 
appropriate package insert applicable to the local country  in which the study  is being conducted.
In the US, all of the oral antidepressant options include a black box warning in the prescribing 
information regarding suicidality  and antidepressant drugs. The black box warning informs the 
prescriber that antidepressant treatments increased the risk compared with placebo of suicidal 
thinking and behavior (suicidality ) in children, adolescents, and young adults in short -term 
studies of MDD and other psychiatric disorders. It states that anyone considering using the 
antidepressant in this population must balance the risk with the clinical need. Refer to the US
prescribing information for the entire content of the black box warning.
1.2.1. Selective Serotonin Reuptake Inhibitors
[IP_ADDRESS]. Escitalopram
Escitalopram is indicated in adults for acute and maintenance treatment of MDD and acute 
treatment of generalized anxiety  disorde r.
The starting dosage for MDD in the US prescribing information is [ADDRESS_199459] been seen at 20 mg/day  dose.
In adult MDD subjects treated with escitalopram, the most commonly  observed adverse reactions 
with escitalopram (incidence of approximately  5% or greater and approximately  twice the 
incidence in placebo subjects) were insomnia, ejaculation disorder (primarily  ejaculatory  delay), 
nausea, sweating increased, fatigue, and somnolence.
Contraindications to the use of escitalopram include serotonin s yndrome and monoamine oxidase 
inhibitor (MAOI) use (concomitant use with MAOIs intended to treat psychiatric disorders, 
linezolid, or IVmethy lene blue; use within 14 days of stoppi[INVESTIGATOR_154855] [in addition, an MAOI should not be used within 14 days 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
77
Status: Approved , Date: 4 April 2017of stoppi[INVESTIGATOR_154856]] ); concomitant use with pi[INVESTIGATOR_3924]; and known hypersensitivity  to 
escitalopram or citalopram or any  of the inactive ingredients.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation of 
escitalopram treatment is recommended whenever possible.
[IP_ADDRESS]. Sertraline
Sertraline hydrochloride is indicated in adults for the treatment of MDD, obsessions and 
compulsions in patients with obsessive compulsive disorder, panic disorder (with or without 
agoraphobia), post-traumatic stress disorder, premenstrual dysphoric disorde r, and social anxiet y 
disorder.
According to the US prescribing information, sertraline should be administered at a dose of 
50mg once daily for the treatment of MDD. While a relationship between dose and effect has 
not been established for MDD, obsessive compulsive disorder, panic disorder, post-traumatic 
stress disorder, or social anxiety  disorder, patients were dosed in a range of 50- 200 mg/day  in the 
clinical trials demonstrating the effectiveness of sertraline for the treatment of these indications. 
Consequent ly, a dose of 50 mg, administered once daily, is recommended as the initial 
therapeutic dose. Patients not responding to a 50 mg dose may benefit from dose increases up to 
a maximum of 200 mg/day . Given the 24-hour elimination half-life of sertraline, dose changes 
should not occur at intervals of less than 1 week. The maximum dose of sertraline in the current 
study  is 200mg/day .
Contraindications to the use of sertraline include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stoppi[INVESTIGATOR_154857]); concomitant use with pi[INVESTIGATOR_3924]; and known hy persensitivity  to sertraline or a ny of the 
inactive ingredien ts.
In adult subjects, the most common TEAEs associated with the use of sertraline (incidence of at 
least 5% for sertraline or at least twice that for placebo within at least one of the indications) 
were ejaculation failure, dry mouth, increased sweating, somnolence, tremor, dizziness, fatigue, 
pain, malaise, abdominal pain, anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, 
agitation, insomnia, and decreased libido.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation treatment is 
recommended whenever possible.
1.2.2. Serotonin and Norepi[INVESTIGATOR_75618]
[IP_ADDRESS]. Duloxetine
Duloxetine is indicated in adults for MDD, generalized anxiety  disorder, diabetic peripheral 
neuropathic pain, fibromyalgia, and chronic musculos keletal pain.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
78
Status: Approved , Date: 4 April 2017The starting dosage for MDD in the US prescribing information is 40 to 60 mg/day . The dosage 
for acute treatment is 40 to 60 mg/day , with maintenance treatment at 60 mg/day . For some 
patients, it may  be desirable to start at [ADDRESS_199460] to 
the medication before increasing to 60 mg once daily .
In the current study , subjects should be initiated with 60 mg/day . Subjects that have in the past 
shown increased sensitivity  towards SSRI /SNRI s can, at the discretion of the treating physician, 
be started on a 30 mg dose and up -titrated to the therapeutic range of 60 mg by  [CONTACT_154904] 
2 of the open -label induction phase. 
The maximum dosage is 120 mg/day , although there is no eviden ce that dosages greater than 
60mg/day  confer any additional benefits. The maximum dose to be used in this study  is 
60mg/day .
For pooled studies for all approved indications, the most commonly  observed adverse reactions 
in duloxetine -treated subjects (incidence of at least 5% and at least twice the incidence in 
placebo subjects) were nausea, dry  mouth, somnolence, fatigue, constipation, decreased appetite, 
and hyperhidrosis. As observed in diabetic peripheral neuropathy  studies, duloxetine treatment 
worsens gl ycemic control in some subjects with diabetes.
Contraindications to the use of duloxetine include use of an MAOI  concomitantly  or within 
2weeks of MAOI use ; and use in patients with uncontrolled narrow -angle glaucoma.
A gradual reduction in the dosage rather than abrupt cessation is recommended whenever 
possible.
[IP_ADDRESS]. Venlafaxine Extended- release
Venlafaxine XR is indicated in adults for MDD and social anxiety  disorder.
The starting dosage for MDD in US prescribing information is 75 mg/day (in some patients, 
37.5 mg/day  for 4 to 7days), with a dosage increase by 75 mg/day  at intervals of 4 days or 
longer, and a maximum dosage of 225mg/day . Dosage reductions are recommended for hepatic 
impairment (including mild) and renal impairment.
Contraindications to the use of venlafaxine XR include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IVmethy lene 
blue; use within 14 days of stoppi[INVESTIGATOR_154857]); concomitant use with pi[INVESTIGATOR_3924]; and known hy persensitivity  to venlafaxine XR or any 
of the inactive ingredients.
In adult subjects with MDD, adverse events in short -term studies that occurred in at least 5% of 
the subjects receiving venlafaxine XR capsules and at a rate at least twice that of the placebo 
group were abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous s ystem complaints (dizziness, somnolence, and abnormal dreams), and sweating.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
79
Status: Approved , Date: [ADDRESS_199461] indications, a dose-related increase in supi[INVESTIGATOR_154859]-treated patients. Across all clinical studies, 1.4% of subjects in 
the venlafaxine XR-treated groups experienced a 15-mm Hg increase in supi[INVESTIGATOR_154860], with blood pressure 105mm Hg, compared with 0.9% of subjects in the placebo 
groups. Similarly , 1% of subjects in the venlafaxine XR-treated groups experienced a 
20-mmHg increase in supi[INVESTIGATOR_9219], with blood pressure 180 mm Hg, 
compared with 0.3% of subjects in the pla cebo groups.
A gradual dosage reduction, individualized as necessary , is recommended to avoid 
discontinuation sy mptoms.
1.3. Overall Rationale for the Study
In contrast to available data about short -term antidepressant effects of esketamine/ketamine, 
much less is known about how to sustain the antidepressant effect over the long term. No 
systematic studies have yet described sustaining the response to ketamine . The only available 
data are case reports and anecdotal reports from clinicians who have been using ketamine over 
extended periods of time to sustain the initial response to ketamine.7On average, the duration of 
response from a single IVdose of ketamine is approximately  [ADDRESS_199462] IVsession following repeated administration studies (up to 6 sessions over 
2 weeks) varies highl y between subjects; the time to relapse has been reported as a median of 
18days (range, 2 to >83 days)90or a mean of 16 days (range, 7 to 28 days).[ADDRESS_199463] with continuation of 
pharmacotherap y. The relapse rates in these studies are typi[INVESTIGATOR_170433] 50% within [ADDRESS_199464] are extremely  high: 
remission may be lost as early  as the first few weeks after the acute course,63~65% in 
3months,73and 84% at 6months.114Relapse rates after ECT are reduced with pharmacotherap y 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
80
Status: Approved , Date: 4 April 2017alone: 60% at 6 months on nortripty line alone and 39% at [ADDRESS_199465] prevented nearl y 100% of the subjects from 
relapsing.[ADDRESS_199466] .As outlined below , 
the sponsor designed this study using anindividualized approach ,with the frequency  of 
intranasal esketamine treatment sessions driven by [CONTACT_170477] y of depressive symptoms.
2. OBJECTIVES A ND HYPOT HESIS
2.1. Objectives
Primary Objective
The primary  objective of this study  is to assess the efficacy  of intranasal esketamine plus an oral 
antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo 
in delay ing relapse of depressive symptoms in subjects with TRD who are in stable remission
(see Section 3.1.2 , Definitions of Terms) after an induction and optimization course ofintranasal 
esketamine plus an oral antidepressant.
Secondary Objective s
To assess the efficacy  of intranasal esketamine plus an oral antidepressant compared with an 
oral antidepressant (active comparator) plus intranasal placebo in delay ing relapse of 
depressive symptoms in subjects with TRD with stable response (but who are not in stable 
remission) (see Section 3.1.2 , Definitions of Terms) after an induction and optimization 
course of intranasal esketamine plus an oral antidepressant
To assess the effect of intranasal esketamine plus an oral antidepressant compared with an 
oral antidepressant (active comparator) plus intranasal placebo on:
Depressive s ymptoms
Overall severity  of depressive illness
Functional impairment and associated disability  
Anxiety  symptoms
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
81
Status: Approved , Date: 4 April 2017Health-related qualit y of life and health status
To investigate the safet y and tolerability  of intranasal esketamine plus an oral antidepressant
compared with an oral antidepressant (active comparator) plus intranasal placebo in subjects 
with TRD, with special attention to the following:
Treatment -emergent adverse e vents (TEAEs) , including AEs of special interest
Local nasal tolerability
Effects o n heart rate, blood pressure, respi[INVESTIGATOR_2842], and blood oxy gen saturation
Effects on alertness and sedation 
Potential psy chosis -like sy mptoms
Dissociative sy mptoms
Potential effects on cognitive function
Potential effects on suicidal ideation/behavior
Potential treatment- emergent s ymptoms of cy stitis and/or lower urinary  tract sy mptoms
Potential withdrawal and/or rebound symptoms following cessation of intranasal 
esketamine treatment
Potential effects on sense of smell
Exploratory Objective
To assess the potential relationship of biomarkers with response/non- response to intranasal 
esketamine plus an oral antidepressant or to an oral antidepressant plus intranasal placebo in 
adult subjects with TRD.
To assess m edical resource utilization .
2.2. Hypothesis
The hypothesis for this study  is that intranasal esketamine plus an oral antidepressant is more 
effective than treatment with an oral antidepressant plus intranasal placebo in delay ing relapse of 
depressive s ymptoms in subject s with TRD in stable re mission.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, double -blind, parallel- group, active -controlled, multicenter study  to 
evaluate the efficacy , safety , and tolerability  of intranasal esketamine plus an oral antidepressant 
compared with an oral antidepressant (active comparator) plus intranasal placebo in delay ing 
relapse of depressive symptoms in adult men and women with TRD who are in stable remission 
after an induction and optimization course with intranasal esketamine plus an oral antidepressant. 
Approximately 211 subjects in stable remission (see Section 3.1.2 , Definition of Terms ) at the 
end of the optimization after treatment with intranasal esketamine plus an oral antidepressant 
will be randomized in a 1:1 ratio to either continue intranasal esketamine (same dose) or be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
82
Status: Approved , Date: 4 April 2017switched to intranasal placebo; all subjects will continue the same oral antidepressant, at the 
same dose.
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study 
(seeSection 11.8).
3.1.1. Study Phases
Subjects will enter the study  either directly  (referred to as direct -entry  subjects) or after 
completing the double -blind induction phase of a short -term study  (ESKETINTRD3001 or 
ESKETINTRD3002) (referred to as transferred- entry  subjects) . 
The study  has 5 phases:
A 4-week screening/prospective observational phase, with an optional taper of up to 3 weeks 
for oral antidepressant medication(s) (direct -entry  subjects only )
A 4-week open-label induction phase (direct- entry  subjects onl y)
A 12-week optimization phase (open -label for direct -entry subjects and double -blind for 
transferred- entry  subjects)
A maintenance phase (variable duration)
A 2-week follow -up phase 
The maximum duration of a subject 's participation will be variable, depending on whether he or 
she enters the study  directly  or is transferred from one of the double -blind short -term studies, and 
whether he or she meets phase -specific criteria (eg, meets criteria for response at the end of the 
induction phase, is in stable remission/response at the end of the optimization phase, and when 
and if he or she relapse sin the maintenance phase). Direct -entry  subjects may  participate in up to 
5 phases and transferred- entry  subjects may  participate in up to 3 phases. 
The study  will be stopped once 84 relapses (in the subjects with stable remission) occur durin g 
the maintenance phase, or earlier based on the results of the interim analy sis for efficacy . At the 
time the study  is stopped, subjects in the induction phase will be able to complete theInduction
phase . Those subjects who are responders after completing an Early Withdrawal Visit may 
proceed to the 54135419TRD3008 study  without completing the follow up phase. Those who are 
not responders will have an Early Withdrawal Visit and proceed directly  to the follow-up phase.
Subjects who are in the optimization or maintenance phase at the time the study  is terminated 
will have an Earl y Withdrawal Visit /End of Maintenance Visit conducted and proceed directly  to 
the follow- up phase .
Screening/Prospective Observational Phase
Direct -entry  subjects will participate in this phase, which prospectively  assesses treatment 
response to the subject’s current oral antidepressant treatment regimen. 
At the start of the screening/prospective observational phase, the subject must have had 
documented non-response to at least 1 antidepressant treatment (based on MGH -ATRQ) in the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
83
Status: Approved , Date: [ADDRESS_199467] istaking a different oral antidepressant treatment
(listed on the MGH -ATRQ ) for at least the previ ous 2 weeks at or above the minimum 
therapeutic dose. This antidepressant treatment, as well as any other ongoing medications being 
taken for depression at screening (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue 
from the start of Week 1 through the end of Week 4 of the screening/prospective observational 
phase. Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment 
is to remain at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end of 
Week 4.
After 4 weeks, subjects who are non-responders to their current oral antidepressant treatment 
may be eligible to proceed to the open -label induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥28 on Week 2 and Week 4. 
Eligible subjects who are entering the open -label induction phase will discontinue all of their 
current antidepressant treatment(s), including adjunctive/augmentation therapi[INVESTIGATOR_014]. Of note, 
subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6 mg/day  of 
lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospec tive observational phase can continue these medications. No dose 
increases beyond the equivalent of 6 mg/day  lorazepam, or new benzodiazepi[INVESTIGATOR_170434]/prospective observational phase. If clinically  indicated, a subject’s current 
antidepressant treatment(s) may be tapered and discontinued over an additional, optional period 
of up to [ADDRESS_199468] -entry  subjects will receive intranasal esketamine (flexible dose: 56 mg or 84 mg) 
treatment sessions twice weekl y for 4 weeks. In addition, all subjects will initiate a new, open -
label oral antidepressant on Day  1 that will be taken daily  for the duration of the induction phase. 
The assigned oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine extended release [XR]), that the subject has not 
previously  had a non-response to in the current depressive epi[INVESTIGATOR_1865], has not been previously  
intolerant to (lifetime), and is available in the participating country .
Subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6 mg/day  of 
lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospective observational phase can continue these medications during the 
induction phase. No dose increases beyond the equivalent of 6 mg/day  of lorazepam, or new 
benzodiaz epi[INVESTIGATOR_154823], with the exception of the 
use of permitted benzodiazepi[INVESTIGATOR_154824] (post -dose on the dosing day  only).
Subjects will self -administer (under clinical supervision) open -label intranasal esk etamine during 
a scheduled treatment session twice a week for 4 weeks, with titration to a dose individualized 
per efficacy  and tolerability  (either 56 or 84 mg). At the end of the induction phase, subjects who 
are responders (defined as 50% reduction in the MADRS total score from baseline [Day  [ADDRESS_199469] intranasal dose] to the end of the 4-week open -label induction phase) may be eligible 
to proceed to the optimization phase. All subjects who do not proceed to the optimization phase
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
84
Status: Approved , Date: [ADDRESS_199470] anEarly  Withdrawal Visit conducted and proceed to the follow -up phase 
(seeSection 3.1.2 ).
At the time the study  is stopped, subjects in the induction phase will be able to complete the 
phase. Those who are responders, after completing an Early  Withdrawal Visit, may proceed to 
the 54135419TRD3008 study  without completing the follow up phase. Those who are not 
responders will have an Early Withdrawal Visit conducted and proceed directl y to the follow -up 
phase.
Optimization Phase
Eligible direct -entry  subjects from the open -label induction phase and transferred- entry  subjects 
from the 2 double -blind short -term studies (ESKETINTRD3001 and ESKETINTRD3002) will 
participate in this 12-week phase .
The intranasal treatment session frequency  will be reduced from that in the induction phase 
(twice weekl y) to weekly  for the first 4weeks of this phase. After the first 4weeks, the 
frequency  of intranasal treatment sessions will be individualized to either once weekly  or once 
every  other week based on the severit y of depressi ve sy mptoms , as assessed by  [CONTACT_170478]. Thedose of intranasal esketamine will remain unchanged from the dose at the end of the 
induction phase. All subjects will continue taking the same oral antidepressant treatment (at the 
same dosage) that was initiated during the induction phase.
At the end of the optimization phase, subjects in stable remission and those with stable response 
(but who are not in stable remission) may be eligible to continue into the maintenance phase; all 
other subjects will have an Early Withdrawal V isit conducted and proceed to the follow -up 
phase.
For subjects in stable remission and those with stable response at the end of this phase, the last 
visit of the optimization phase (Visit 3.13; Week 16) also serves as the baseline visit (Visit 4.1; 
Week 16) of themaintenance phase. Subjects eligible for the maintenance phase will be 
randomized and receive their first double -blind intranasal treatment session of the maintenance 
phase at this visit. 
At the time the study  is stopped, subjects in the optimization phase will have an Early 
Withdrawal V isit conducted and proceed d irectl y to the follow -up phase.
Maintenance P hase
On Day  1 of this phase:
Approximately  211 subjects in stable remission at the end of the optimization phase (after 
treatment with intranasal esketamine plus an oral antidepressa nt) will be randomized in a 
1:1ratio to either continue with intranasal esketamine (same dose) and the same oral 
antidepressant or to continue with the same oral antidepressant (active comparator) but 
switch to intranasal placebo. The primary  efficacy  analysis will be performed for these 
subjects only . 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
85
Status: Approved , Date: 4 April 2017Additionally , subjects with stable response (but who are not in stable remission) at the end 
of the optimization phase (after treatment with intranasal esketamine plus an oral 
antidepressant) will be randomized in a 1:1 ratio (using aseparate randomization list) to 
either continue with intranasal esketamine (same dose) and the same oral antidepressant or 
to continue with the same oral antidepressant (active comparator) but switch to intranasal 
placebo (for a secondary  efficacy  anal ysis onl y). 
Transferred -entry  subjects who achieve stable remission or stable response at the end of the 
optimization phase after treatment with an oral antidepressant plus intranasal placebo will 
continue to receive the same treatment in order to maintain the blinding for the ongoing 
short -term studies. These subjects will not be included in the efficacy  analyses, but will be 
included in safet y anal yses.
The frequency  of intranasal treatment sessions will be further individualized during the 
maintenance phaseto once weekl y or once every  other week based on the severit y of depressive 
symptoms, as assessed by [CONTACT_170468] . Subjects will only be permitted to switch 
from weekl y to every  other weekl y dosing a total of [ADDRESS_199471] 1 dose of intranasal study  
medica tion in this study .For those subjects who relapse in the Maintenance phase, if clinicall y 
indicated based on investigator’s judgment, after completing the end of maintenance visit, the 
subject may proceed to the open -label safet y extension study , [ADDRESS_199472] clinic visit .
At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by [CONTACT_154941]/or the subject’s treating physician. 
There will be no intranasal treatment administered during this phase. Subjects will be provided 
with an additional 2-week supply  of the oral antidepressant medication to ensure that there is no 
interruption of oral antidepressant therapy  during the transition to further clinical/standard of 
care. The decision to continue th e oral antidepressant in this phase will be at the discretion of the 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
86
Status: Approved , Date: 4 April 2017study  drug, the oral antidepressant should be continued during the 2-week follow -up phase 
unless determined as not clinically  appropriate.
An open -label safet y extension study , 54135419TRD3008, may be available (pending country  
and site approval) for eligible subjects participating in the ESKETINTRD3003 study . Please 
refer to the 54135419TRD3008 protocol for full details of potential pathways for entry .
A diagram of the stud y design is provided in Figure 1.
Figure 1: Schematic Overview of the Study
AC = active comparator; AD = antidepressant; DB = double- blind; ESK = esketamine; OL = open -label; PBO = 
placebo. TRD = treatment -resistant depression.
The study will end when 84 relapses are reached. An interim analysis will be performed at 30 relapses .
3.1.2. Definitions of Terms
Open -label Induction Phase
Response: 50% reduction in the MADRS total score from baseline (Day  [ADDRESS_199473] 
intranasal dose) to the end of the 4-week open -label induction phase
Optimization P hase
Stable remission: 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
87
Status: Approved , Date: 4 April 2017MADRS total score ≤[ADDRESS_199474] 4 weeks of the optimization phase, but 
one excursion of a MADRS total score >[ADDRESS_199475] be ≤ 12.
Stable response: 50% reduction in the MADRS total score from baseline (Day  1  o f 
induction phase; pre-randomization/prior to the first intranasal dose) in each of the last 
2weeks of the optimization phase, but does not meet criteria for stable remission .Note: For 
transferred- entry  subjects, Day [ADDRESS_199476] in 
ESKETINTRD3001 or ESKETINTRD3002.
Maintenance P hase
Relapse is defined as an y of the following:
MADRS total score 22 for 2 consecutive assessments separated by 5to 15 days. The date 
of the second MADRS assessment will be used for the date of relapse .
Hospi[INVESTIGATOR_170435] y relevant event determined 
per clinical judgment to be suggestive of a relapse of depressive illness such as suicide 
attempt, completed suicide, or hospi[INVESTIGATOR_170421]. If hospi[INVESTIGATOR_170436], thestart date of hospi[INVESTIGATOR_170423]. 
Otherwise the date of the event will be used if the subject is not hospi[INVESTIGATOR_057].
In case both relapse criteria are met, the earlier date will be defined as the date of relapse for 
this subject. 
3.2. Study Design Rationale
3.2.1. Study Population
Subjects will enter the study  either directly  (referred to as direct -entry  subjects) or after 
completing the double -blind induction phase of a short -term study  (ESKETINTRD3001 or 
ESKETINTRD3002) (referred to as transferred- entry  subjects). Both patient populations are 
considered similar as both have met the same rigorous criteria for TRD, including prospective 
confirmation of non-response in the screening/prospective observational phase prior to the 
4-week ind uction phase.
Direct -entry Subjects
The study  population will include adult men and women, therefore the age range of 18(or older 
if the minimum legal age of consent in the country  in which the study  is taking place is >18) to 
64 years of age (inclusive) is considered appropriate.
Subjects will meet DSM -5diagnostic criteria for single -epi[INVESTIGATOR_154831] (if single epi[INVESTIGATOR_1865] ,
duration of epi[INVESTIGATOR_154832] 2 years) or recurrent MDD, without psy chotic features, based upon 
clinical assessment, and confirmed by [CONTACT_11605] . At the start of the screening/prospective 
observational phase, subject smust have an Inventory  of Depressive Symptomatology -Clinician 
rated, 30- item (IDS -C30) total score of  34, which corresponds to moderate to severe depression.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
88
Status: Approved , Date: [ADDRESS_199477] had non- response (defined as 
≤25% improvement) to 1 but 5 (if current epi[INVESTIGATOR_154806] >[ADDRESS_199478] 2 years) oral antidepressant treatments taken at adequate dosage and for adequate 
duration, as assessed on the MGH -ATRQ and documented by [CONTACT_154918] (eg, 
medical/pharmacy /prescription records or a letter from the treating phy sician ,etc.) for the current 
epi[INVESTIGATOR_17108]. Subjects who have had some initial response but then lose the response 
(eg, tolerance effects/brady phylaxis) to an antidepressant treatment will not be considered to 
have failed that antidepressant treatment. The use of historical data to define non-response to 
treatment prior to patient enrollment in a treatment study  is considered practical and valid. The
MGH -ATRQ is a validated tool assessing treatment response. 
In addition, at the start of the screening/prospective observational phase, the subject is taking a 
different oral antidepressant treatment (on the MGH -ATRQ) for at least the previous 2 weeks at 
or above the minimum therapeutic dose. This antidepressant treatment, as well as any other 
ongoing medications being taken for depression at screening (including adjunctive/ augmentation 
therapi[INVESTIGATOR_014]), will continue from the start of Week 1 through the end ofWeek 4 of the 
screening/prospective observational phase. Dose adjustment is permitted per clinical judgment, 
but the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total score of 
≥[ADDRESS_199479]’s current major depressive epi[INVESTIGATOR_1865], depression symptom severity  (Week 1 MADRS 
total score ≥28 required), and antidepressant treatment response in their current depressive 
epi[INVESTIGATOR_1865] (retrospectivel y assessed) must be deemed valid for participation in the clinical study  
based on a Site-Independent Qualifica tion Assessment. The Site Independent Qualification 
Assessment is a tool to facilitate subject selection for MDD clinical studies, with a goal to ensure 
enrollment of subjects who have symptoms that reflect the current state of illness and that these 
symptoms can be reliably  measured with appropriate measurement tools, as well as to minimize 
placebo response.
Transferred -entry Subjects
The same study  population (ie, same inclusion and exclusion criteria) will be enrolled into the 
2short -term studies (ESKET INTRD3001 and ESKETINTRD3002). The transferred- entry  
subjects in this study  are subjects who complete the double -blind induction phase and have 
demonstrated response at the end of this phase in 1 of the short -term studies.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
89
Status: Approved , Date: 4 April [ZIP_CODE].2.2. Study Phases
Screening/Prospectiv e Observational Phase
The 4-week duration of the screening/prospective observational phase for direct -entry  subjects 
will provide adequate time to assess subject eligibility  according to the study  entry  criteria, while 
also allowing for a prospective confirmation of non-response to the current antidepressant 
treatment(s) that is continued for the duration of this phase. This method of recruitment allows 
subjects to enter the study  on a variety  of different antidepressant medications that they  had been 
taking, which mimics clinical practice and yet allows for prospective demonstration of treatment 
resistance to the current antidepressant treatment . Even thoug h there is no depression rating score 
available at the start of the antidepressant treatment, the subjects at screening will have to meet 
criteria for moderat e to severe depression. After 4 weeks of prospective observation of 
continuation of the current antidepressant treatment and assessment of treatment response, 
subjects who meet the predefined non-response criteria (≤25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥28 on Week 2 and Week 4 ) and are 
eligible to enter the open -label induction phase will discontinue all of the current antidepressant 
treatments, including adjunctive/augmentation therapi[INVESTIGATOR_014], prior to starting the next phase. 
Non-responders that are eligible to enter the open -label induction phase are permitted to have up 
to 3 additional weeks to taper and discontinue the all current medication(s) being used for 
depression prior to entry  into the open -label induction phase , per the local prescribing 
information or clinical judgment (eg, tolerability conc erns). The duration of up to [ADDRESS_199480] of t ypi[INVESTIGATOR_170437], with a 4 -week duration considered to be 
sufficiently  long to show the antidepressant effects of the active comparator. Preliminary 
findings from an analy sis of antidepressants were presented recently , as well as a completed 
analysis of 24recent MDD studies that compared study  durations of 4, 6, and 8 weeks. 
Exploratory  analyses were conducted for each of the study  durations using mixed -model 
repeated measures (MMRM), but excluding data beyond the duration of intere st. These 
preliminary  findings suggest that it is plausible to shorten study  duration down to 4 weeks .68,142
Similarly , it has been demonstrated that improvement of 25% on the Hamilton Depression 
Rating Scale on Day [ADDRESS_199481] response after 5 weeks of 
treatm ent,and a lack of improvement (ie, <25%) by [CONTACT_2006] [ADDRESS_199482] -entry  and transferred -
entry  subjects allow sfor a reduction in the frequency  of intranasal treatment sessions and 
subsequent individualization and stabilization of the treatment session frequency  (weekly  or 
every  other week) for a given subject (using the MADRS total score to assess depressive 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
90
Status: Approved , Date: 4 April 2017symptoms). For the primary  analysis, asubject must be in stable remission (see full definitio n,
section 3.1.2 )to enter the maintenance phase. This duration of the optimization phase is critical 
to the time to relapse. Shorter duration of stabilization (referred to as the optimization phase in 
this study) is associated with faster relapses. A recent meta -analy sis showed that beyond [ADDRESS_199483] relapses .3
Subjects with stable response (50% reduction in the MADRS total score from baseline [Day 1 
of induction phase; pre-randomization/prior to the first intranasal dose]) in each of the last 
2weeks of the optimization phase who donot meet criteria forstable remission, will also enter 
the maintenance phase ,but will not be part of the primary  analysis. Although not part of the 
primary  analysis, this subject population is of clinical interest. A 2-week duration to confirm 
stable respons e is considered appropriate to ascertain the subject’s status prior to the next 
treatment phase.
Maintenance Phase
The duration of the maintenance phase is variable ,and the phase will continue until the required 
number of relapses is achieved or until thestudy is recommended to be stopped based on the 
interim analy sis results. Assumptions regarding the duration of time to relapse are provided in 
Section 1.3, Overall Rationale for the Study . While all subjects will enter this phase at the same 
frequency  of intranasal treatment sessions that they had in the optimization phase, the frequency  
of intranasal treatment sessions will continue to be individua lized to once weekl y or once every  
other week based on the severity  of depression, as assessed by [CONTACT_170468], during 
this phase; however, there will be a limit (ie, no more than 3 times) on the number of times a 
subject can be switched from week ly to every  other week. This is considered a sufficient number 
of times to evaluate if a subject can sustain antidepressant efficacy  with every -other -week 
dosing.
Follow -up Phase
The 2-week duration of the follow -up phase will allow sufficient time to assess safety  and 
tolerability  after cessation of intranasal dosing, including potential withdrawal symptoms. At the 
start ofthis phase, further clinical/standard of care for the treatment of depression will be 
arranged b y the stud y investigator and/or the subject’s treating ph ysician.
3.2.3. Blinding and Randomization
Blinded intranasal treatment will be used in the optimization phase (for transferred- entry 
subjects) to avoid unblinding the short -term studies at the individual level , and in the 
maintenance phase (for all subjects) to reduce potential bias during data collection and 
evaluation of clinical endpoints.
Randomization will be used in the maintenance phase for subjects in stable remission (primary 
analysis) and subjects with stable response but who are not in stable remission (secondary 
analysis) to minimize bias in the assignment of subjects to treatment groups, to increase the 
likelihood that known and unknown subject attributes (eg, demographic and baseline 
characteristic s) are evenly  balanced across treatment groups, and to enhance the validity  of 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
91
Status: Approved , Date: 4 April 2017statistical comparisons across treatment groups. The randomizations will be stratified by [CONTACT_170479] 1:1 to intranasal placebo or intranasal esketamine. The stratification is 
aimed at balancing treatment groups across country .
Transferred -entry  subjects who achieve stable remission or stable response after treatment with 
intranasal placebo plus an oral antidepressant will continue to receive the same trea tment in order 
to maintain the blinding for the ongoing short- term studies. These subjects will not be 
randomized during the maintenance phase.
3.2.4. Treatment Groups and Dos e Selection
[IP_ADDRESS]. Intranasal Study  Drug
Open -label Induction Phase
All direct -entry  subjects will receive intranasal esketamine during this phase. The dose selection 
(56 mg and 84 mg) and administration interval (2 treatment sessions per week for 4 weeks) for 
this phase were based on the sponsor’s previous clinical data, in particular the results from 
Studies ESKETIVTRD2001, KETIVTRD2002, ESKETINTRD1001, and Panel A of 
Study ESKETINTRD2003, described above in Section 1.1.[ADDRESS_199484]; that they have 
a rapid onset of effect; and that [ADDRESS_199485] as clinically  required, the dose of antidepressant 
medication.
Optimization Phase
There will be no changes to the intranasal dose permitted during the optimization phase. Subjects 
will continue to receive the same intranasal treatment (esketamine or placebo) from the induction 
phase; therefore, direct -entry  and transferred- entry  subject s will continue to receive open -label 
and double -blind intranasal treatment, respectivel y.
The intranasal treatment session frequency  will be reduced from that in the induction phase 
(twice weekl y) to weekly  for the first [ADDRESS_199486] 4 weeks, the 
frequency  of intranasal treatment sessions will be individualized to once weekl y or once every 
other week based on the severity  of depression, as assessed by [CONTACT_170468]. This 
reduction in frequency and individualization is intended to allow subjects to sustain the 
antidepressant response while minimizing the frequency  of intranasal treatment sessions 
required.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
92
Status: Approved , Date: 4 April 2017Maintenance P hase
Subjects in stable remission after treatment with intranasal esketamine plus an oral 
antidepressant will be randomized in a 1:1 ratio to either continue with intranasal esketamine 
(same dose) and the same oral antidepressant or to continue with the same oral antidepressant 
(active comparator) but switch to intranasal placebo (for the primary  efficacy  anal ysis). 
Subjects with stable response (but who are not in stable remission) after treatment with intranasal 
esketamine plus an oral antidepressant will be randomized in a 1:1 ratio (using a separate 
randomization list) to either continue with intranasal esketamine (same dose) and the same oral 
antidepressant or to continue with the same oral antidepressant (active comparator) but switch to 
intranasal placebo (for secondary efficacy  anal ysisonly). 
Transferred -entry  subjects who achieve stable remission or stable response after treatment with 
intranasal placebo plus an oral antidepressant will continue to receive the same treatment in order 
to maintain the blinding for the ongoing short -term studies. These subjects will not be included 
in the efficacy  analy ses, but will be included in safety  anal yses.
The frequency  of intranasal treatment sessions will be individualized to once weekl y or once 
every  other week based on the severity  of depression, as assessed by  [CONTACT_170468]. As 
noted above, however, there will be a limit (ie, no more than 3 times) to the number of times the 
frequency  can be switched from weekl y to every other week. This further individualization of 
treatment session frequency  is intended to allow subjects to sustain the antidepressant response 
while minimizing the frequency  of intranasal treatment sessions required.
[IP_ADDRESS]. Oral A ntidepressant
On Day [ADDRESS_199487] will be assigned to receive 1 of 4 oral 
antidepressant medications from 2 different classes of antidepressant treatments, an SSRI 
(escitalopram or sertraline) or an SNRI (duloxetine or venlafaxine XR). The assignment of the 
oral antidepressant will be done by [CONTACT_170471] -ATRQ and 
relevant prior antidep ressant medication information.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
93
Status: Approved , Date: [ADDRESS_199488] has not previously  had a non-response to in the current 
epi[INVESTIGATOR_1865], has not been previously  intolerant to (lifetime), and is available in the participating 
country . Dosing of the oral antidepressant will begin on Day [ADDRESS_199489]. If highe r 
doses are not tolerated, a down -titration is permitted based on clinician’s judgment. However, the 
subject’s dose should not be lower than the follow ing minimum therapeutic doses at the end of 
the induction phase : sertraline (50mg/day),venlafaxine XR (150 mg/day ), escitalopram 
(10mg/day ), and duloxetine (60mg/day ).While subjects requiring lower doses can contin ue in 
the study  and complete the induction phase, such subjects will not be eligible to participate in the 
optimization phase and will proceed to the follow -up phase after completion of the induction 
phase.
For all subjects, the same oral antidepressant treatment will be continued throughout the 
optimization , maintenance , and follow -up (if clinically  indicated) phases.
The rationale for initiating and continuing an oral antidepressant in combination with intranasal 
esketamine treatment is provided in Sectio n 1.3, Overall Rationale for the Study .
3.2.5. Efficacy  Measures
MADRS
The 10-item clinician -administered MADRS was designed to be used in subjects with MDD to 
measure the overall severity  of depressive symptoms .83The MADRS scale has been selected as 
anefficacy  measure for this study  because it is validated, reliable, and acceptable to regulatory 
health authorities as a primary  scale to determine effi cacy in major depression. 
Response is defined as a 50% reduction in the initial symptom score, and remission is defined 
as a total score of 12. At the end of the open -label induction phase, subjects who meet this 
criterion for response (ie, 50% reducti on in the initial symptom score) will be considered 
responders and are eligible to continue into the optimization phase. 
During the optimization phase, the MADRS will be used to measure severit y of depressive 
symptoms to individualize intranasal treatment session frequency  as well as to determine stable 
remission and response for eligibility  to enter the maintenance phase.
During the maintenance phase, the primary  efficacy  evaluation will include the MADRS total 
score as it pertains to relapses. A MADRS total score 22 for 2 consecutive assessments 
separated by 5to 15 days (the date of the second MADRS assessment in the 2-week period will 
be used for the date of relapse) is a relapse criteri ain this study . In addition, it will continue to be 
used to measu re severity of depressive symptoms to further individualize intranasal treatment 
session frequency .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
94
Status: Approved , Date: 4 April 2017PHQ -9
The PHQ -9 will be used as a patient -reported measure of depressive symptomatology .128
Please refer to Section [IP_ADDRESS] for additional information regarding PHQ -9.
SDS 
The Sheehan Disability  Scale (SDS) is patient -reported outcome measure included as an 
assessment of functional impair ment and associated disability .74,121Please refer to 
Section [IP_ADDRESS] for additional information regarding SDS.
CGI -S 
The CGI-S is included to rate the severit y of the subject’s illness at the time of assessment, 
relative to the clinician’s past experience with subjects who have the same diagnosis and 
improvement with treatment .50Please refer to Section [IP_ADDRESS] for additional information 
regarding CGI- S.
GAD -7
The GAD -7 is included as a brief and validated measure of overall anxiety .127Please refer to 
Section [IP_ADDRESS] for additional information regarding GAD-7.
EQ-5D-5L
The EQ-5D- 5L is included as a standardized patient -completed instrument for use as a 
measure of health-related quality  of life and health status.41,42Please refer to Section [IP_ADDRESS]
for additional information regarding EQ-5D- 5L.
3.2.6. Safety  Evaluations
Physical examination, body  weight, vital signs (including blood pressure me asurements), [ADDRESS_199490] will be examined separate ly grouped in the following categories: drug 
abuse, dependence and withdrawal [standardized Medical Dictionary  for Regulatory  Activities 
(MedDRA )queries (SMQ)], increased blood pressure, increased heart rate, transient 
dizziness/vertigo; impaired cognitio n; anxiety  and cy stitis.
A subject -completed nasal symptom questionnaire will also be conducted as per the Time and 
Event Schedule to assess for an y treatment -emergent nasal tolerability  symptoms.
The C-SSRS will be performed to assess suicidal ideation and behavior, the CADSS will be 
administered to assess treatment -emergent dissociative symptoms, the Brief Psychiatric Rating 
Scale (BPRS+; four-item positive symptom subscale) will be administered to assess treatment -
emergent psychotic symptoms, the MOAA/ S will be used to measure treatment -emergent 
sedation, the CGADR will be used to measure the subject’s readiness for discharge based on 
parameters including sedation, blood pressure, and adverse events, and the PWC -20 will be 
administered (as applicable) to assess potential withdrawal symptoms after cessation of 
esketamine treatment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
95
Status: Approved , Date: [ADDRESS_199491] -completed BPIC-SS at specific 
time points.55A score >[ADDRESS_199492] -Revised 
(HVLT -R). The cognitive battery  will provide assessment of multiple cognitive domains, 
including attention, visual learning and memory, and executive function. The HVL T-R is a 
measure of verbal learning and memory .
The University  of Pennsy lvania Smell I dentification Test (UPSI T) and Smell Threshold Test will 
be performed to assess any  treatment -emergent effects on the sense of smell.
On all intranasal dosing days, subjects must remain at the site until study  procedures have been 
completed and the subject is ready for discharge .Subjects should be accompanied by a 
responsible adult when released from the clinical site. Subjects must not drive a car or work with 
machines for [ADDRESS_199493] of prohibited medications is provided in Attachment 1asgeneral guidance for the 
investigator (but is not all-inclusive).
3.2.7. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA ) 
Evaluations 
Assessment of biomarkers (protein and RNA) and their potential relationship to the different 
treatment groups and to maintenance/stabilization of response, non-response, and relapse will be 
explored. Blood samples will be collected to measure genetic and epi[INVESTIGATOR_27787] (including 
but not limited to BDNF allelic variants) and protein markers (including but not limited to 
growth factors, inflammation, endocrine, or metabolic). Samples of DNA and biomarker smay be 
used to help address emerging issues and to enable the development of safer, mor e effective, and 
ultimately  individualized therapi[INVESTIGATOR_014].
Genetic variation can be an importa nt contributory  factor to interindividual differences in drug 
distribution and response and can also serve as a marker for disease susceptibility  and prognosis. 
Pharma cogenomic research may help to explain interindividual variability in clinical outcomes 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
96
Status: Approved , Date: [ADDRESS_199494] or MDD. Specifically , gen etic and epi[INVESTIGATOR_170438] (eg, hypothalamic -pi[INVESTIGATOR_2117] -adrenal axis, inflammation, 
growth factors, monoamine transporters, ion channels, and circadian rh ythm) will be evaluated.
Protein, metabolite, and RNA biomarkers may aid in the elucidation of the mechanism of action 
of the different treatment groups or help to explain interindividual variability  in clinical 
outcomes or may  help to identify  population subgroups that respond differently  to a drug or may 
help to identify  subgroups that are more susceptible to relapse . The goal of the biomarker 
analyses is to evaluate the pharmacod ynamics of the different treatment groups , and aid in 
evaluating the drug- clinical response relationship. 
On the day of biomarker sample collection, it is preferred that subjects adhere to a low fat diet 
(as an alternative to fasting) to reduce the level of postprandial lipemia in blood samples, since 
moderatel y or grossl y lipemic specimens may  interfere with assay  results.
3.2.8. Other A ssessments
Patient Adherence Questionnaire
During the screening/prospective observational phase, the self-reported PAQ will be used to 
assess how often the subject has taken, and whether he or she has made any changes to, his or 
her antidepressant treatment regimen in the last 2 weeks. This assessment will provide 
confirmation of medication compliance when evaluating antidepressant treatment response. 
Subjects who report missing 4 days of antidepressant medication during a 2-week recall period 
willbe discontinued because of inadequate adherence.
3.2.9. Medical Resource Utilization Data Collection
Delay  of relapse and maintenance of response/remission may result in lower utilization of
healthcare services (such as outpatient visits, emergency  room visits, or hospi[INVESTIGATOR_059] ) 
associated with relapse of symptoms of depression ; therefore ,comparison will be done across 
treatment groups. The Healthcare Resource Use Questionnaire (HRUQ) will be used to assess 
medical resource utilization. It includes information regarding utilization of healthcare services 
over the course of the study , including the type and duration of services, enabling changes in 
level and quantit y of services to be considered as a variable in economic models.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
97
Status: Approved , Date: [ADDRESS_199495] selection, refer to Section 11.2, 
Sample Size Determination.
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a case -
by-case basis.
4.1. Inclusion Criteria
4.1.1. Direct -entry Subjects
The following criteria apply  only to those su bjects entering directly  into the study .Each potential 
subject must satisfy  all of the following criteria to be enrolled in the study . 
1. At the time of signing the informed consent form (ICF) the subject, a man or woman , must 
be 18 (or older if the minimum legal age of consent in the country  in which the study  is 
taking place is >18) to 64 y ears of age, inclusive.
2. At the start of the screening/prospective observational phase , each subject must meet 
Diagnostic and Statistical Manual of Mental Disorders -fifth edition (DSM -5) diagnostic 
criteria for single -epi[INVESTIGATOR_154831] (if single -epi[INVESTIGATOR_154831], the duration must be 2years) or 
recurrent MDD, without psychotic features, based on clinical assessment and confirmed by 
[CONTACT_941] M iniInternational Neuropsy chiatric Interview (MINI).
3. Criterion modified per Amendment 2:
3.1. Criterion modified per Amendment 3:
3.2. At the start of the screening/prospective observational phase, subject must have had 
non-response (≤25% improvement) to 1 but 5(if current epi[INVESTIGATOR_154806] >[ADDRESS_199496] 2 years) oral antidepressant treatments in the current epi[INVESTIGATOR_154807], assessed using the MGH -ATRQ and confirmed by [CONTACT_154899] (eg, 
medical/pharmacy /prescription records or a letter from a treating physician , etc.). In 
addition, the subject is taking a different oral antidepressant treatment (on the MGH -ATRQ ) 
for at least the previous 2 weeks at or above the minim umtherapeutic dose.
For specific tricy clic antidepressants which are ongoing and being taken at a dose below 
the MGH -ATRQ minimum therapeutic dose, a blood level that is within the therapeutic 
(antidepressant) range, is acceptable to establish the adequacy of the antidepressa nt 
treatment.
Subjects must be adherent to the continued oral antidepressant treatment medication(s) 
through the screening/prospective observational phase, as documented on the PAQ. 
Missing 4 days of antidepressant medication in the prior 2-week period will be 
considered as inadequate adherence.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
98
Status: Approved , Date: 4 April 2017Subjects who are non -responders to their current oral antidepressant medication(s) from 
the screening/prospective observational phase (as assessed by [CONTACT_6222], remote 
raters) may be eligible to continue tothe open-label induction phase. Non-response at 
the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of ≥28 on Week 2 and Week 4.
4. At the start of the screening/prospective observational phase , each subject must have an 
Inventory  of Depressive Symptomatology , Clinician -rated, 30-item (IDS-C30)total score of 
34.
5. Criterion modified per Amendment 2:
5.1. The subject 's current major depressive epi[INVESTIGATOR_1865] ,depression symptom severit y (Week 1 
MADRS total score ≥28 required) , and antidepressant treatment response in the current 
depressive epi[INVESTIGATOR_1865], must be confirmed using the Site I ndependent Qualification Assessment.
6.Subject must be medically  stable on the ba sis of phy sical examination, medical history , vital 
signs (including blood pressure), pulse oximetry, and 12-lead ECG performed in the 
screening/prospective observational phase. If there are any abnormalities that are not 
specified in the inclusion and exclusion criteria, their clinical significance must be 
determined by [CONTACT_57127] 's source documents and initialed 
by [CONTACT_093] .
7.Criterion modified per Amendment 2:
7.1.Criterion modified per Amendment 3:
7.[ADDRESS_199497] be medically  stable on the basis of clinical laboratory  tests performed in 
the screening/prospective observational phase. If the results of the serum chemistry  panel, 
hematology , or urinal ysis are outside the normal reference ranges, the subject may be 
included only if the investigator judges the abnormalities or deviations from normal to be 
not clinically  significant or to be appropriate and reasonable for the population under study . 
This determination must be recorded in the subject 's source document s and initialed by [CONTACT_1275] .
Subjects with a pre-existing history  of thyroid disease/disorder who are treated with 
thyroid hormones must be on a stable dosage for 3 months prior to the start of the 
screening/prospective observational phase.
For anysubject (regardless of thyroid history ), if the thyroid-stimulating hormone 
(TSH )value is out of range, a free thyroxine (FT4) will be conducted. If the FT4 value 
is abnormal and considered to be clinically  significant (after discussion with the medical 
monitor) , the subject is not eligible.
8.Subject must be comfortable with self -administration of intranasal medication and be able to 
follow the intranasal administration instructions provided.
9.Criterion modified per Amendment 2:
9.1. Criterion modified per Amendment 3:
9.2. Contraceptive use by [CONTACT_170480].
A woman must be either:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
99
Status: Approved , Date: 4 April 2017a.Not of childbearing potential defined as:
opostmenopausal
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimu lating hormone (FSH) level 
(>40 IU/L or mIU/mL in the postmenopausal range) will be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy, however in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient.
opermanentl y sterile 
Permanent sterilization methods include hysterectomy, bilateral salpi[INVESTIGATOR_1656], 
bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy.
b.Of childbearing potential and
opracticing a highl y effective method of contraception (failure rate of <1% per year 
when used consistentl y and correctly).
Examples of hi ghly effective contraceptives include 
user-independent methods:
implantable progestogen- only hormone contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine hormone -
releasing system (IUS); vasectomized partner; sexua l abstinence ( sexual 
abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with 
the study drug. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
subject.)
user-dependent methods:
combined (estrogen- and progestogen- containing) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, and transdermal; 
progestogen-onl y hormone contraception associated with inhibition of 
ovulation: oral and injectable
Typi[INVESTIGATOR_170439]. Use should be consistent with local regulations regarding the use of 
contraceptive methods for subjects participating in clinical studies.
Hormonal contraception may be susceptible to interaction with the study drug, 
which may reduce the efficacy of the contraceptive method.
oagrees to use a highly  effective method througho ut the study  and for at least 
6weeks after the last dose of study  drug
Note: If the childbearing potential changes after start of the study  or the risk of pregnancy  
changes (eg, a woman who is not heterosexually  active becomes active,) a woman must 
begin a highl y effective method of contraception, as described throughout the inclusion 
criteria.
10. Criterion modified per Amendment 2:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
100
Status: Approved , Date: [ADDRESS_199498] a negative highl y sensitive serum (β-
human chorionic gonadotropin [β-hCG]) at the start of the screening/prospective 
observational phase and a negative urine pregnancy  test must be obtained before the first 
dose of study  drug on Day  1 of the open -label induction phase prior to randomization.
11.Criterion modified per Amendment 2:
11.1. Criterion modified per Amendment 3:
11.2 During the study  (ie, from Day 1 of the open -label induction phase, prior to intranasal 
dosing) and for a minimum of 1 spermatogenesis cycle (defined as approximately  90 days) 
after receiving the last dose of intranasal study  medication, a man who is sexua lly active 
with a woman of childbearing potential
must be practicing a highly  effective method of contraception with his female partner 
from those listed above (see examples of highly  effective methods of contraception 
provided for female subjects).
must u se a condom if his partner is pregnant .
must agree not to donate sperm .
Note: If the childbearing potential changes after start of the study , a female partner of a male 
study  subject, must begin a highl y effective method of birth control, as described abov e.
4.1.2. Transferred -entry Subjects 
The following criteri aapplyto subjects who enter this study  after participation in a short -term 
study (ESKETINTRD3001 orESKETI NTRD3002). Each potential subject must satisfy  the 
following criteri ato be enrolled in the stud y:
12. Criterion modified per Amendment 2:
12.1. The subject must have completed the double -blind induction phase in 
ESKETINTRD3001 or ESKETINTRD3002 and must have demonstrated response at the 
end of that phase (50% reduction in the MADRS total score from baseline [Day  1  pre-
randomization] at the end of the 4- week double -blind induction phase ).
Note that the following criterion is intentionally  not numbered sequentiall y:
15. Criterion added per Amendment 2: Transferred -entry subjects must meet the same crit eria at 
the point of entry  to this study  as the direct-entry subjects at the same time point (ie,
beginning of optimization phase).
4.1.3. Direct -entry Subjects and Transferred-e ntry Subjects 
The following inclusion criteria applyto both groups of subjects; ie, those entering the study 
directly  or those who have complet edashort -term study (ESKETINTRD3001 or
ESKETINTRD3002):
13.Each subject must be willing and able to adhere to the prohibitions and restrictions specified 
in this pro tocol.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
101
Status: Approved , Date: [ADDRESS_199499] sign an informed consent form ( ICF)indicating that he or she understands 
the purpose of and procedures required for the study  and iswilling to participate in the 
study .
15.Criterion added per Amendment 2, in Section 4.1.[ADDRESS_199500] y to those subjects entering directly  into the study :
1.Criterion modified per Amendment 2:
1.1. Subject 's depressive sy mptoms have previously  not responded t oany of the following :
Esketamine or ketamine in the current major depressive epi[INVESTIGATOR_154866] , 
or
Allof the oral antidepressant treatment options available in the respective country  for 
the open -label induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine 
XR) in the current major depressive epi[INVESTIGATOR_1865] (based on MGH -ATRQ) , or
An adequate course of treatment with electroconvulsive therap y (ECT) in the current 
major depressive epi[INVESTIGATOR_1865], defined as at least 7 treatments with unilateral/bilateral ECT .
2. Criterion modified per Amendment 2:
2.1. Subject has received vagal nerve stimulation (VNS) or has received deep brain 
stimulation (DBS) in the current epi[INVESTIGATOR_17108].
3. Criterion modified per Amendment 2:
3.1. Subject has a current or prior DSM -5 diagnosis of a psychotic disorder or MDD with 
psychotic features, bipolar or related disorders (confirmed by [CONTACT_42145]), obsessive 
compulsive disorder (current only), intellectual disability  (DSM -5 diagnostic codes 317, 
318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
disorder, antisocial personality  disorder, histrionic personality  disorder, or narcissistic 
personality  disorder .
4. Subject has homicidal ideation/intent, per the investigator’s clinical judgment, or has 
suicidal ideation with some intent to act within 6 months prior to the start of the 
screening/prospective observational phase, per the investigator’s clinical judgment or based 
on the C-SSRS, corresponding to a response of “Yes” on Item 4 (active suicidal ideation 
with some intent to act, without specific plan) or Item5 (active suicidal ideation with 
specific plan and intent) for suicidal ideation on the C-SSRS, or a history  of suicidal 
behavior within the past year prior to the start of the screening/prospective observational 
phase. Subjects reportin g suicidal ideation with intent to act or suicidal behavior prior to the 
start of the open -label induction phase should be excluded.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
102
Status: Approved , Date: [ADDRESS_199501] has a history  of moderate or severe substance or alcohol use disorder according to 
DSM -5 criteria, except nicotine or caffeine, within 6 months before the start of the 
screening/prospective observational phase. 
A history  (lifetime) of ketamine, phency clidine (PCP), lysergic acid diethy lamide 
(LSD), or 3,4-methy lenedioxy -methamphetamine (MDMA) hallucinogen -related use 
disorder is exclusionary .
6.Subject has a current or past history  of seizures (uncomplicated childhood febrile seizures 
with no sequelae are not exclusionary ).
7. Subject has an UPSI T total score 18, indicative of anosmia , in the screening/prospective 
observational phase .
8. Criterion modified per Amendment 2:
8.1. Subject has one of the following cardiovascular- related conditions:
Cerebrovascular disease with a history  of stroke or transient ischemic attack.
Aneury smal vascular disease (including intracranial, thoracic, or abdominal aorta, or 
peripheral arterial vessels) .
Coronary  artery  disease with myocardial infarction, unstable angina, or 
revascularization procedure (eg, coronary  angioplasty  or by[CONTACT_10956] ) within 
12months before the start of the screening/prospective observational phase . Subjects 
who have had a revascularization performed >12 months prior to screening and are 
clinically  stable and symptom -free, per investigator 's clinical judgment, can be 
included .
Hemody namicall y significant valvular heart disease such as mitral regurgitation, aortic 
stenosis, or aortic regurgitation.
[LOCATION_001] Heart Association (NYHA) Class III-IV heart failure of any etiology  (refer 
toAttachment 2).
9. Criterion modified per Amendment 2:
9.1. Subject has a history  of uncontrolled hypertension despi[INVESTIGATOR_154867], exercise, or 
antihy pertensive therapy  at the start of the screening/prospective observational phase or any 
past history  of hy pertensive crisis or ongoing evidence of uncontrolled hypertension defined 
as a supi[INVESTIGATOR_9219] (SBP) >140 mmHg or diastolic blood pressure (DBP) 
>90 mmHg during screening/prospective observational phase which continues to be above 
this range with repeated testing during this phase. Note: On Day 1  o f the open -label
induction phase (prior to the first intranasal treatment session) a supi[INVESTIGATOR_152358] >140 mmHg or 
DBP >90 mmHg is exclusionary .
A potential subject may have his/her current antihy pertensive medication (s)adjusted 
during the screening/prospective observational phase and be re-evaluated to assess their 
blood pressure control. The subject must be on a stable regimen for at least 2weeks 
before Day  [ADDRESS_199502] history  of significant pulmonary  insufficiency /condition or with 
an arterial blood oxygen saturation (SpO 2) of <93% at the start of the screening/prospective 
observational phase or Day [ADDRESS_199503] intranasal 
treatment session .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
103
Status: Approved , Date: 4 April 201711. Criterion modified per Amendment 2:
11.1. Criterion modified per Amendment 3:
11.2. Subject has clinically  significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day [ADDRESS_199504] intranasal treatment session, defined as:
During screening, a QT interval corrected according to Fridericia's formula (QTcF): 
450 msec; if the QTcF is prolonged on the initial ECG, the average QTcF of three 
ECGs, recorded [ADDRESS_199505] not be ≥450 msec.
On Day 1 (predose), a QT interval corrected according to Fridericia’s formula (QTcF): 
≥450 msec based on the site-evaluated ECG; if the QTcF is prolonged on the initial 
ECG, the average QTcF of three ECGs, recorded [ADDRESS_199506] not be ≥450 
msec.
Evidence of 2ndand 3rddegree AV block, complete left bundle branch block (LBBB), or 
complete right bundle branch block (RBBB).
Features of new ischemia.
Arrh ythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs]).
12. Criterion modified per Amendment 2:
12.1. Subject has a history  of additional risk factors for torsades des pointes (eg, heart 
failure, h ypokalemia, or family  history  of long QT s yndrome) .
13. Criterion modified per Amendment 2:
13.1. Subject has a history  of, or symptoms and signs suggestive of, liver cirrhosis (eg, 
esophageal varices, ascites, and increased prothrombin time) OR alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) values 2x the upper limit of normal or total 
bilirubin >1.[ADDRESS_199507] in the screening/prospective observational phase.
Repeat of screening test for abnormal ALT and AST is permitted once during the 
screening period provided per investigator discretion and provide there is an alternative 
explanation for the out of range value.
For elevations in bilirubin if, in the opi[INVESTIGATOR_154868]’s medical officer, the elevation in bilirubin is consistent with Gilber t’s disease, 
the subject may  participate in the study .
14. Criterion modified per Amendment 2:
14.1. Criterion modified per Amendment 3:
14.2. Subject has positive test result(s) for drugs of abuse (including barbiturates, 
methadone, opi[INVESTIGATOR_858], cocaine, phency clidine , and amphetamine/methamphetamine) at the 
start of the screening/prospective observational phase or Day [ADDRESS_199508] intranasal treatment session .
Subjects who have a positive test result at screening due to p rescribed psychostimulants 
(eg, amphetamine, methy lphenidate, etc.),taken for an indication other than MDD ,are 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
104
Status: Approved , Date: 4 April 2017permitted to continue to take this medication during the study  in accordance with 
Attachment 1.
Otherwise, subjects who have a positive test result at screening due to prescribed/over -
the-counter opi[INVESTIGATOR_154869]/prospective observational phase if the medication is discontinued at least [ADDRESS_199509] intranasal treatment session, in accordance with Attachment 1
restrictions. The result of the Day 1 (prior to the first intranasal treatment session) test
for drugs of abuse must be negative for the subject to have the first intranasal treatment 
session.
oRetesting is not permitted for positive test result(s), except for reasons stated above.
Prior intermittent use of cannabinoids prior to the start of the screening/prospective 
observational phase is not exclusionary  as long as the subject does not meet the criteria 
for substance use disorder. Apositive test for cannabinoids at the start of the 
screening/prospective observational phase is not exclusionary ; however, a positive test 
result for cannabinoids predose on Day 1  o f the open -label induction phase is 
exclusionary .
15. Criterion modified per Amendment 2:
15.1. Subject has uncontrolled diabetes mellitus, as evidenced by [CONTACT_13505]1c >9% in the 
screening/prospective observational phase or history  in the prior 3months prior to the start 
of the screening/prosp ective observational phase of diabetic ketoacidosis, hypergl ycemic 
coma, or severe h ypogl ycemia with loss of consciousness.
16. Subject has untreated glaucoma, current penetrating or perforating eye injury , brain injury , 
hypertensive encephalopathy , intratheca l therapy  with ventricular shunts, or any other 
condition associated with increased intracranial pressure or increased intraocular pressure or 
planned ey e surgery .
17. Criterion modified per Amendment 2:
17.1. Subject has any anatomical or medical condition that, per the investigator's clinical 
judgment based on assessment, may impede delivery  or absorption of intranasal study  drug.
18. Criterion deleted per Amendment [ADDRESS_199510] has a history of malignancy  within 5 years before the start of the 
screening/prospective observational phase (exceptions are squamous and basal cell 
carcinomas of the skin and carcinoma in situ of the cervix, or malignancy  that, in the 
opi[INVESTIGATOR_871] , with concurrence with the sponsor 's medical monitor , is 
considered cured with minimal risk of recurrence).
20. Subject has known allergies, hypersensitivity , intolerance, or contraindications to 
esketamine/ketamine and/or its excipi[INVESTIGATOR_170440] -label induction phase.
21. Subject has taken any prohibited therapi[INVESTIGATOR_154871] 1, as noted 
in Section 8(Prest udy and Concomitant Therap y) and Attachment 1.
22. Subject is taking a total daily  dose of benzodiazepi[INVESTIGATOR_154872] 
6mg/day  of lorazepam at the start of the screening/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
105
Status: Approved , Date: 4 April 201723. Criterion modified per Amendment 2:
23.1. Subject has a score of [ADDRESS_199511] be ruled out (eg, apnea -hypopnea index [AHI ] must be <30). A subject 
with obstructive sleep apnea can be included if he or she is using a positive airway  pressure 
device or other treatment/therapy  that is effectively  treating (ie, AHI <30) his or her sleep 
apnea.
24. Criterion modified per Amendment 2:
24.1. Subject has received an investigational drug (including investigational vaccines) or 
used an invasive investigational medical device within 60 days before the start of the 
screening/prospective observational phase, or has participated in 2 or more MDD or other 
psychiatric condition clinical interventional studies (with different investigational 
medication) in the previous 1 y ear before the start of the screening/prospective observational 
phase, or is currentl y enrolled in an investigational interventional study.
25. Subject is a woman who is pregnant, breast -feeding, or planning to become pregnant while 
enrolled in this study  or within [ADDRESS_199512] has a diagnosis of acquired immunodeficiency  syndrome (AIDS). Huma n 
immunodeficiency  virus (HIV) testing is not required for this study .
27. Subject has any condition or situation/circumstance for which, in the opi[INVESTIGATOR_1070], participation would not be in the best interest of the subject (eg, compromise 
the wel l-being) or that could prevent, limit, or confound the protocol- specified assessments.
28.Subject has had major surgery , (eg, requiring general anesthesia) within 12 weeks before the 
start of the screening/prospective observational phase, or will not have fully recovered from 
surgery , or has surgery  planned during the time the subject is expected to participate in the 
study .
Note: Subjects with planned surgical procedures to be conducted under local anesthesia 
may participate.
29. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  members of the employ ees or the investigator.
Note that the following criterion is intentional ly not numbered sequentiall y:
31. Criterion added per Amendment 2: Subject has severe renal impairment (creatinine 
clearance <30 mL /min).
4.2.2. Transferred -entry Subjects
The following exclusion criterion applies to transferred- entry subjects:
30. Subject has any condition or situation/circumstance for which, in the opi[INVESTIGATOR_1070], participation would not be in the best interest of the subject (eg, compromise 
the well -being) or that could prevent, limit, or confound the protocol- specified assessments .
31.Criterion added per Amendment 2, in Section 4.2.1 .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
106
Status: Approved , Date: 4 April 201732. Criterion added per Amendment 2: Transferred -entry subjects must meet the same criteria at 
the point of entry  tothis study  as the direct-entry subjects at the same time point (ie,
beginning of optimization phase).
NOTE: Investigators should ensure that all relevant study  enrollment criteria have been met 
prior to Day 1 of the open -label induction phase (direct entry ) or the start of the optimization 
phase (transferred entry ). If a subject 's status changes (including laboratory  results or receipt of 
additional medical records) before the first dose of intranasal study  drug is given in this study  
such that he or she no longer meets applicable eligibility  criteria, then the subject should be 
excluded from participation in the study . Section 17.4 (Sour ce Documentation )describes the 
required documentation to support meeting the enrollment criteria.
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a case -
by-case basis.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
Refer to Section 4.1(Inclusion Criteria) and Section 4.2(Exclusion Criteria) for information 
regarding contraception requirements.
Refer to Section 4.3(Prestudy  and Concomitant Therap y) and Attachment 1(Prohibited 
Concomitant Medications With Intranasal Study  Medication [Esketamine or Placebo]) for 
further information on prohibited therapi[INVESTIGATOR_014].
Subjects who were taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalen t of 
6 mg/day  of lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, 
zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational phase can continue these 
medications during the induction phase. No dose increases beyond the equivale nt of 
6mg/day  of lorazepam, or new benzodiazepi[INVESTIGATOR_170441], with the exception of the use of permitted benzodiazepi[INVESTIGATOR_154830] (post -dose on the dosing day only).Benzodiazepi[INVESTIGATOR_92650]-benzodiazepi[INVESTIGATOR_154896] (eg, zolpi[INVESTIGATOR_6730], zaleplon, eszopi[INVESTIGATOR_11123], and ramelteon) are prohibited 
within 12 hours prior to the start of each intranasal treatment session or cognition testing.
A positive urine drug screen for use of phency clidine (PCP), or cocaine from Day 1 of the 
induction phase through the final visit in the final treatment phase (open -label induction, 
optimization, or maintenance phase ) will lead to discontinuation.
Subjects must abstain from using alcohol within [ADDRESS_199513] appears intoxicated, dosing should not occur (delay edper the 
permitted visit window; see the Time and Events Schedule).
On all intranasal study  drug dosing days, all subjects must remain at the clinical study  site 
until study  procedures have been completed and the subject is ready for discharge . Subjects
should be accompanied by a responsible adult when released from the clinical study  site. 
Subjects must not drive a car or wor k with machines for 24 hours after study  drug dosing.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
107
Status: Approved , Date: 4 April 2017Electroconvulsive therapy , DBS, transcranial magnetic stimulation (TMS), and VNS are 
prohibited from study  entry through the end of the last treatment phase (open -label 
induction, optimization, or maint enance phase).
Subjects receiving psychotherap y (including cognitive behavioral therapy  [CBT ]) can 
continue receiving ps ychotherap y; however, CBT must have been ongoing for the last 
3months prior to the start of the screening/prospective observational phase.With the 
exception of new CBT, which is prohibited, new psy chotherap y is allowed during this study . 
Any change in existing therap y or new therap y must be documented on the concomitant 
therapi[INVESTIGATOR_77235].
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocati onand Randomization
Intranasal Study Drug
Randomization is not applicable for the screening/prospective observational phase, open -label 
induction phase, or optimization phase of this study.
Central randomization will be implemented in the maintenance phase of this study . At the start of 
the maintenance phase , subjects in stable remission after treatment with intranasal esketamine 
plus an oral antidepressant will be randomly assigned to 1 of 2treatment groups (intranasal 
esketamine or intranasal placeb o) in a 1:1 ratio based on computer -generated randomization 
schedule prepared before the study  by [CONTACT_43754]. The 
randomization will be balanced by [CONTACT_170481] . 
Although notpart of the primary  analysis, at the start of this phase, subjects in stable response 
(but who are not in stable remission) after treatment with intranasal esketamine plus an oral 
antidepressant will also be randoml y assigned to 1 of 2 treatment groups in a 1:1 ratio based on a 
separate computer -generated randomization schedule (ie, different schedule from the subjects in 
stable remission) prepared before the study  by [CONTACT_43754]. The 
randomization will be balanced by [CONTACT_170481] .
Transferred -entry  subjects who achieved stable remission or stable response after treatment with 
intranasal placebo plus an oral antidepressant will continue to receive the same treatment in order 
to maintain the blinding for the ongoing short- term studies.
The Interactive Web Response System (IWRS) will assign a unique treatment code, which will 
dictate the treatment assignment and matching intranasal study  drug kit for the subject. The 
requestor must use his or her own user identification and personal identification number when 
contact[CONTACT_170482], and will then give the relevant subject details to uniquely  identify  the 
subject.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
108
Status: Approved , Date: [ADDRESS_199514] -entry  subjects, after the investigator assigns the oral antidepressant treatment for the 
open -label induction phase, the site will enter this information into IWRS and it will be 
dispensed throughout the study  at the time points specified in the Time and Events Schedule.
For transf erred -entry  subjects, the IWRS will continue to dispense the same open -label oral 
antidepressant used in ESKETINTRD3001 and ESKETINTRD3002 throughout the study  
(optimization ,maintenance, and follow -up phases) of this study  at the time points specified in 
the Time and Events Schedule.
Blinding
To maintain the blinding of intranasal study  medication, the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the phy sical characteristics of the intranasal study  drug.
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (ie, treatment allocation, biomarker 
or other specific lab data) will be handled with special care to ensure that the integrit y of the 
blind is maintained and the potential for bias is minimized. This can include making special 
provisions, such as segregating the data in question from view by  [CONTACT_170483], clinical team, 
or others as appropriate until the time of database lock and unblinding.
Under normal circumstances, the blind should not be broken until the maintenance and follow -up 
phase sarecompleted and the database is finalized. Otherwise , the blind should be broken only  if 
specific emergency  treatment/course of action would be dictated by [CONTACT_170484]. In such cases, the investigator may  in an emergency determine the 
identity  of the intranasal treatment by [CONTACT_170485]. It is recommended that the 
investigator contact [CONTACT_97499], 
before breaking the blind. Telephone contact [CONTACT_97500] 
[ADDRESS_199515] be documented in the appropriate section of the electronic case 
report form (eCRF) and in the source document. The documentation received from the IWRS 
indicating the code break must be retained with the subject 's source documents in a secure 
manner.
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled earl y withdrawal and follow up visits.
In general, randomization codes will be disclosed fully  only  if the study  is completed through the 
follow -upphase and the clinical database is closed. However, for the prespecified interim 
analysis, the randomization codes and, if required, the translation of randomization codes into 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
109
Status: Approved , Date: 4 April 2017treatment and control groups will be disclosed to those authorized and only for those subjects 
included in the interim analy sis.At the end of the follow -up phase ,the database will be locked 
for the analy sis and reporting of this study .
6. DOSA GE A ND A DMINISTR ATION
6.1. Intranasal Study  Drug
On all intranasal treatment session days, a site staff mem ber with training incardiopulmonary 
resuscitation (eg, a basic life support course or equivalent course) that is up to date per local 
regulations ,must be present with the subject during the intranasal treatment session and the 
postdose observation period . In addition, equipment for supportive ventilation and resuscitation 
needs to be present.
Instructions for use documents (subject and healthcare provider versions) for intranasal study 
drug administration will be provided as separate documents. Details regarding study  drug 
administration will be recorded in the source documents and the eCRF.
Prior to the first intranasal dose on Day 1, direct -entry  subjects will practice spray ing (into the 
air, not intranasall y) a demonstration intranasal device that is fi lled with a placebo solution.
All subjects will self-administer the intranasal study  drug (esketamine or placebo) at treatment 
sessions at the study  site. Intranasal treatment sessions should not take place on consecutive 
days.
Food will be restricted for at least [ADDRESS_199516] has nasal congestion on the dosing day, an intranasal decongestant can be used to 
reduce congestion or the dosing day can be delay ed (per the permitted visit window; see the 
Time and Events Schedule). If an intranasal decongestant is used to reduce congestion, it cannot 
be used within [ADDRESS_199517] a car or work 
with machines for 24 hours after receiving intranasal study  drug.
Guidance for Blood Pressure Monitoring on Intranasal Treatment Session Days :
Given the potential for treatment -emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be followed on intranasal dosing day s:
If subsequent to fulfilling the inclusion and exclusion criteria on Day  1(ie, applicable forall 
other intranasal treatment session days after Day 1), a subject’s pre-dose systolic blood 
pressure (SBP) is >140 mmHg and/or diastolic blood pressure (DBP) is >90mmHg, it is 
recommended to repeat the blood pressure measurement after the subject rests in sitting or 
recumbent position. If after rest and repeated measurements, pre- dose SBP is >140 mmHg  
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
110
Status: Approved , Date: 4 April 2017and/or DBP is >[ADDRESS_199518], or primary  care phy sician, prior to further dosing.
If at any postdose time point on the dosing day, the SBP is 180 mmHg but <200 mmHg 
and/or the DBP is 110 mmHg but <[ADDRESS_199519], or primary 
care ph ysician for a follow -up assessment.
After the assessment by a  cardiologist, other specialist, or primary  care physician, if 
recomm ended by [CONTACT_170486] , then the subject may continue 
with intranasal dosing if the predose blood pressure at the next scheduled visit is within 
the acceptable range (see bullet point above).
If at any postdose time point on the dosing day the SBP is 200 mmHg and/or the DBP is 
[ADDRESS_199520], or primary  care physician for a follow -up 
assessment.
At 1.5 hours postdose, if the SBP is 160 mmHg and/or the DBP 100 mmHg, assessments 
should continue every  30 minutes until :
the blood pressure is <160 mmHg SBP and <100 mmHg DBP , or 
in the investigator’s clinical judgment, the subject it is clinicall y stable and can be 
discharged from the study site, or 
the subject is referred for appropriate medical care, if clinically  indicated.
If the blood pressure remains ≥180 mmHg SBP and/or ≥[ADDRESS_199521] -entry  subjects will self-administer open -label intranasal esketamine (56 mg or 84 mg) 
twice a week for 4 weeks as a flexible dose regimen at the study  site. In addition, subjects will 
simultaneously  initiate (switch to) a new, open -label oral antidepressant (duloxetine, 
escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of 
this phase .
OnDay 1, subjects will start with a dose of 56 mg. On Day 4, the dose may be increased to 
84mg or remain at 56 mg, as determined by [CONTACT_170487] . 
On Day 8, the dose may be increased to 84 mg (if Day 4 dose was 56 mg),remain the same, or 
be reduced to 56 mg (if Day 4 dose was 84 mg), as determined by [CONTACT_170488] y. Similarly , on Days 11, 15, 18, and 22, the dose may be increased to 
84mg, remain the same, or be reduced to 56 mg, ifapplicable as determined by [CONTACT_170489] . On Day 25, a dose reduction from 84 mg to 56 mg is 
permitted if required for tolerability ; no dose increase is permitted. 
The intranasal treatment sessions will be administ ered in this phase as described in Table 1.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
111
Status: Approved , Date: 4 April 2017Table 1: Intranasal Esketamine Treatm ent Sessions: Open -label Induction Phase
Intranasal TreatmentTime of Administrationa
0a5 minutes [ADDRESS_199522] intranasal 
device.
bOne device will be used at each time point. Each intranasal device contains 2 sprays. The intran asal devices 
containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
6.1.2. Optimization Phase
[IP_ADDRESS]. Transferred -entry  Subjects
In the optimization phase , subjects will continue the same double -blind intranasal study  drug 
(same dose) from the double -blind induction phase of ESK ETINTRD3001 or 
ESKETINTRD3002.
[IP_ADDRESS]. Direct -entry  Subjects
In the optimization phase , subjects will continue the same open -label intranasal esketamine 
treatment (same dose) from the open -label induction phase.
All subjects will continue their oral antidepressant medication (at the same dosage) during this 
phase.
[IP_ADDRESS]. Intranasal Treatment Session Frequency (All Subjects)
During this phase, the MADRS will be performed weekl y by [CONTACT_10981], remote rater, and 
this MADRS total score will be used for intranasal treatment session frequency  decisions (if 
applicable) at that visit.
For all subjects, the frequency  of intranasal treatment sessions will be reduced from the twice -
weekly frequency  used in the induction phase to weekl y for the first 4weeks of the optimization 
phase (Week 5 to Week 8). 
During this phase, there are t wofixed time points (Week 8 and Week 12 ) in which a nadjustment 
to the frequency  will be made , if applicable :
Week 8
Subjects with a MADRS total score >12 at Week 8 visit will continue to receive weekl y 
intranasal treatment sessions for the remainder of the optimization phase. No further change 
to the treatment session frequency  is permitted for the remainder of the optimization phase 
(through Week 16).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
112
Status: Approved , Date: 4 April 2017If the MADRS total score is [ADDRESS_199523] will reduce the frequency  to receive 
intranasal treatment sessions every  other week for the next 4 weeks (ie, next treatment 
sessions will be at Wee k 10 and Week 12 ). 
This is the only time during the optimization phase that a subject will be permitted to 
change to a frequency  of every  other week.
If the MADRS assessment is missed at Week 8, the last MADRS total score available prior 
to Week 8 will beused to determine if a change in treatment session frequency  is indicated 
at Week 8. In this case:
If the MADRS total score is ≤12, the subject will reduce the frequency  to receive 
intranasal treatment sessions every  other week for the next 4 weeks (ie, next treatment 
sessions will be at Weeks 10 and 12).
If the MADRS total score is>12, the subject will continue to receive weekly  intranasal 
treatment sessions for the remainder of the optimization phase. No further change to the 
treatment session frequenc y is permitted for the remainder of the optimization phase 
(through Week 16).
Week 12 (only for those on an every other week treatment session frequency):
If the MADRS total score is >12 at Week 12, the frequency  of intranasal treatment sessions 
will be increased to weekly  for the remainder of the optimization phase; no further change to 
the treatment session frequency  is permitted for the remainder of the optimization phase 
(through Week 16).
If the MADRS total score is ≤[ADDRESS_199524] will remain on the treatment 
session frequency  of every  other week for the next 4 weeks (ie,through to Week 16).
If the MADRS is missed at Week 12, the last MADRS total score available prior to Week 12 
will be used to determine if a change in treatment session frequency  is indicated at Week 12. 
In this case:
If the MADRS total score is ≤12, the subject will remain on the treatment session 
frequency  of every  other week for the next 4 weeks ( ie,through to Week 16).
If the MADRS total score is>12 at that week, the frequency  of intranasal treatment 
sessions will be increased to weekl y for the remainder of the optimization phase; no 
further change to the treatment session frequency  is permitted for the remainder of the 
optimization phase (through Week 16).
Table 2and Table 3describe the administration of intranasal study  drug during the optimization 
phase.
Table 2: Intranasal Esketamine Treatm ent Sessions: Optimization Phase (Direct entry Subjects )
Time of Administration
0a5 minutes [ADDRESS_199525]
Esketamine 56 mg 1 spray of esketamine
to each nostril1 spray of esketamine
to each nostrilNo device required
Esketamine 84 mg 1 spray of esketamine
to each nostril1 spray of esketamine
to each nostril1 spray of esketamine
to each nostril
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
113
Status: Approved , Date: [ADDRESS_199526] 
intranasal device.
bOne device will be used at each designated time point. Each intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 
2sprays).
Table 3: Intranasal Esketamine or Placebo Treatment Sessions: Optimization Phase
(Transferred -entry Subjects )
Time of Administration
0a5 minutes [ADDRESS_199527] 
intranasal device.
bOne device will be used at each designated time point. Each intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 
2sprays). The intranasal devices for each intranasal treatment session should be administered in th e 
medication kit order provided by [CONTACT_80356] (IWRS).
6.1.3. Maintenance P hase
All subjects will receive double -blind intranasal study  drug in this phase, as described above (see 
Section 3.1.1 ).
During this phase, the MADRS will continue to be assessed weekl y by [CONTACT_10981], remote 
rater,and changes to the intranasal treatment session frequency  will occur at 4-week intervals, if 
applicable, and be based on the MADRS total score (see below) . 
At the start of this phase (Visit 4.1; Week 16) :
Subjects who currently  receive intranasal treatment sessions on a weekl y basis will stay at 
the same weekly  intranasal treatment session frequency  for the first 4 weeks of this phase. 
For those on an every  other week frequency :
 If the MADRS total score is >12 at Week 16, the frequency  of intranasal treatment 
sessions will be increased to weekl y for the next 4 weeks.
If the MADRS total score is ≤[ADDRESS_199528] 4weeks of this phase (ie, starting at Week 20) the intranasal treatment session 
frequency  willbe adjust ed (if applicable) at fixed, 4 -week intervals (eg, Week 20, 24, 28, 32, 36, 
40, 44 and every  4 weeks until the end of the phase ),based on the guidance below. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
114
Status: Approved , Date: 4 April 2017If the MADRS total score is 12at that week:
If the frequency  is weekly , the frequency  willbe changed to every  other week.
If the frequency  is every  other week, there will be no change in frequency .
If the MADRS total score is>12at that week :
If the frequency  is weekly , there will be no change in frequency .
If the frequency  is every  other week, the frequency  will be changed to weekly .
If the MADRS is missed at that week, the last MADRS total score available prior to that 
week will be used to determine if a change in treatment session frequency  is indicated at that 
week. In this case:
If the MADRS total score is ≤12, and the frequency  is every  other week, there will be 
no change in frequency .
If the MADRS total score is ≤12, and the frequency  is weekly , the frequency  will be 
changed to every  other week.
If the MADRS total score is >12, and the frequency  is weekl y,there will be no change 
in frequency .
If the MADRS total score is >12, and the frequency  is every  other week, the frequency 
will be changed to weekly
A maximum of [ADDRESS_199529] is unable to 
sustain improvement on every  other week dosing they will remain on a weekl y dosing regimen 
for the duration of this phase.
Table 4 describes the administration of intranasal study  drug in the maintenance phase.
Table 4: Intranasal Esketamine or Placebo Treatment Sessions: Maintenance Phase
Time of Administration
0a5 minutes [ADDRESS_199530] 
intranasal device. 
bOne device will be used at each designated time point. Each intranasal device contains 2 spr ays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 sprays).
The 3 intranasal devices for each intranasal treatment session should be administered in the medication kit 
order provided by [CONTACT_80356] (IWRS).
6.1.4. Follow -up Phase
No intranasal study medication will be administered during this phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
115
Status: Approved , Date: [ADDRESS_199531] subjects on how to take/use and store the oral antidepressants 
supplied during this study  for at-home use. A subject diary  to capture oral antidepressant intake 
between clinic visits will be provided for use.
On intranasal dosing days, itis recommended that oral antidepressant treatment not be taken 
until at least 3 hours after the intranasal treatment session.
6.2.1. Screening/Prospective Observational Phase (Direct -entry  Subjects 
Only )
At the start of this phase, direct -entry  subjects areto be taking a different oral antidepressant 
treatment (on the MGH -ATRQ ) for at least the previous 2 weeks at or above the minimum 
therapeutic dose. This antidepressant treatment, as well as any other ongoing medications being 
taken for depression at screening (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will continue 
from the start of Week 1 through the end of Week 4 of the screening/prospective observational 
phase, to confirm non-response . Dose adjustment is permitted per clinical judgment, but the oral 
antidepressant treatment is to remain at or above the minimum therapeutic dose (per the MGH -
ATRQ) through the end of Week 4. The sponsor will not supply  these antidepressant 
medication(s).
During this phase, antidepressant treatment adherence will be assessed using the PAQ.
After 4 weeks subjects who are non -responders to their current or al antidepressant treatment may 
be eligible to proceed to the open -label induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS tot al score of ≥28 on Week 2 and Week 4. 
After the completion of 4 weeks of prospective antidepressant treatment and assessment of the 
antidepressant treatment response, eligible subjects who are entering the open -label induction 
phase will discontinue all of their medication(s), including adjunctive/augmentation therapi[INVESTIGATOR_014]. Of 
note, subjects taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal to or less than the equivalent of 6 mg/day  
of lorazepam) and/or permitted non-benzodiazepi[INVESTIGATOR_154822] (eg, zolpi[INVESTIGATOR_6730], zaleplon) 
during the screening/prospective observational phase can continue these medications. No dose 
increases beyond the equivalent of 6 mg/day lorazepam or new benzodiazepi[INVESTIGATOR_154874]/prospective observational phase. If clinically  indicated, the 
antidepressant medication may be tapered and discontinued over a period of up to 3 weeks per 
the local prescribing information or clinical judgment (eg, antidepressant treatments with short 
half lives, such as paroxetine and venlafaxine XR; or tolerability  concerns). Eligible subjects 
who do not require a tapered discontinuation of their antidepressant treatment(s) can proceed 
immediately  into the open -label induction phase .
6.2.2. Open -label Induction Phase (Direct -entry  Subjects Onl y)
Starting on Day 1of the open -label induction phase , a new, open -label oral antidepressant 
treatment will be initiated forall direct -entry  subjects, and continued for the duration of this 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
116
Status: Approved , Date: 4 April 2017phase . The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine XR). The antidepressant medication will be assigned by 
[CONTACT_170471] -ATRQ and relevant prior antidepressant 
medication information ,and will be one that the s ubject has not previousl y had a non-response to 
in the current epi[INVESTIGATOR_1865] (based on MGH -ATRQ) , has not been previously  intolerant to (lifetime), 
and is availabl e in the participating country .
Dosing of the oral antidepressant will begin on Day 1. A mandatory titration schedule is 
provided in Attachment 3.Doses are not to exceed the maximum dose defined in the titration 
schedule. If higher doses are not tolerated, a down -titration is permitted based on clinical 
judgment. However, the subject’s dose should not be lower than the following minimum 
therapeutic doses at the end of the induction phase: sertraline (50 mg/day), venlafaxine XR 
(150 mg/day ), escitalopram (10 mg/day ), and duloxetine (60 mg/day ).While subjects requiring 
lower doses can continue in the study  and complete the induction phase, such subjec ts will not be 
eligible to participate in the optimization phase and will proceed to the follow -up phase after 
completion of the induction phase.
Study -site personnel will instruct subjects on how to take and store the oral antidepressant 
treatments suppli ed during this study  for at-home use. A subject diary  to capture oral 
antidepressant stud y medication use will be provided.
On intranasal dosing days, it is recommended the oral antidepressant medication not be taken 
until at least 3 hours after an intrana sal treatment session.
6.2.3. Optimization and Maintenance Phases (Direct -entry  and Transferred -
entry  Subjects)
For all subjects, the same oral antidepressant treatment (duloxetine, escitalopram, sertraline, or 
venlafaxine XR) started on Day 1 of the induction phase will be continued through the 
optimization and maintenance phases. The oral antidepressant dosage at the end of the induction 
phase will remain unchanged through the maintenance phase.
Subjects who miss 21 day sof the oral antidepressant doses (total daily  dose) inthe optimization 
phase will not be eligible to continue into the maintenance phase .
6.2.4. Follow -upPhase
At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by  [CONTACT_170490]/or the subject’s treating phy sician.
No intranasal study  medication will be administered during this phase. The decision to continue 
the oral antidepressant medication in this phase will be at the discretion of the investigator; 
however, in order to better assess potential withdrawal symptoms from the intranasal study  
medication, the oral antidepressant should be continued during the 2-week follow -up phase , 
unless determined as not clinically  appropriate.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
117
Status: Approved , Date: [ADDRESS_199532] clinic visit prior to entering the follow -up phase, to ensure there is no 
interruption of antidepressant therapy during the transition to further clinical/standard of care.
7. TREA TMENT COMPLIA NCE
All doses of intranasal study  drug will be self-administered by [CONTACT_154950], and will be recorded.
Subjects will receive instructions on compliance with the oral antidepressant treatment. During 
the course of the study , the investigator or designated study -site personnel will be responsible for 
providing additional instruction to re-educate any subject to ensure compliance with taking the 
oral antidepress ant. A subject diary  will be provided to capture oral antidepressant intake 
between clinic visits.
The investigator or designated study -site personnel will maintain a log of all intranasal study 
drug and oral antidepressant medication dispensed and returned. Drug supplies for each subject 
will be inventoried and accounted for throughout the study  (see Section 14.5, Drug 
Accountability ).
During the screening/prospective observational phase , antidepressant treatment compliance will 
be assessed using the PAQ. Missing 4 days of antidepressant medication in the prior 2-week 
period will be considered as inadequate adherence.
For all other phases, antidepressant treatment compliance will be assessed by [CONTACT_170491][INVESTIGATOR_10705] (ie, compliance check) anddrug accountability  at the time points specified in the Time 
and Events Schedule (see Section 14.5, Drug Accountability ). 
Subjects who miss 21 day s of the oral antidepressant doses (total daily  dose) in the optimization 
phase will not be eligible to continue into the maintenance phase.
8. PRESTUDY AND CONCOMITA NT THERAPY
Prestudy  non-antidepressant therapi[INVESTIGATOR_43710] 30 days before the start of the 
screening/prospective observational phase must be recorded at the start of this phase. 
All antidepressant treatment(s), including adjunctive treatment for MDD, taken during the 
current depressive epi[INVESTIGATOR_1865] (ie, including those taken more than 30 daysprior to the start of the 
screening/prospective observational phase) will be recorded at the start of the 
screening/prospective observational phase. In addition, information will also be obtained 
regarding any history  of intolerance to any of the 4 antide pressant choices (ie, duloxetine, 
escitalopram, sertraline, and venlafaxine XR). Antidepressant treatments which are not listed on 
the MGH -ATRQ but were used, or are currently  being used, as antidepressant treatment in the 
current depressive epi[INVESTIGATOR_170442] b e recorded in " Concomitant Therap y"eCRF .
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase for an indication other than depression (eg, insomnia) 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
118
Status: Approved , Date: 4 April 2017should be continued during the screening/prospective observational phase but must be 
discontinued before the start of the double- blind induction phase.
Concomitant therapi[INVESTIGATOR_154875] , beginning with signing of the 
informed consent and continuing up to the last visit. Information on concomitant therapi[INVESTIGATOR_170443].
Subjects should continue to take their permitted concomitant medications (eg, antihypertensive 
medications) at their regular schedule; however, restrictions as outlined in Section 4.3and 
Attachment 1should be taken into account. Of note, if a subject has routinely  takenhis/her oral 
antihy pertensive medications in the morning on dosing days, the morning dose should be taken 
prior to intranasal dosing.
Subjects receiving psychotherap y (including cognitive behavioral therapy ;CBT) can continue 
receiving psychotherapy ;however, CBT must have been ongoing for the last 3months prior to 
the start of the screening/prospective observational phase .With the exception of new CBT, 
which is prohibited, new psychotherap y is allowed during the study . Any change in existing 
therap y or an y new therapy must be documented on the concomitant therapi[INVESTIGATOR_77235] .
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medi cations, including vaccines, vitamins, herbal 
supplements; nonpharmacologic therapi[INVESTIGATOR_014], such as psychotherapy , electrical stimulation, 
acupuncture, special diets, and exercise regimens) dif ferent from the stud y drug must be recorded 
in the eCRF . Modificatio n of an effective preexisting therap y should not be made for the explicit 
purpose of entering a subject into the study , unless permitted by [CONTACT_990] (eg, adjustment of 
blood pressure medications.
Rescue Medications
Rescue medications will not be supplied by [CONTACT_456] . In case of treatment-emergent adverse 
events that cannot be resolved by [CONTACT_13635][INVESTIGATOR_170444]/placebo, the following rescue medications may  be considered:
For agitat ion or anxiety : As required, midazolam (maximum dose 2.5 mg orally or IM) or 
short acting benzodiazepi[INVESTIGATOR_050] (only  permitted post -dose on the day  of dosing).
For nausea: As required, ondansetron 8 mg sublinguall y, metoclopramide (10 mg orally or 
IV or IM) or dimenhy drinate (25 to 50 mg, IV or IM)
Unless clinically  indicated, it is recommended that transient increases in blood pressure not 
be treated, as the blood pressure typi[INVESTIGATOR_154877] [ADDRESS_199533] of prohibited medications is provided in Attachment 1as general guidance for the 
investigator (but is not allinclusive).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
119
Status: Approved , Date: [ADDRESS_199534] be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing ofefficacy , biomarker, 
pharmacogenomic, health economic, medical resource utilization, and safet y measurements 
applicable to this study .
With the exception of postdose assessments, visit-specific subject -reported outcomes 
assessments should be conducted/completed before any tests, procedures, or other consultations 
for that visit to prevent influencing subject perceptions. A recommended order of study 
procedures will be provided to sites as a separate document.
Actual dates and times of assessments will be recorded in the source documentation and eCRF.
The approximate total blood volume to be collected from each subject will depend on the 
number of study  phases thesubject participates in, but should not exceed 189mL, as shown in 
Table 5.Note that the values listed in Table 5represent the maximum total blood volume to be 
collected, based on the volume for direct -entry  subjects; smaller amounts will be collected from 
the transferred -entry  subjects, who will not participate in all study  phases. Repeat or u nscheduled 
samples may be taken for safety  reasons or for technical issues with the samples. Additional 
serum or urine pregnancy  tests may  be performed, as determined necessary  by [CONTACT_170492], to establish the absence of pregnancy  at any time during the 
subject 's participation in the study .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
120
Status: Approved , Date: 4 April 2017Table 5: Volume of Blood to Be Collected From  Each Subject
Type of Sam pleVolume per 
Sample (mL)No. of Samples 
per SubjectTotal Volum e 
of Blood (m L)a
Screening/Prospective Observational Phase
Serum chemistryb5 1 5
TSH 3.5 1 3.5
Hem atologyc2 1 2
Biomarker: protein 10 1 10
Biomarker: RNA 2.5 1 2.5
Biomarker: DNA 6 1 6
Tricyclic antidepressant blood level, if applicable d6 1 6
FT4, if applicable e3.5 1 3.5
Open -label Induction Phase
Serum chemistry 2.5 2 5
Hem atology 2 2 4
Biomarker: protein 10 3 30
Biomarker: RNA 2.5 3 7.5
Biomarker: DNA 6 1 6
Optimization Phase
Serum chemistry 2.5 3 7.5
Hem atology 2 3 6
Biomarker: protein 10 2 20
Biomarker: RNA 2.5 2 5
Biomarker: DNA 6 2 12
Maintenance P hase
Serum chemistry 2.5 2 5
Hem atology 2 2 4
Biomarker: protein 13 1 13
Biomarker: RNA 2.5 1 2.5
Biomarker: DNA 6 1 6
Follow -up Phase
Serum chemistry 2.5 1 2.5
Hem atology 2 1 2
Biomarker: protein 10 1 10
Biomarker: RNA 2.5 1 2.5
Approxim ate volume of blood collected during the study 189 mL
Key: DNA = deoxyribonucleic acid; FT4 = free thy roxine; RNA = ribonucleic acid; TSH = thyroid -stimulating hormone.
aCalculated as number of samples multiplied by  [CONTACT_40987].
bSerum chemistry includes highly sensitive serum β-human chorionic gonadotropin ( β-hCG )pregnancy  tests (for 
women of childbea ring potential) and lipid panel.
cAs needed, gly cated hemoglobin (HbA1c) will be measured from the sample collected for hematology .
dDuring eligibility assessments, if a subject is taking a tricyclic antidepressant at a dose below the minimum therapeutic
dose recommended in the MGH -ATRQ, then the blood level of that antidepressant will be assessed to determine 
whether the therapeutic (antidepressant) range has been attained.
eFor any subject (regardless of thyroid history), if the TSH value is out of ran ge, then the FT4 level will be assessed.
Note: An indwelling IVcannula may be used for blood sample coll ection.
Note: Repeat or unscheduled samples may be taken for safety  reasons or technical issues with the samples.
Note : The values listed above represent the maximum total blood volume to be collected, based on the volume for direct -
entry  subjects; smaller amounts will be collected from the transferred -entry  subjects, who will not participate in all study  
phases.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
121
Status: Approved , Date: 4 April [ZIP_CODE].1.2. Screening/Prospective Observatio nal Phase
This phase is only  for direct -entry  subjects.
Prior to conducting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written ICF to each direct entry subject. After signing the ICF, subjects 
who are 18 years of age (or older if the minimum legal age of consent in the country  in which the 
study  is taking place is >18 years) to 64 years of age (inclusive) will begin to be screened to 
determine eligibility  for study  participation (please refer to the study entry criteria listed in 
Section 4).
Subjects must meet DSM -5 diagnostic criteria for single (if a single epi[INVESTIGATOR_1865] ,duration of epi[INVESTIGATOR_170445] 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment 
and confirmed by [CONTACT_170493] I. In addition, at the start of the screening/prospective observational 
phase, the subject must have an IDS -C30 total score 34.
At the start of this phase, subjec ts must have had non-response (≤25% improvement) to 1but 
5(if current epi[INVESTIGATOR_154806] >[ADDRESS_199535] 2 years) oral 
antidepressant treatments taken at adequate dosage and for adequate duration, as assessed using 
the MGH -ATRQ and documented by [CONTACT_154918] (eg, medical/pharmacy /prescription records or a 
letter from treating physician , etc.) for the current epi[INVESTIGATOR_17108]. In addition, at the start 
of the screening/prospective observational phase, the subject is taking a different oral 
antidepressant treatment (on the MGH ATRQ) for at least the previous 2 weeks at or above the 
minimum therapeutic dose. This antidepressant treatment, as well as any other ongoing 
medications being taken for depression (including adjunctive/augmentation therapi[INVESTIGATOR_014]), will 
continue from the start of Week 1 through the end of Week 4 of the screeni ng/prospective 
observational phase to confirm non-response prospectively . Dose adjustment is permitted per 
clinical judgment, but the oral antidepressant treatment is to remain at or above the minimum 
therapeutic dose (per the MGH- ATRQ) through the end of Week 4.
Antidepressant treatment adherence will be assessed using the PAQ. Missing [ADDRESS_199536]’s current major depressive epi[INVESTIGATOR_1865], depression symptom severity  (Week 1 MADRS 
total score ≥28 required), and antidepressant treatment response in the current depressive epi[INVESTIGATOR_170446] I ndependent Qualification Assessme nt.
An independent, remote, blinded rater will perform remote MADRS assessments to assess 
depressive s ymptoms during this phase. 
After 4 weeks, subjects who are non-responders to the current oral antidepressant treatment may 
be eligible to proceed to the open -label induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤25% improvement in the MADRS total 
score from Week 1 to Week 4 and a MADRS total score of ≥28 on Week 2 and Week 4 . Eligible 
subjects (deter mined by [CONTACT_170494]) who are entering the open -label induction phase 
will discontinue all of their current medication(s) being used for depression treatment, including 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
122
Status: Approved , Date: 4 April 2017adjunctive/augmentative therapi[INVESTIGATOR_014], and any other prohibited psychotropic medi cations, including 
adjunctive atypi[INVESTIGATOR_34922]. Subjects who were taking benzodiazepi[INVESTIGATOR_1651] (at dosages equal 
to or less than the equivalent of 6 mg/day  of lorazepam) and/or permitted nonbenzodiazepi[INVESTIGATOR_154815] (eg, zolpi[INVESTIGATOR_6730], zaleplon) during the screening/prospective observational phase 
can continue these medications during the induction phase. No dose increases beyond the 
equivalent of 6 mg/day  of lorazepam or new benzodiazepi[INVESTIGATOR_154879], with the exception of the use of permitted benzodiazepi[INVESTIGATOR_050] (post -dose on the 
dosing day only)rescue medication. Benzodiazepi[INVESTIGATOR_92650]-benzodiazepi[INVESTIGATOR_170447] (eg, zolpi[INVESTIGATOR_6730], zaleplon, eszopi[INVESTIGATOR_11123], and ramelteon) are prohibited within [ADDRESS_199537] -entry  subjects.
During this phase, subjects will self-administer open -label intranasal esketamine treatment 
(56mg or 84 mg) twice a week for 4 weeks as a flexible dose regimen . In addition, subjects will 
simultaneously  initiate (switch to) a new, open -label oral antidepressant (see Section 6, Dosage 
and Administration) .A mandatory  titration schedule is provided inAttachment 3. Doses are not 
to exceed the maximum dose defined in the titration schedule.
An independent, remote , blinded rater will perform all MADRS assessments during this phase. 
At the end of the open -label induction phase , subjects who arerespon ders (as defined in 
Section 3.1.2 ) will be eligible to enter the optimization phase .
Those subjects who do not enter the optimization phase will have an Early Withdrawal Visit 
conducted and proceed to the follow -up phase (see Section 3.1.2 ).
Results for all assessments performed on Day [ADDRESS_199538]-entry  subjects 
(Visit 2.9) and transferred -entry  subjects (Visit 2.[ADDRESS_199539] 3002) will serve as the baseline values for the optimization phase and will not be 
repeated as part of Visit 3.1. The Day 28 visit should coincide with Day 28 (Visit 3.1) for this 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
123
Status: Approved , Date: [ADDRESS_199540] -specific 
inclusion criteria and none of the exclusion criteria in order to be enrolled.
9.1.4. Optimization Phase
Transferred -entry Subjects
Prior to conducting any study  procedure for ESKETINTRD3003, the investigator (or designated 
study  personnel) willreview and explain the written ICF to each transferred entry subject . After 
signing the ICF, transferred- entry subjects will be evaluated todetermine eligibility  for study  
participation.
The ICF will be signed at the start of this phase (after completion of Day [ADDRESS_199541] -entry  subjects 
(Visit 2.9) and transferred -entry  subjects (Visit 2.10 of Study  ESKETINTRD3001 or 
ESKETINTRD3002) will serve as the baseline values for the optimization phase and will not be 
repeated as part of Visit 3.1. The Day 28 visit should coincide with Day 28 (Visit 3.1) for this 
study .All transferred- entry  subjects must meet all of the transferred -entry  subject -specific 
inclusion criteria and none of the exclusion criteria in order to be enrolled.
All Subjects
The intranasal treatment session frequency  will be reduced from that in the induction phase 
(twice weekl y) to weekly  for the first [ADDRESS_199542] 4 weeks, the 
frequency  of intranasal treatment sessions will be individualized to once weekl y or once every 
other week based on the severit y of depression, as assessed by [CONTACT_170468]. All 
subjects will continue taking the same oral antidepressant trea tment from the induction phase.
An independent, remote, blinded rater will perform weekly  MADRS assessments during this 
phase.
At the end of the optimization phase , subjects in stable remission and those with stable response 
(but who are not in stable remission), as defined in Section 3.1.2 , may  be eligible to continue into 
the maintenance phase; all other subjects will have an Early Withdrawal Visit conducted and 
proceed to the follow -up phase.
For subjects in stable remission and those with stable response at the end of this phase, the last 
visit of the optimization phase (Visit 3.13; Week 16) also serves as the baseline visit (Visit 4.1; 
Week 16) for the maintenance phase .Subjects eligible for the maintenance phase will be 
randomized and receive their first double -blind intranasal treatme nt session of the maintenance 
phase at this visit.
A subject will not be eligible to proceed into the maintenance phase if he or she:
Misses 21 day sof the oral antidepressant doses ( total daily  dose ) 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
124
Status: Approved , Date: 4 April [ZIP_CODE].1.5. Maintenance Phase
Day of Randomization
At the next schedul ed intranasal treatment session (Day  1 of this phase):
Approximately  211 subjects in stable remission at the end of the optimization phase (after 
treatment with intranasal esketamine plus an oral antidepressa nt) will be randomized in a 
1:1ratio to either continue with intranasal esketamine (same dose) and the same oral 
antidepressant or to continue with the same oral antidepressant (active comparator) but 
switch to intranasal placebo. The primary  efficacy  analysis will be performed for these 
subject s only . 
Additionally , subjects with stable response (but who are not in stable remission) at the end 
of the optimization phase (after treatment with intranasal esketamine plus an oral 
antidepressant) will be randomized in a 1:1 ratio (using a separate randomization list) to 
either continue with intranasal esketamine (same dose) and the same oral antidepressant or 
to continue with the same oral antidepressant (active comparator) but switch to intranasal 
placebo (for a secondary  efficacy  anal ysis onl y). 
Transferred -entry  subjects who achieve stable remission or stable response at the end of the 
optimization phase after treatment with an oral antidepressant plus intranasal placebo will 
and continue to receive the same treatment in order to maintain the blinding for the ongoing 
short -term studies. These subjects will not be included in the efficacy  analyses, but will be 
included in safet y anal yses
The last MADRS assessment performed prior to the first intranasal treatment session of the 
maintenance phase will be the baseline value for this phase.
Assessment of Relapse
During this phase, depressive sy mptom severity  will be assessed weekly  by [CONTACT_6222], remote ,
blinded raters using the MADRS.
Time to relapse will be assessed by [CONTACT_170495] a relapse, as defined in Section 3.1.2.
9.1.6. Early  Withdrawal /End of Maintenance Phase
Early Withdrawal
If a subject withdraws before the end of the induction, optimization, or maintenance phase for 
reasons other than withdrawal of consent, or has completed the induction or optimization phase 
but is not eligible to continue to the next treatment phase, an Early Withdrawal V isit should be 
conducted, followed by [CONTACT_154952]. If the Early Withdrawal Visit occurs on the same 
day as a scheduled visit, the Early Withdrawal Visit can be performed on the same day and 
duplicate assessments are not required.
A subject meeting relapse criteria during the maintenance phase is not considered an early 
withdrawal. These subjects, and subjects in the maintenance phase who remain relapse -free at 
study  termination, will have an End of Maintenance Phase Visit conducted, followed by [CONTACT_941] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
125
Status: Approved , Date: 4 April 2017follow up phase. If clinically  indicated, subjects who relapse in the Maintenance phase may 
proceed to the open -label safety  extension study , 54135419TRD3008, without completing the 
follow up phase. If the End of Maintenanc e Phase Visit occurs on the same day as a scheduled 
visit, the End of Maintenance Phase Visit can be performed on the same day and duplicate 
assessments are not required.
Further clinical/standard of care for the treatment of depression will be arranged by[CONTACT_154953]/or the subject’s treating physician. The study  investigator and/or treating 
physician will determine whether or not the current oral antidepressant medication will continue.
Subjects who withdraw early will receive additional oral antidepressant medication, if 
applicable, and it will be recommended that they continue taking the oral antidepressant 
medication for at least the 2-week follow -up phase unless determined as not clinically  
appropriate.
9.1.7. Follow -up Phase
This phase will include all subjects who have received at least 1 dose of intranasal study  
medication in this study .For those subjects who relapse in the Maintenance phase, if clinicall y 
indicated based on investigator’s judgment, after completing the endof maintenance visit, the 
subject may proceed to the open -label safet y extension study , 54135419TRD3008, without 
completing the follow up phase. Similarl y, when the study  is stopped, subjects in the Induction 
phase who are responders, after completing theearly withdrawal visit, may proceed to the 
54135419TRD3008 study, without completing the follow up phase. 
Follow -up visits will be performed at [ADDRESS_199543] clinic visit .
At the start of the follow -up phase , further clinical/standard of care for thetreatment of 
depression will be arranged by [CONTACT_154941]/or the subject’s treating physician. 
Refer to the Time and Events Schedule for a list of study  evaluations that will be performed 
during the follow -upphase .
No intranasal study medication will be administered during this phase. Subjects will be provided 
with an additional 2-week supply  of their oral antidepressant medication, to ensure there is no 
interruption of oral antidepressant therapy  during the transition to further clinical/standard of 
care. The decision to continue the oral antidepressant in this phase will be at the discretion of the 
investigator ;however, in order to better assess potential withdrawal symptoms from intranasal 
study  drug, the oral antidepressant should be continued during the 2-week follow -up phase 
unless determined as not clinically  appropriat e.
An open -label safet y extension study , 54135419TRD3008, may be available (pending country  
and site approval) for eligible subjects participating in the ESKET INTRD3003 study . Please 
refer to the 54135419TRD3008 protocol for full details of potential pathways for entry .
If information is obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
126
Status: Approved , Date: [ADDRESS_199544] 's safet y or survival status (refer to Section 16.2.3 , Informed Consent).
Any clinicall y significant abnormalities persisting at the end of the study  will be followed by  [CONTACT_91343] a clinicall y stable endpoint is reached. All adverse events 
and special reporting situatio ns, whether serious or non- serious, will be reported until completion 
of the subject 's last study -related procedure.
9.2. Efficacy
9.2.1. Evaluations
[IP_ADDRESS]. Primary  Efficacy  Evaluation: Montgomery -Asberg Depression Rating 
Scale (MA DRS)
The primary  efficacy  evaluation will include the use of the MADRS total score as it pertains to 
relapse s.The MADRS will be performed by [CONTACT_154921] , using 
the Structured Interview Guide for the MADRS .138
The MADRS is a clinician -rated scale designed to measure depression severit y and detects 
changes due to antidepressant treatment.83The scale consists of 10 items, each of which is scored 
from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a 
total possible score of 60. Higher scores represent a more severe condition. The MADRS 
evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, 
lassitude, inability  to feel (interest level), pessimistic thoughts, and suicidal thoughts. The test 
exhibits high interrater relia bility . The MADRS will be administered with its ty pi[INVESTIGATOR_170448] 7 day s. See Section 3.1.2 for the definition of relapse srelated to the MAD RS total score.
The MADRS also will be used to measure the secondary  objective of effects on depressive 
symptoms.
[IP_ADDRESS]. Clinical Global Impression -Severity (CGI -S)
The CGI-S provides an overall clinician -determined summary  measure of the severit y of the 
subjec t’s illness that takes into account all available information, including knowledge of the 
subject’s history , psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the subject’s abilit y to function.50The CGI-S evaluates the severit y of 
psychopathology  on a scale of [ADDRESS_199545] is assessed 
on severit y of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at 
all ill); 2=borderline mentally  ill; 3=mildly  ill; 4=moderatel y ill; 5=markedly  ill; 6=severel y ill; 
7=among the most extremely  ill patients. The CGI-S permits a globa l evaluation of the subject’s 
condition at a given time.
[IP_ADDRESS]. Patient Health Questionnaire , 9-Item (PHQ -9)
The PHQ -9 is a 9-item,patient- report edoutcome measure toassess depressive sy mptoms .128The 
scale scores each of the 9symptom domains of the DSM -5 MDD criteria and it has been used 
both as a screening tool and a measure of response to treatment for depression. Each item is rated 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
127
Status: Approved , Date: 4 April 2017on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearl y every  
day).The subject’s item responses are summed to provide a total score (range of 0 to 27), with 
higher scores indicating greater severity  of depressive sy mptoms. The recall period is 2 weeks.
[IP_ADDRESS]. Generalized A nxiety Disorder, 7 -item (GA D-7)
The subject -reported Generalized Anxiety  Disorder, 7 -item ( GAD-7) will be used to measure the 
secondary  objective of symptoms of anxiety . The GAD-7 is brief and validated measure of 
overall anxiety .127Each item is rated on a 4-point scale (0=not at all; 1=several days; 2=more 
than half the days; 3=nearly  every day). Item responses are summed to yielda total score (range 
of0 to 21), with highe r scores indicating more anxiety .The recall period is 2 weeks.
[IP_ADDRESS]. European Quality  of Life (EuroQol) Group, 5 -Dimension, 5 -Level 
(EQ- 5D-5L)
The EQ-5D- 5L is a standardized instrument for use as a measure of health outcom e, primarily 
designed for self -completion by  [CONTACT_170496]. It consists of the EQ -5D- 5L descriptive sy stem and 
the EQ visual analogue scale (EQ- VAS). The EQ-5D- 5L descriptive system comprises the 
following 5 dimensions: Mobility , self-care, usual activities, pain/discomfort and 
anxiety /depression. Each of the 5 dimensions is divided into 5 levels of perceived problems 
(Level 1 indicating no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, a nd Level 5 indicating extreme problems).
The subject selects an answer for each of the [ADDRESS_199546] 
matches his or her health “today .” The descriptive system can be represented as a health state. 
The EQ-VAS self-rating records the respondent’s own assessment of his or her overall health 
status at the time of comp letion, on a scale of 0 to 100.
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely  to be around 1 minute.
[IP_ADDRESS]. Sheeh an Disability  Scale (SDS)
The Sheehan Disability Scale (SDS)74,117will be used to assess the secondary  objective of 
functional impairment and associated disabilit y. The SDS, apatient -reported outcome measure, 
is a 5-item questionnaire that has been widel y used and accepted for assessment of functional 
impairment and associated disability . The first 3 items cover (1) work/school, (2) social life, and 
(3) family  life/home responsibilities using a rating scale from [ADDRESS_199547] 3items are summed to create a total score o f 0 to 30, where higher score 
indicates greater impairment. The recall period for this study  is 7 day s.
9.2.2. Endpoints
Primary Efficacy Evaluation/ Endpoint
The primary  efficacy  evaluation will include the MADRS total score as it pertains to relapses.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
128
Status: Approved , Date: [ADDRESS_199548] documentation (earliest date) 
of a relapse in the maintenance phase . Relapse criteria are defined in Section 3.1.2 ,Definitions 
of Terms .
Secondary Efficacy Evaluations/ Endpoints
Secondary  efficacy  evaluations/ endpoints include the following:
The time between subject randomization and the first documentation (earliest date) of a 
relapse in the main tenance phase for subjects with stable response (not in remission) at the 
end of the optimization phase after treatment with intranasal esketamine plus an oral 
antidepressant. Relapse criteria are defined in Section 3.1.2 , Definitions of Terms .
The change from baseline (of maintenance phase) to endpoint in:
Depressive symptoms, using the MADRS and the self-reported Patient Health 
Questionnaire 9- item ( PHQ -9)scale
Overall severity of illness, using the Clinical Global I mpression -Severity  (CGI -S)
Symptoms of anxiety , using the Generalized Anxiety  Disorder, 7- item (GAD -7) scale
Health-related quality  of life and health status, using the European Quality  of Life 
(EuroQol) Group, 5 -Dimension, 5 -Level (EQ -5D- 5L) questionnaire
Functioning and associated disability , using the Sheehan Disabilit y Scale (SDS)
9.3. Medical Resource Utilization
Medical resource utilization data, associated with healthcare encounters, will be collec ted using 
the HRUQ during the optimization, maintenance, and follow -up phases. Protocol -mandated 
procedures, tests, and encounters will be excluded. The data collected may be used to conduct 
economic analy ses and will include:
Number ,duration, and t ypeofhealthcare encounters (inpatient and outpatient).
Duration of hospi[INVESTIGATOR_059] (total day s length of stay , including duration by [CONTACT_54006]).
9.4. Safety  Evaluations
Details regarding the IDMCare provided in Section 11.8.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
129
Status: Approved , Date: [ADDRESS_199549] has started a scheduled clinic visit in which an intranasal 
treatment session is planned, butthen apredose observation (eg, blood pressure results or nasal 
congestion asdescribed in Section 6.1or intoxication as described in Section 4.3) prompts the 
site staff to postpone the intranasal treatment session within the visit window permitted per 
protocol. In such cases, all time points (including predose) of the following assessments must be 
repeated on the actual intranasal treatment session day: vital signs(ie, blood pressure, pulse, 
respir atory  rate, and temperature), 12-lead ECG, C-SSRS (since last visit), MOAA/S, pulse 
oximetry , BPRS+, and CADSS.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule:
Adverse Events
Treatment -emergent adverse events will be assessed.
TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (SMQ ), increased blood pressure, increased heart rate, 
transient dizziness/vertigo; impaired cognition; anxiety  and cy stitis.
Adverse events will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, 
or the subject 's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and urine sample sfor urinal ysis will be 
collected. The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the adverse event section of the 
eCRF. The laboratory  reports must be filed with the source documents.
The use of local laboratories is allowed in cases where initiation of treatment or safety  follow -up 
is time-critical and the central laboratory  results are not expected to be available before the need 
to begin dosing or if actions need to be taken for safet y reasons.
The following tests will be performed b y the central labo ratory , unless noted otherwise:
Hematology panel:
-hemoglobin -white blood cell count with differential
-hematocrit -platelet count
-red blood cell count
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
130
Status: Approved , Date: 4 April 2017Serum chemistry panel:
-sodium -gamma -glutam yltransferase
-potassium -total bilirubin
-chloride - alkaline phosphatase
- bicarbonate -creatine phosphokinase
-blood urea nitrogen -calcium
-creatinine -phosphate
-glucose -albumin
- aspartate aminotransferase - total protein
-alanine aminotransferase
Urinalysis:
Dipstick: Sediment (if dipstick result is abnormal):
-specific gravit y -red blood cells
- pH -white blood cells
-glucose -epi[INVESTIGATOR_1663]
-protein -crystals
-blood -casts
-ketones - bacteria
-bilirubin
-urobilinogen
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cy tometry  or microscopy  will be used to measure 
sediment. I n case of discordance between the dipstick results and the flow cy tometric 
results, the sediment will be examined microscopi[INVESTIGATOR_897] .
The following tests will be done at time points specified in the Time and Events Schedule , or as 
required based on a subject's status as noted below :
Lipid panel: total cholesterol, low-density  lipoprotein (LDL ) cholesterol, high-densit y 
lipoprotein ( HDL ) cholesterol, and trigly cerides
Serum and urine pregnancy  testing (for women of childbearing potential only )
Urine drug screen: barbiturates, methadone, opi[INVESTIGATOR_858], cocaine, cannabinoids (cannabinoids 
are only exclusionary at Day 1  p redose ), phency clidine, and 
amphetamine/methamphetamine
Alcohol breath test
Thyroid- stimulating hormone (TSH)
Free thy roxine (FT4), only  if required for abnormal TSH (refer to Inclusion Criteria) .
Calculation of creatinine clearance .
HbA1c
A serum follicle stimulating hormone (FSH) level test, only if required for documentation 
that a female subject is not of childbearing potential (refer to Sec. 4.1, Inclusion Criteria) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
131
Status: Approved , Date: 4 April 2017Single, 12- Lead ECG s
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supi[INVESTIGATOR_21683] [ADDRESS_199550] be discontinued at any  time point after baseline (Day  1, predose), if:
QTcF change from baseline is ≥ 60 msec andQTcF > 480 msec, or 
QTcF > 500 msec.
Vital Signs ( Temperature, Pulse/ Heart Rate, Respi[INVESTIGATOR_696] R ate, and Blood Pressure)
Blood pressure and pulse/heart rate measurements will be assessed supi[INVESTIGATOR_139731] a completely 
automated device or using m anual techniques.
Blood pressure and pulse/heart rate measurements should be preceded by [CONTACT_2669] [ADDRESS_199551] in a quiet setting without distractions (eg, television, cell phones).
For further details regarding blood pressure, see Section 6.1under the subheading entitled 
"Guidance for Blood Pressure Monitoring on Intranasal T reatment Session Days."
Tympanic temperature is recommended.
An automated device will be used for measurement of respi[INVESTIGATOR_2842].
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation. 
On each dosing day, the device will be attached to the finger, toe, or ear before the first nasal 
spray  and then, after the first spray  it will be monitored and documented at prespecified 
timepoints. Any arterial oxygen saturation (SpO 2) <93% should be confirmed by [CONTACT_170497] y.
On intranasal treatment session days, pulse oximetry  will berecorded every  15 minutes from 
predose to t=1.5 hours postdose. If oxygen saturation levels are <93% at any time during the 
1.5hour postdose interval, pulse oximetry  will be recorded every  5 minutes until levels return to 
93% or until the subject is referred for appropriate medical care, if clinically  indicated.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
132
Status: Approved , Date: 4 April 2017Physical Examination, Height, Body Weight, and Neck Circumference
Physical examinations, body  weight, and height will be performed/measured as per the Time and 
Events Schedule.
In addition, body  mass index (BMI) will be calculated and neck circumference measured as part 
of the information required for the STOP -Bang questionnaire.
Nasal Examinations
Nasal examinations (including the upper respi[INVESTIGATOR_53121]/throat) will be conducted by  a qualified 
healthcare practitioner. The objective of the examination at screening isto rule out any subjects 
with anatomical or medical conditions that may  impede drug delivery  or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption, and epi[INVESTIGATOR_3940], 
and will be graded as follows: absent , mild, moderate, or severe. 
Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire. The nasal symptom questionnaire was 
developed by [CONTACT_78265] r to assess nasal tolerability  following intranasal administration of study  
drug. The questionnaire asks about nasal s ymptoms, which are rated by  [CONTACT_154959], mild, 
moderate, or severe, based on how he or she feels at the time of the assessment.
Columbia Suicide Severity Rating Scale (C -SSRS)
The C -SSRS will be used to assess potential suicidal ideation and behavior. 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in the National Institute of Mental Health Treatment of Adolescent Suicide 
Attempters Study  to assess severit y and track suicidal events through any treatment.106It is a 
clinical interview providing a summary  of both ideation and behavior that can be administered 
during any evaluation or risk assessment to identify  the level and type of suicidality  present. The 
C-SSRS can also be used during treatment to monitor f or clinical worsening.
Two versions of the C-SSRS will be used in this study , the Baseline/Screening version, and the 
Since Last Visit version. The Baseline/Screening version of the C-SSRS will be used in the 
screening/prospective observational phase. In this version, suicidal ideation will be assessed at 
2timepoints: “lifetime” and “in the past 6 months,” and suicidal behavior will be assessed at 
2timepoints: “lifetime” and “in the past year.” All subsequent C- SSRS assessments in this study 
will use the Since Last Visit version, which will assess suicidal ideation and behavior since the 
subject’s last visit.
Clinician Administered Dissociative States Scale (CADSS)
The CADSS is an instrument for the measurement of present- state dissociative symptoms,8and 
will be administered to assess treatment -emergent dissociative sy mptoms.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
133
Status: Approved , Date: 4 April 2017The CADSS consists of 23 subjective items, divided into 3 components: depersonalization 
(Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia 
(Items 14, 15, and 22). Participant’s responses are coded on a 5-point scale (0=not at all through 
to 4=extremely ). CADSS has excellent inter -rater reliability  and internal consistency . 
Positive -symptom Subscale of the Brief Psychiatric Rating Scale (BPRS+)
Four items of the BPRS will be administered to assess potential treatment -emergent psychotic 
symptoms. 
The BPRS is an 18-item rating scale that is used to assess a range of psychotic and affective 
symptoms, rated from both observation of the subject and the subject 's own report.97,98It 
reportedl y provides a rapid and efficient evaluation of treatment response in clinic drug studies 
and in clinical settings.111
Only  the 4-item positive symptom subscale BPRS+ (ie, suspi[INVESTIGATOR_23703], hallucinations, unusual 
thought content, and conceptual disorganization) will be used in this study . It is highl y sensitive
to change, and excellent inter-rater reliability  can be achieved with training and a standard 
interview procedure.
Modified Observer 's Assessment of Alertness/Sedation (MOAA/S)
The MOAA/S will be used to measure treatment -emergent sedation with correlation to levels of 
sedation defined b y the American Societ y of Anesthesiologists continuum .
The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA 
continuum for general anesthesia) to 5=readil y responds to name [CONTACT_154992] (awake; 
corresponds to ASA continuum for minimal sedation).
On each intranasal dosing day, the MOAA/S will be performed every  15 minutes from predose 
to t=+1.5 hours postdose.
If the score is 3 at any time during the 1.5 hour postdo se interval, the MOAA/S will be 
performed every  5 minutes until a score of 4 is reached (at which point a frequency  of every 
15 minutes can be resumed until t=+1.[ADDRESS_199552] dose). 
If a subject does not have a score of at least 5 at t=+1.5 hours postdose , they  should continue 
to be monitored. For subjects with a score of 4, the assessment should be repeated every 
15minutes. And for subjects with a score of 3, the assessment should be repeated every 
5minutes until the score returns to [ADDRESS_199553] is referred for appropriate medical care, 
if clinically  indicated.
Clinical Global Assessment of Discharge Readiness (CGADR )
The CGADR will be used to measure the subject’s current clinical status and is the clinician’s 
assessment of the readiness to be dis charged from the study  site. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
134
Status: Approved , Date: 4 April 2017The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status (eg, sedation, blood pressure, and other adverse 
events)?”
On each intranasal dosing day, the CGADR will be performed at 1 hour and 1.5 hours postdose; 
if the response is not "Yes"at 1.5 hours postdose, the assessment will be repeated every 
15minutes until a “Yes” response is achieved or until the subject is referred for appropriate 
medical care, if clinically indicated. A subject should not be discharged prior to the 1.[ADDRESS_199554], 20- item (PWC -20)
The PWC -20 will be administered to assess potential withdrawal symptoms following cessation 
of intranasal esketamine treatment. An assessment will be performed for all subjects on Day 25 
to establish a baseline prior to discontinuation of intranasal esketamine treatment –although only  
relevant for those subjects not continuing to the optimization phase . For those subjects who 
proceed to the optimization and maintenance phases, the PWC -20 is conducted at the End of 
Study  Visit. If subjects withdraw early  from the study  during any phase, the PWC -20 will be 
conducted at the Early  Withdrawal Visit. In order to better assess potential withdrawal sy mptoms 
from the intranasal medication ,the oral antidepressant medication should be continued for the 2-
week follow -up phase unless determined as not clinically appropriate.
The PWC -20 is a 20-item simple and accurate method to assess potential development of 
discontinuation symptoms after stoppi[INVESTIGATOR_250]. The PWC -20 is a reliable and sensitive 
instrument for the assessment of discontinuation symptoms.109Discontinuation symptoms occur 
early and disappear rather swiftl y, depending upon speed of taper, daily medication dose, and 
drug elimination half- life.
Bladder Pain/Interstitial Cystitis Symptom Score (BPIC- SS)
The BPIC-SS will be used to monitor subjects for potential symptoms of cystitis , bladder pain, 
and interstitial cy stitis. 
The BPIC-SS a patient- reported outcome measure that was developed to identify  an appropriate 
bladder pain syndrome/interstitial cystitis population for clinical studies to evaluate new 
treatments for bladder pain syndrome.[ADDRESS_199555] 7 daysand addresses key 
symptoms identified by  [CONTACT_170498] (BPS) including symptom concepts 
of pain and/or pressure of the bladder and urinary frequency . Subjects respond to items using a 
5-point scale (0=never, 1=rarel y, 2=sometimes, 3=most of the time, 4=always for frequency -
based questions, and 0=not at all, 1=a little, 2=somewhat, 3=moderatel y, and 4=a great deal for 
items related to bother associated with symptoms). Question [ADDRESS_199556] 7 days using a 0-10 numerical rating scale. A total score is calculated by [CONTACT_170499] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
135
Status: Approved , Date: [ADDRESS_199557]. A total score of 19 or more has 
demonstrated good sensitivity /specificit yand is considered a relevant cut -off to distinguish those 
with significant bladder symptoms or cystitis .55If any items are missing, a total score cannot be 
calculated.
In the current study , if a subject has a score greater than [ADDRESS_199558] be discontinued from the study  and followed up with appropriate 
medical care. As such, in addition to urinaly sis, a urine culture should also be obtain if BPIC-SS 
on applicable stud y day is >18.
Cogniti on Testing
The tests described below should be administered in the following order: HVLT -R, 
computerized cognitive battery , and HVLT -R Delay ed.All subjects will complete a practice 
session for the computerized cognitive battery  during the screening/prospective observational 
phase. There is no practice session for the HVLT -R.
Computerized Cognitive Battery
The computerized cognitive battery  provides assessment of multiple cognitive domains, 
including attention, visual learning and memory , and executive function. The tests use culture -
neutral stimuli, enabling use in multilingual/multicultural settings. The computerized battery  
includes:
Simple and choice reaction time tests; scored for speed of response (mean of the log [ADDRESS_199559] responses)
Visual epi[INVESTIGATOR_10682] ; visual recall test scored using arcsine transformation of the 
proportion of correct responses
Working memory  (n back); scored for speed of correct response (mean of the log [ADDRESS_199560] responses).
Executive function; maze/sequencing test, scored fo r total number of errors .
All measures have been validated against traditional neuropsy chological tests and are sensitive to 
the effects of various drugs on cognitive performance, including alcohol and benzodiazepi[INVESTIGATOR_1651]. 
Completing the cognitive battery  requ ires approximately  [ADDRESS_199561] -Revised (HVLT -R)
The HVLT -R, a measure of verbal learning and memory , is a 12-item word list recall test.
Administration includes 3 learning trials, a delay ed recall (20-minute) trial, and a 24-word 
recognition list (including 12 target and 12 foil words) .5The test administrator reads instructions 
and word lists aloud, and records word srecalled /recognized by [CONTACT_423]. Scores include 
learning, delay ed recall ,and recognition. The HVLT -R is a well-validated and widely used 
measure of verbal epi[INVESTIGATOR_10682] .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
136
Status: Approved , Date: [ADDRESS_199562] (UPSIT) and Smell Threshold Test
To assess any potential treatment -emergent effects on the sense of smell, olfactory  function will 
be qualitatively  and quantitatively  assessed using validated standardized olfactory  tests prior to 
and at specified time points during the stud y. The 2 tes ts to be administered are: 
The UPSI T assesses a subject’s ability  to identify  odors. This standardized test, the most 
widely  used olfactory test in the world, is derived from basic psychological test 
measurement theory  and focuses on the comparative ability of subjects to identify  odorants 
at the suprathreshold level. The UPSI T consists of 4 envelope -sized booklets, each 
containing 10 “scratch and sniff” odorants embedded in 10-to 50-µm polymer 
microcapsules positioned on brown strips at the bottom of thepages of the booklets. The 
internal consistency  and test-retest reliability  coefficients of this instrument are >0.90.27,28,[ADDRESS_199563] shown this and related tests to be sensitive to sub tle changes in smell 
function associated with multiple etiologies, including those due to viruses, head trauma, 
and a number of neurodegenerative diseases.
The Smell Threshold Test will assess the smell threshold using a forced -choice single 
staircase threshold procedure. This test quantifies a detection threshold for the rose-like 
smelling odorant pheny l ethyl alcohol (PEA). This odorant is used because it has little 
propensity  to stimulate the trigeminal nerve within the nose. This test is sensitive to 
olfactory  deficits from a wide range of disorders. 
These tests will be administered bilaterally  (ie, both nostrils at the same time). Testing will occur 
during the screening/prospective observational phase to establish a subject’s baseline sensitivity . 
Thedegree of change from this baseline will be determined subsequently  over time. The percent 
change from baseline will serve as the dependent measure for each subject for each test.
If the subject has significant nasal congestion on the day of a scheduled UPSIT and/or Smell 
Threshold Test, the site should consider postponing the smell test assessment(s) to the next 
scheduled clinic visit.
9.5. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA )Evaluations
During the study , blood will be collected for the assessment of biomarkers (protein, metabolite, 
and RNA) at the time points indicated in the Time and Events Schedule. The biomarker blood 
samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet 
the day  of collection.
In blood, biomarkers (protein, metabolite, and RNA) related to (but not limited to) the immune 
system activit y, hypothalamus pi[INVESTIGATOR_80560] (HPA) axis activation, neurotrophic factors and 
metabolic factors will be investigated. Biomarkers may be added or deleted based on scientific 
information or technical innovations under the condition that the total volume of blood collected 
will not be increased.
The biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to investigate the relationship between depression severity and phenot ypes and 
biomarkers.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
137
Status: Approved , Date: [ADDRESS_199564] s 
relevant to depression (eg, HPA axis, inflammation, growth factors, monoamine transporters, ion 
channels, and circadian rhy thm, etc).
Genoty pi[INVESTIGATOR_154885] y on the screening/baseline sample; pharmacogenomic and 
epi[INVESTIGATOR_170449] /all collected samples.
DNA samples will be used for research related to esketamine, oral antidepressants, TRD, or 
MDD. They  may  also be used to develop tests/assay s related to esketamine, oral antidepressants, 
TRD, or MDD. Pharmacogenomic research may consist of the analy sis of 1 or more candidate 
genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to 
esketamine, oral antidepressants, TRD, or MDD clinical endpoints.
Further information regarding handling, shipment, and labeling of biological samples will be 
provided in a separate laboratory  manual.
9.6. Other Evaluations
[LOCATION_005] General Hospi[INVESTIGATOR_154887] (MGH -FRLHQ): Module I a nd Menstrual Cycle Tracking
The MGH -FRLHQ: Module I (childbearing potential, menopausal status, and menstrual cy cle) is 
a brief questionnaire aimed at standardizing the minimal collection of relevant information about 
reproductive hormones and status. It will be completed by a clinician. This information will not 
only assist with assessing eligibility  criteria, but also may facilitate exploratory  analyses of the 
impact of endogenous and exogenous reproductive hormones on the course of treatment of MDD 
and p otentially  inform care of women with MDD in the future.48
Menstrual cycle tracking (start date of last menstrual period) is captured as part of MGH -FRLHQ 
at Week 1 of the screening/ prospective o bservational phase, and then is tracked separatel y 
thereafter only for women with a menstrual cycleat the study  visits specified in the Time and 
Events Schedule.
[LOCATION_005] General Hospi[INVESTIGATOR_307] - Antidepressant Treatment Response Questionnaire 
(MGH -ATRQ)
The MGH -ATRQ is used to determine treatment resistance in MDD.25
The MGH -ATRQ evaluates the adequacy  of duration and dose of all antidepressant medications 
used for the current major depressive epi[INVESTIGATOR_1865]. In addition, the MGH -ATRQ assesses the degree 
of improvement on a scale from 0% (not improved at all) to 100% (completely  improved). The 
MGH -ATRQ will be completed by  [CONTACT_170500].
Inventory of Depressive Symptomatology -Clinician -rated, 30- item (IDS -C30)
The 30-item IDS-C30was designed to assess all the criterion symptom domains designated by 
[CONTACT_170501], fourth edition (DSM -IV) to diagnose a 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
138
Status: Approved , Date: 4 April 2017major depressive epi[INVESTIGATOR_1865]112; these criteria have not changed in the DSM -5.2These assessments 
can be used to screen for depression, although they  have been used predominantly  as meas ures of 
symptom severit y. The 7-day period prior to assessment is the usual time frame for assessing 
symptom severity . The psychometric properties of the IDS-C30have been established in various 
study  samples.131
Snoring, Tiredness, Observed Apnea, High Blood Pressure, B ody Mass Index, Age, Neck 
Size, G ender (STOP -Bang) Questionnaire 
The STOP -Bang Questionnaire129is a concise, easy-to-use, validated, and sensitive screening 
tool for obstructive sleep apnea (OSA). This questionnaire has 8 items which address key risk 
factors for obstructive sleep apnea: snoring, tiredness, observed breathing interruption during 
sleep, high blood pressure, body mass index, age, neck size, and gender. The STOP -Bang 
questions do not specify a recall period. Subjects will answer yes or no to questions about 
snoring, tiredness, observed breathing interruption, and high blood pressure (these are the 
“STOP” items in the STOP-B angacron ym); this takes approximately  1 minute.
Study  site staff will answer yes or no to questions about body  mass index (more than 35 kg/m²?), 
age (older than 50 years?), neck circumference (larger than 17 inches [43 cm] in men, or larger 
than 16 inches [41 cm] in women?), and gender (male?).
The total STOP -Bangscore is calculated by  [CONTACT_154962], yielding 
a score range of 0 to 8. A score of 5 on the STOP -Bang indicates a moderate to severe risk for 
obstructiv e sleep apnea (apnea hypopnea index of >30).
Site Indep endent Qualification Assessment
Independent psychiatrists/psy chologists will perform the Site Independent Qualificati on 
Assessment in the screening/prospective observational phase for all subjects to confirm the 
subject's current major depressive epi[INVESTIGATOR_1865], depression symptom severity  (including by [CONTACT_170502] , 
required at Week 1 to be total score ≥28), and antidepressant treatm ent response in the current 
depressive epi[INVESTIGATOR_1865], in terms of eligibility  for the study .130
Further information regarding this assessment will be provided to sites in a separate document.
PAQ
Subjects’ adherence to their oral antidepressant treatment regimen during the 
screening/prospective observational phase will be assessed using the PAQ. It is a brief, 2-item 
self-report scale that was developed at the University  of [LOCATION_007] Southwestern Medic al Center to 
assess how often the subject has taken, and whether he or she has made any changes to his/her 
antidepressant treatment regimen in the last 2 weeks. The total score is based on the response 
selected to Q uestion 1, and is interpreted as 0-1 = adherent and 2or more =nonadherent.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
139
Status: Approved , Date: [ADDRESS_199565] be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, [LOCATION_002] 
Pharmacopeia (USP) (or equivalent) and charged with a volume equal to the dead space volume 
of the lock.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections. 
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the lab oratory  manual.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Criteria for Completion
A subject will be considered as having completed the study  ifhe or she either :
Has had a relapse during the maintenance phase
Has remained relapse -free during the maintenance phase up to the time that the study  is 
terminated
Subjects in the Screening Prospective Observational phase at the time of study  termination may 
be eligible to proceed to the 54135419TRD3008 study . Subjects in the induction phase of the 
study  at the time of study termination will be allowed to complete theinduction phase . These 
subjects, after completing the Early Withdrawal visit, may proceed to the 54135419TRD3008 
study ,but will not be considered completers for this study .Subjects in the optimization phase at 
time of study  termination will not need to complete this phase, and will complete an Early  
Withdrawal Visit, and continue into the follow up phase, but they will not be considered 
completers.
10.2. Withdrawal From the Study
During any phase of the study , a subject will be withdrawn from the study  for any of the 
following reasons:
The investigator believes that for safet y reasons (eg, an adverse event) it is in the best 
interest of the subject to stop treatment .
See also guidance on blood pressure monitoring on intranasal dosing daysin 
Section 6.1.
The subject becomes pregna nt.
The blind is broken by  [CONTACT_093] (where applicable) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
140
Status: Approved , Date: 4 April 2017Lack of efficacy (induction and optimization phases only )
The subject does notmeet response criteria for continuing into the optimization phase at the 
end of the ope n-label induction phase (direct- entry  subjects onl y).
The subject does notmeet criteria for continuing into the maintenance phase at the end of 
the optimization phase .
The subject does not meet criteria forstable remission or stable response.
Subject misses 21 days of the oral antidepressant doses (total daily dose)in the 
optimization phase .
Lost to follow -up
Withdraw alofconsent (Note: See the "Withdrawal of Consent" section below; this should 
only be selected as a reason for withdrawal if the subject does not agree to any  further study 
assessments or procedures. If the subject is agreeable to participating in the Early 
Withdrawal V isit and the follow -up phase, another reason for withdrawal should be 
selected.)
Violation of protocol procedures (determined on a case- by-case basis)
The subject is unwilling or unable to adhere to the intranasal treatmen t schedule.
At any  time point after baseline (Day  1, predose), the subject has a:
QTcF change from baseline ≥60 msec and QTcF >480 msec, or 
QTcF >500 msec.
The sponsor terminates the study .
Death
If a subject withdraws before the end of the induction, optimization, or maintenance phase for 
reasons other than withdrawal of consent, or has completed the induction or optimization phase 
but is not eligible to continue to the next treatm ent phase, an Early Withdrawal V isit should be 
conducted, followed by [CONTACT_154952]. If the Early Withdrawal Visit occurs on the same 
day as a scheduled visit, the Early Withdrawal Visit can be performed on the same day and 
duplicate assessments are not required.
A subject meeting relapse criteria during the maintenance phase is not considered an early 
withdrawal. If clinicall y indicated, after completing the end of maintenance visit, subjects who 
have met relapse criteria may proceed to the open -label safety  extension study , 
54135419TRD3008, without completing the follow up phase. Subjects who remain relapse -free 
at study  termination, will have an End of Maintenance Phase Visit conducted, followed by [CONTACT_170503]. If the End of Maintenance Phase Visit occurs on the same day as a scheduled 
visit, the End of Maintenance Phase Visit can be performed on the same day and duplicate 
assessments are not required.
If a subject is lost to follow -up, every reasonable effort must be made by  [CONTACT_170504]/withdrawal. This should 
include at least 3 telephone calls, certified letters, email requests, etc. To ensure access to follow -
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
141
Status: Approved , Date: [ADDRESS_199566] numbers (eg, home, work, and mobile phone numbers), as well as other contact 
[CONTACT_3031] (eg, email addresses) from subjects before the first dose of study  drug is 
administered . In addition, the study  site should emphasize the importance of follow -up 
information to the subject before the first dose of study  drug is administered . The attempted 
follow -up measures must be documented.
When a subject withdraws , the reason for withdrawal is to be documented in the eCRF and in the 
source document. Subjects who withdraw will not be replaced.
Withdrawal of Consent
Every  effort will be made in the study  to ensure withdrawal of consent is not selected as a reason 
for discontinuation when in fact the subject withdrew for an identifiable reason (eg, due to an 
adverse event or lack of efficacy ).
Subjects who wish to withdraw from the study  should be asked if they are agreeable to continue 
to an Early Withdrawal V isit (if withdrawing from the induction, optimization or maintenance 
phase) and the follow up phase, or to be contact[CONTACT_132610] -up information. Subjects 
who are not agreeable to follow -up contact [CONTACT_170505] "withdrawal of 
consent." Subjects who no longer wish to take study  drug but agree to provide follow -up 
information will be withdrawn with the reason no ted as " Other "and will specify  the reason wh y. 
For a subject who "withdraws consent ,"it is recommended that the subject withdraw consent in 
writing; if the subject refuses or is physicall y unavailable, the study  site should document and 
sign the reason for the subject’s failure to withdraw consent in writing and maintain it with the 
subject 's source records.
The investigator will be responsible for making all required notifications to the Institutional 
Review Board (I RB) or Independent Ethics Committee ( IEC).
10.3. Withdrawal From the Use of Samples in Future Research
The subject may  withdraw consent for use of samples for research (refer to Section 16.2.5 , Long-
term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retention 
for research are presented in the main I CF.
11. STATISTICA L ME THODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan (SAP) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
142
Status: Approved , Date: [ADDRESS_199567] Information
The following analysis sets will be anal yzed:
Full Analysis Sets for Primary Efficacy Evaluation :
At Interim Anal ysis:All subjects who are in stable remission at the end of the 
optimization phase and who receive at least 1 dose of intranasal study  drug and 1 dose 
of oral antidepressant during the maintenance phase at the time of the interim analy sis 
data cutoff
At Final Anal ysis:All subjects who are in stable remission at the end of the 
optimization phase and who receive at least 1 dose of intranasal study  drug and 1 dose 
of oral antidepressant during the maintenance phase
Safety Analysis Sets :
For open -label induction phase :All subjects who receive at least 1 dose of intranasal 
study  drug or 1 dose of oral antidepressant in the open -label induction phase
For optimization phase :All subjects who receive at least 1 dose of intranasal study  drug 
or 1 dose of oral antidepressant in the optimization phase
For maintenance phase :All randomized subjects who receive at least 1 dose of 
intranasal study drug or 1 dose of oral antidepressant during the maintenance phase
Transferred -entry  subjects who continue to receive an oral antidepressant plus intranasal placebo 
will be summarized separatel yin both optimization and maintenance phase s.
11.2. Sample Size Determination
The maximum number of relapses (in the subjects with stable remission) required for this study 
is 84, which provides 90% power to detect a hazard ratio of 0.[ADDRESS_199568] relapse follows an exponential distribution with a median time of 6 months for 
oral antidepressant alone and 12.17 months for intranasal esketamine plus oral antidepressant 
(hazard ratio = 0.493). The corresponding 6-month relapse rates are 50% for oral antidepressant 
alone and 28.95% for oral antidepressant plus intranasal esketamine . 
Based on the subsequent assumptions, a total of approximately 211 subjects in stable remission 
need to be randomized (in a 1:1 ratio) in order to obtain 84 relapses:
A maximum accrual period of 18 months and a maximum study  duration of 20 months (this 
is the maximum duration for the full study , not for each subject) ;
Accrual rate of approximately  11.7 subjects/month during the accrual period;
Subjects a re followed until relapse, drop out,or end of study ;
35% dropout rate in each group over 6 months.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
143
Status: Approved , Date: 4 April 2017In addition to the 1:1 randomization of the 211 subjects in stable remission described above, 
subjects with stable response (but who are notin stable remission) also will be randomized 1:1. 
The actual number of subjects randomized ( which includes both those in stable remission and 
those with stable response )will depend on the time it takes to obtain thenecessary  number of 
relapse s. Blinded surveillance of the total number of relapse s in the maintenance phase will be 
performed during the study  to assess the appropriateness of the assumptions regarding accrual 
and dropout rates. The number of subjects enrolled and the number of subjects who discontinue 
before entering the maintenance phase will be closely  monitored. A sample size re-estimation 
rule will be provided in the SAP.
11.3. Efficacy  Analyses
To evaluate the assumptions used in sample size calculation, relapse rates will be monitored 
sequentially  during the maintenance phase . In particular, a 2-stage group -sequential design will 
beadopted, with 1 interim analy sis to be performed when a total of 30 relapses are observed. 
Early termination of the maintenance phase for efficacy  will be based on interim analysis results. 
If the interim analysis results show that the study should proceed to the second stage (ie, 
continue to record more relapses after the interim cutoff), sample size re-estimation will be 
performed based on the interim analysis results to determine how many  additional relapses 
should be obtained . 
The primary  analysis for efficacy  will be carried out on the Full Analysis Set and only for 
subjects who arein stable remission at the end of the optimization phase . The primary  efficacy 
endpoint will be the time between subject randomization into the maintenance phase and the first 
documentation of a relapse event . Subjects who meet at least [ADDRESS_199569] a relapse by [CONTACT_170506].
The cumulative distribution function of the time to relapse will be estimated by [CONTACT_8761] -
Meier method. Time to relapse will be summarized (number of relapses, number of censored 
subjects, median, 25th and 75th percentile of time to relapse, if estimable) by [CONTACT_1570]. 
Treatment differences will be compared using a 2-sided log-rank test as the primary  analysis. 
The estimate of the hazards ratio and its 95% confidence interval will be based on the Cox 
proportional hazards model with treatment as a factor.
Treatment comparison between intranasal esketamine plus oral antidepressant and oral 
antidepressant (active comparator) plus intranasal placebo in the changes from baseline to 
endpoint of MADRS total score, PHQ -9, CGI -S, SDS ,and GAD -7 during the maintenance phase
will be performed using an analysis of covariance model with treatment and country  as factors 
and baseline (maintenance phase ) value as a covariate. Least -squares estimates of the treatment 
differences and 95% confidence intervals will be presented. Dimension scores of EQ-5D- 5L 
data, health status index, and the overall health status score will be summarized over time. These 
analyses wil l be provided separately  for stable remitters and stable responders (not in remission).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
144
Status: Approved , Date: [ADDRESS_199570] with stable response (but who are 
not instable remission) and the first documentation of a relapse for that subject in the 
maintenance phase will be analyzed using the log-rank test as described above for the primary 
efficacy  endpoint.
11.4. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA ) Analy ses
Baseline biomarker values and changes from baseline biomarker values to the time points 
specified in the Time and Events Schedule will be summarized. Exploratory  analyses may 
include comparison of biomarker measures between the treatment groups and correlation with 
baseline and change from baseline biomarker values in the efficacy and other measures. 
Additional exploratory  analyses may also include relationship of baseline and change from 
baseline in biomarker measures to clinical response, maintenance/stabilization of response, 
relapse, and non -response.
Pharmacogen omic analyses may include candidate gene analy ses or genome -wide association 
analyses in relation to treatment response, maintenance/stabilization of response, relapse, and 
non-response and MDD/TRD. Expression analyses may include testing of known 
mRNA/miR NA transcripts or transcriptome -wide analysis in relation to antidepressant treatment 
and MDD/TRD.
Details of the analy sis plan and summary  of result sfrom both biomarker and pharmacogenomics 
analyses will be reported separately .
11.5. Medical Resource Utilizati on A nalyses
Medical resource utilization data (including HRUQ results) will be descriptively  summarized by 
[CONTACT_1570].
11.6. Safety  Analyses
All safet y data will be analyzed separately for each phase .
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_23820] (MedDRA). All reported adverse events 
with onset during the treatment phase (ie, TEAEs , and adverse events that have worsened since 
baseline) will b e included in the analy sis. For each adverse event, the percentage of subjects who 
experience at least [ADDRESS_199571] will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (SMQ), increased blood pressure, increased heart rate, 
transient dizziness/vertigo; impaired cognition; anxiety  and cy stitis.
Adverse events occurring during the follow -up phase will be summarized separatel y.For 
transferred- entry  subjects, adverse events ongoing at the time of entry  into the study  will be 
summarized separatel y.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
145
Status: Approved , Date: [ADDRESS_199572]. Reference ranges and markedl y 
abnormal results (specified in the SAP) will be used in the summary of laboratory  data. 
Descriptive statistics will be calculated for each laboratory  analyte at baseline and at each 
scheduled time point in each phase of the study . Changes from baseline results will be presented 
in pre-versus posttreatment cross -tabulations (with classes for below, within, and above normal 
ranges). Frequency  tabulations of the abnormalities will be provided. Listings of subjects with 
laboratory  results outside the reference ranges and markedl y abnormal results will be provided.
Electrocardiogram (ECG)
The effects on cardiovascular variab les will be evaluated by [CONTACT_23822]. These tables will include observed values and changes from baseline 
values.
Electrocardiogram data will be summarized by [CONTACT_105292] . Descriptive statistics will be 
calcu lated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and QT interval corrected (QTc) according to Bazett 's formula (QTcB)andFridericia 's formula 
(QTcF).4,117
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 msec , >480 msec , or 
>500 msec will be summarized, as will the percentage of subjects with QTc interval increases 
from baseline <30 msec , 30 to 60 msec , or >60 msec .
All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T-wave morphology  or the occurrence of U- waves.
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_2842], pulse oximetry , and supi[INVESTIGATOR_39761] (systolic and diastolic) values and changes from baseline will be summarize d at 
each scheduled time point. The percentage of subjects with values beyond clinically  important 
limits will be summarized.
Nasal Examination and Nasal Symptom Questionnaire
Changes in findings from the baseline nasal examination (including the upper respi[INVESTIGATOR_53075]/throat) will be listed by [CONTACT_1570]. Examinations will provide ratings (none, mild, 
moderate, or severe) that are based on a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capil lary/blood vessel disruption and epi[INVESTIGATOR_3940]. A 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
146
Status: Approved , Date: 4 April 2017shift table for changes from baseline in ratings for each examination will be presented by 
[CONTACT_1570].
In addition, scoring from the nasal tolerability  questionnaire will be summarized descriptively 
for ea ch scheduled time point by  [CONTACT_1570].
Other Safety and Tolerability Questionnaires and Assessments
C-SSRS: Suicide -related thoughts and behaviors based on the C-SSRS will be summarized 
by [CONTACT_23762]. Separate endpoints for suicidal ideation and 
suicidal behavior will be defined and summarized descriptivel y by [CONTACT_1570].
BPIC-SS, BPRS+, CADSS, CGADR , MOAA/S , Smell Threshold Test, PWC-20, and 
UPSI T: Descriptive statistics of scores and their changes (and/or percent changes) from 
predose or baseline will be summarized at each scheduled time point.
Computerized cognitive battery and HVLT -R: Descriptive statistics of each of the cognitive 
domain scores and changes from baseline will be summarized at each scheduled time point.
11.7. Interim A nalysis
See Section 11.1 for a description of the interim analysis population, Section 11.3 for efficacy 
analyses to be conducted at interim, and Section 11.8 for a description of the involvement of the 
IDMC with the interim analysis.As described in those sections, a 2-stage group -sequential 
design will beadopted ,with 1 interim analy sis to be performed when a total of 30 events (of the 
84maximum) are observed. At the interim analy sis, if the study  is not stopped for efficacy  and a 
sample size re-estimation is performed, none of the esketamine team members or staff members 
at the investigational sites conducting the clinical study  will be informed of the specific sample 
size adjustment resulting from this interim analy sis. However, the Clinical Supplies group will 
be informed of the decision made at interim analy sis so that only the required amount of study 
medication will be packaged.
11.8. Independent Data Monitoring Committee
An IDMC will be established to monitor data on an ongoing basis to ensure the continuing safet y 
of the subjects enrolled in this study . In additi on, the committee will review [ADDRESS_199573] the sample size (ie, number of 
relaps es) to achieve the desired power while maintaining control of the overall Type I error. The 
details will be provided in a separate IDMC charter.
The IDMC will consist of at least 1medical expert [INVESTIGATOR_170519] 
1statistician. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
147
Status: Approved , Date: [ADDRESS_199574] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
inform ation; all clinical studies conducted by [CONTACT_43765].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (inc luding an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_199575] adverse event recording).
Serious Adverse Event
A serious adverse event based on I CH and E uropean U nion Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is an y untoward medical occurrence that at any dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persis tent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important *
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
148
Status: Approved , Date: 4 April 2017*Medical and scientific judgment should be exercised in deciding whether expe dited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  lifethreatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endp oint (eg, all -cause mortalit y).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For , the expectedness of an adverse event will 
be determined by [CONTACT_154970] y Information Secti on of the 
Investigator’s Brochure .
For oral antidepressants with marketing authorization s(duloxetine, escitalopram, sertraline, and 
venlafaxine XR), the expectedness of an adverse event will be determined by [CONTACT_170507] /US Prescribing Information .
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by [CONTACT_23826] 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanat ion is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitan t drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
149
Status: Approved , Date: 4 April 2017Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_32982], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical
descriptors:
Mild :Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate :Sufficient discomfort is present to cause interference with normal activity .
Severe :Extreme distress, c ausing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug .
Suspected abuse/misuse of a sponsor study  drug .
Inadvertent or accidental exposure to a sponsor study  drug .
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Special reporting situations should be recorded in the eCRF. A ny special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject 's last 
study -related procedure (which may include contact [CONTACT_20687] -up o f safet y), with the exception 
of pregnancy  which will be reported up to [ADDRESS_199576] dose of study  medication 
(females) or [ADDRESS_199577] dose of study  medication (partners of male participants) . 
Serious adverse events, including those spontaneously  reported to the investigator , must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
150
Status: Approved , Date: [ADDRESS_199578] be recorded using medical terminology  in the source document and the eCRF. Wheneve r 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739] "). Investigators must record in the eCRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) . The 
investigato r (or sponsor where required) must report S[LOCATION_003]Rs to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/I RB) that approved the protocol unless 
otherwise required and documented by [CONTACT_6179]/IRB .A S[LOCATION_003]R will be reported to regulatory
authorities unblinded. Participating investigators and IEC/I RB will receive a blinded S[LOCATION_003]R 
summary , unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card"and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number .
Statement, in the local language(s), that the subject is participating in a clinical study .
Investigator 's name [INVESTIGATOR_1238] [ADDRESS_199579] telephone number.
Local sponsor 's name [INVESTIGATOR_1238] [ADDRESS_199580] telephone number (for medical staf f onl y).
Site number .
Subject number .
Any other information that is required to do an emergency  breaking of the blind.
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact [CONTACT_9702] b ystudy -site personnel within [ADDRESS_199581] be completed and signed by a physician from the study  site, 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
151
Status: Approved , Date: 4 April 2017and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax).
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject 's participation in the study , must be followed until 
any of the following occurs:
The event resolves.
The event stabilizes.
The event returns to baseline, if a baseline value/status is available .
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct .
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts) .
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject 's participation in a study  must be reported as a serious 
adverse event , except hospi[INVESTIGATOR_23741] :
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospi[INVESTIGATOR_170450], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the or iginall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
For convenience the investigator may choose to hospi[INVESTIGATOR_154891].
The cause of death of a subject in a study , whether or not the e vent is expected or associated with 
the study  drug , is considered a serious adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by [CONTACT_1758] -site personnel
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered serious adverse events and must be reported using 
the Serious Adverse Event Form. Any subject who becomes pregnant during the study  must be 
promptly  withdrawn from the study  and discontinue further stud y treatment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
152
Status: Approved , Date: [ADDRESS_199582] of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported by [CONTACT_1758] -site personnel within 24 hours of their 
knowledge of the event using the appropriate pregnancy  notification form.
Follow -up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed on the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, anydissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_199583] report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by [CONTACT_456] .
13.2. Contact[CONTACT_111169] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate document.
14. STUDY DRUG INF ORMA TION
14.1. Physical Description of Study Drugs
Intranasal Study Drug
Esketamine will be supplied as a clear, colorless intranasal solution of esketamine hydrochloride 
(16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine base) in a nasal spray  
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
153
Status: Approved , Date: [ADDRESS_199584] of 161.4 mg/mL  esketamine hydrochloride (equivalent to 
140mg of esketamine base) formulated in 0.12 mg/mL ethylenediaminetetraacetic acid (EDTA) 
and 1.5mg/mL citric acid at a pH of 4.5 in water for injection. It is provide d in a nasal spray 
pump, which delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) per 100-L 
spray . Each individual nasal spray  pump (device) contains a total of 28 mg (ie, 2 spray s). 
The placebo solution will be provided as a clear, color less intranasal solution of water for 
injection, with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001mg/mL) added to simulate the taste of the intranasal solution with active drug, in a nasal 
spray  pump. Benzalkonium chloride is added as a preservative at a concentration of 0.3 mg/mL .
Each individual nasal spray  pump (device) contains 2 spray s.
Esketamine and placebo will be manufactured and provided under the responsibility  of the 
sponsor .Refer to the Investigator ’s Broc hure for a list of excipi[INVESTIGATOR_840].
Oral Antidepressant Medications
Duloxetine
Duloxetine [ADDRESS_199585] Characteristics (SmPC)/Package Insert (PI) for 
the phy sical description and a list of excipi[INVESTIGATOR_840].
Escitalopram
Escitalopram [ADDRESS_199586] Characteristics (SmPC)/Package 
Insert ( PI) for the ph ysical description and a list of excipi[INVESTIGATOR_840].
Sertraline
Sertraline 50 mg and 25mg (as applicable) will be obtained from commercial stock and provided 
under the responsibility of the sponsor. Refer to the Summary  of Product Characteristics 
(SmPC)/Package Insert (PI ) for the ph ysical description and a list of excipi[INVESTIGATOR_840].
Venlafaxine XR
Venlafaxine XR75 mg and 37.5mg (as applicable) will be obtained from commercial stock and 
provided under the responsibility  of the sponsor. Refer to the Summary  of Product 
Characteristics (SmPC) /Package Insert (PI) for the phy sical description and a list of excipi[INVESTIGATOR_840].
14.2. Packaging
Intranasal Study Drug
Study  drug (ie, intranasal esketamine and placebo solution) will be supplied by [CONTACT_104222] a 
bi-dose nasal spray device. The devices will contain 200 µL. Each device delivers 16.14 mg 
esketamine hydrochloride (14 mg esketamine base) or 0.1 µg of denatonium benzoate per 
100-µL spray . 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
154
Status: Approved , Date: [ADDRESS_199587] kit, labeled with a 
unique medication kit number.
Device for Practicing Intranasal Study Drug Administration
The demonstration intranasal device will also be supplie d by [CONTACT_170508]. Subjects will practice spraying (into the air, not intranasal).
Oral Antidepressant Medication
Oral antidepressant tablets or capsules will remain in their commercial packaging . If blisters are 
supplied, each blister will be packaged into a child -resistant dose pack to constitute a subject kit,
labeled with a unique medication kit number. These will be labeled according to applicable 
regulatory  requirements .
14.3. Labeling
Study  drug labels will contain informa tion to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
Study drug will be stored at the study  site in a secure area with restricted access until dispensed to 
the subjects. 
All study  drugs must be stored at controlled temperatures as indicated on the product -specific 
labeling.
Refer to the pharmacy  manual/ study  site investigational product manual for additional guidance on 
study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .
The dispensing of study drug to the subject, and the return of study  drug from the subject (if 
applicable), must be documented on the drug accountability  form. Subjects must be instructed to 
return all original containers, whether empt y or containing study drug.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by [CONTACT_423], must be 
available for verification by [CONTACT_456] 's study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented on the investigational product destruction form. When the study site is an authorized 
destruction unit and study  drug supplie s are destroy ed on-site, this must also be documented on 
the investigational product destruction f orm.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
155
Status: Approved , Date: 4 April 2017Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained fo r drug accountability  purposes.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Whenever a subject brings his or her study  drug to the study  site for pi[INVESTIGATOR_692], 
this is not seen as a return of supplies. Study  drug may not be relabeled or reassigned for use by 
[CONTACT_23837]. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The inves tigator will be provided with the following supplies:
Practice intranasal devices
Investigator’s Brochure for esketamine
SmPC/USPI  [INVESTIGATOR_1238] l ocal prescribing information for oral antidepressant study medication
Investigational Product (IP) Binder, including the investigat ional product procedures manual
Laboratory  manual and materials
Clinician -administered and subject -completed outcomes assessments
Paper versions, as applicable
Electronic d evices and associated materials
IWRS Manual
ECG equipment and as sociated m aterials (eg, manual)
Instructions for Use documents (subject and healthcare provider versions) for intranasal 
study  medication
Subject diary
Rater qualifications/requirements for select cli nician -administered assessments
Computerized cognitive battery  and HVLT -R, and all associated equipment and materials
Device to measure respi[INVESTIGATOR_2842]
Procedural documents for Site -Independent Qualification Assessment .
Procedural documents for independent, remote rater interviews
Guidance on recomm ended order of study procedures
MGH -ATRQ guidance document
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
156
Status: Approved , Date: [ADDRESS_199588] 1 prior antidepressant 
treatment and be currently  taking an antidepressant treatment at the start of the 
screening/prospective observational phase that will be continued as prospective treatment in the 
screening/prospective observational phase. Only subjects with non-response to their current 
antidepressant treatment after 4 weeks of prospectively  observed treatment (total duration of at 
least 6 weeks by [CONTACT_154974]/prospective observational phase), will be eligible to 
proceed to the open -label induction phase, whe nall subject swill receive a new oral 
antidepressant in ad dition to intranasal esketamine . 
Direct -entry  subjects will receive 4 weeks of esketamine treatment in the open -label induction 
phase ;at the end of this phase ,those who are responders will be eligible to participate in the 
12-week optimization phase. At the end of the optimization phase, subjects who are stable 
responders or stable remitters may be eligible to enter the maintenance phase. At any  time during 
the study , subjects may discontinue and proceed to the 2-week follow -up phase; they will be 
provided with an additional 2-week suppl y of oral antidepressant and appropriate follow -up care 
will be arranged.
At the start of the maintenance phase, eligible subject sin stable remission, or with stable 
response, willbe randomized to either continue intranasal treatment with esketamine or switch to 
intranasal placebo . All subjects will continue to take the same oral antidep ressant .
The study  will be stopped once 84 relapses (in the subjects with stable remission) occur durin g 
the maintenance phase, or earlier based on the results of the interim analy sis for efficacy . At the 
time the study  is stopped, subjects in the inductio n phase will be able to complete the Induction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
157
Status: Approved , Date: [ADDRESS_199589] an EarlyWithdrawal Visit /End of Maintenance Phase Visit conducted and proceed 
directly  to the follow -up phase.
Subjects will be told that their consent to participate in the study  is voluntary  and may be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understan d the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
Justification for Using Placebo
Intranasal placebo is being used as a double -blind for esketamine to maintain study  blinding for 
trans ferred -entry  subjects from [ADDRESS_199590] shown response to placebo varies 
considerabl y, from 10% to 55%. Therefore, there is a concern that randomized, controlled 
studies that rely on comparison with standard antidepressants alone will generate unreliable 
results with limited assay sensitivity . However, some have considered it unethical to do placebo -
controlled studies in major depression due to the potential risk of irreversible harm.110In a meta -
analysis of drug studies conducted in MDD, it was reported that adult subjects did not have 
higher rates of suicide behaviors or attempts in the placebo group compared with those receiving 
an active antidepressant.67These studies showed annual suicide rates of 0.8% on the 
investigational drug, 0.7% on the active comparator, and 0.4% on placebo. Thus, the risk of 
irrevers ible harm was not higher in the placebo arm compared with the active control arms. 
Some subjects may  decide not to participate in a placebo -controlled study  due to the potential for 
increased distress and d ysfunction from prolonged depression. 
Therefore, the use of an active -controlled study  allows for assessment of efficacy  of a new 
compound to allow for scientifically  meaningful results. 
Subjects will visit the study  site at least every  other week during the study , and their symptoms 
will be carefully  monitored during each study  visit. Safety  evaluations will include evaluation of 
suicidal ideation/behavior at each clinic visit. At any point in the study , the subject may 
withdraw consent or be removed from the study  by [CONTACT_170509].
Intranasal esketamine may or may not be available for subjects after the study . However, 
following completion of the study , subjects can be treated according to standard of care. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
158
Status: Approved , Date: [ADDRESS_199591] and the 
study  investigator and/or the subject' s phy sician.
Compensation for any procedure will be fair per local standards and approved by [CONTACT_122844] 's IRB, in order to avoid offering any  undue incentive to participate in the study .
Subjects will be carefully monitored during the study  and subjects who are unable to tolerate 
study  drugs will be discontinued from the study.If the investigator judges it to be necessary  to 
immediately  stop study  drug, he or she has the option to do so. Specific guidance is provided 
regarding blood pressure monitoring on dosing day s (see Section 6.1).
Only  subjects who had non-response to their current oral antidepressant treatment, where a 
clinician would consider changing it in the future due to lack of response, will be enrolled (dire ct 
entry ).
Only  qualified and trained investigators will participate in the study .
The total blood volume to be collected is considered to be within the normal range allowed for 
this subject population over this time frame. The total blood volume to be col lected is 
approximately  189mL, which will be less than a Red Cross blood donation.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki , and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
159
Status: Approved , Date: 4 April 2017Final protocol and, if applicable, amendments .
Sponsor -approved ICF(and any  other written materials to be provided to the subjects) .
Investigator’s Brochure (or equivalent information) and amendments/addenda .
Sponsor -approved subject recruiting materials.
Sponsor -approved training and informational materials.
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable .
Investigator 's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB) .
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects .
Any other documents that the IEC/IRB requests to fulfill its obligation.
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct ), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct) .
Revision(s) to ICFand any  other written materials to be provided to subjects.
If applicable, new or revised subject recruiting materials approved b y the sponsor.
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable .
New edition(s) of the Investigator ’s Brochure and amendments/addenda .
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y).
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug.
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study .
Deviations from or changes to the protocol to eliminat e immediate hazards to the subjects.
Report of deaths of subjects under the investigator 's care.
Notification if a new investigator is responsible for the study  at the site .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
160
Status: Approved , Date: 4 April 2017Development Safet y Update Report and Line Listings, where applicable .
Any other requirements of the IEC/I RB.
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required . The reapproval should be documented in writing (excluding the ones that are purel y 
administrative, with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Conse nt
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/areused must be approved by [CONTACT_170510]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicab le regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Subjects will be told 
that alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally , they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records 
may be accessed by [CONTACT_170511], to the extent permitted by [CONTACT_6983](s) or regulations. By 
[CONTACT_23842] , and agrees to allow his or her study  
physician to recontact [CONTACT_170512] t for additional safet y 
evaluations, if needed .
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by [CONTACT_19720] 's personall y dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Where local regulations require, a separate ICF may  be used for the required DNA component of 
the study .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
161
Status: Approved , Date: [ADDRESS_199592] includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reason able steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA andbiomarker research is not conducted under standards approp riate for the 
return of data to subjects. I n addition, the sponsor cannot make decisions as to the significance of 
any findings resulting from exploratory  research. Therefore, exploratory  research data will not be 
returned to subjects or investigators, unless required by [CONTACT_23844]. Privacy  and 
confidentiality  of data generated in the future on stored samples will be protected by [CONTACT_67828].
16.2.5. Long -term Retention of Samples for Additional Future Rese arch 
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand oral 
antidepressant s, to understand depression, to understand differential drug responders, and to 
develop tests/assay s related to oral antidepressant s,anddepression. The research may begin at 
any time during the study or the post -study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and w ill not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.3 [Withdrawal From the Use of Samples in Future 
Research )]).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
162
Status: Approved , Date: [ADDRESS_199593], unless explicitly  addressed as a specific ethical 
consideration in Section 16.1 (Study -specific Design Considerations ).
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_456], and signed and dated by 
[CONTACT_093]. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_43779] (see Contact [CONTACT_23774](s) provided separatel y). Except in emerge ncy 
situations, this contact [CONTACT_41042]. In 
all cases, contact [CONTACT_43780]. The data recorde d in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
163
Status: Approved , Date: 4 April 2017Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
Regulatory  authority  approval or notification, if applicable .
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable .
Documentation of investigator qualifications (eg, curriculum vitae).
Completed investigator financial disclosure form from the principal investigator, where 
required .
Signed and dated clinical trial agreement, which includes the finan cial agreement .
Any other documentation required by  [CONTACT_427].
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators .
Documentatio n of subinvestigator qualifications (eg, curriculum vitae).
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable .
Local laboratory  documentation demonst rating compe tence and test reliability  (eg, 
accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document ations consistent in the type and level of detail with that 
commonly  recorded at the study  site as a basis for standard medical care must be available for 
the following: subject identification, eligibility , and study  identification; study  discussion and 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
164
Status: Approved , Date: 4 April 2017date of signed informed consent; dates of visits; results of safety  and efficacy  parameters as 
required by [CONTACT_760]; record of all adverse events and follow -up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
informa tion; and date of study  completion and reason for early discontinuation of study  drug or 
withdrawal from the study , if applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The minimum source documentation requirements for inclusion and exclusion criteri a (in 
Section 4) that specify  a need for documented medical history  are as follows: referral letter from 
treating physician or complete history  of medical notes at the site, discharge summaries, and 
antidepr essant treatment in the current epi[INVESTIGATOR_17108]. Inclusion and exclusion criteria not 
requiring documented medical history  must be verified at a minimum by [CONTACT_170513] (eg, physical examination, laboratory assessment) and 
documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format .All CRF entries, 
corrections, and alterations must be made by [CONTACT_70464] -site personnel. 
The investigator must verify  that all data entries in the CRF are accurate and correct.
Electronic data capture (eDC) will be used for thisstudy .The study  data will be transcribed by 
[CONTACT_3449] -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study  site. 
The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject 's source document s. All data relating to the study  
must be recorded in eCRFs prepared by [CONTACT_456] .Data must be entered into e CRFs in English.
Study site personnel must complete the eCRF as soon as possible after a subject visit, and the 
forms should be available for review at the next scheduled monitoring visit.
The investigator must verify that all data entries in the eCRF s are accurate and correct.
All eCRF entries, corrections, and alterations must be made by [CONTACT_97528] -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or study -site personnel must adjust the e CRF (if applicable) and complete the query . 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
165
Status: Approved , Date: 4 April 2017If correctio ns to an eCRF are needed after the initial entry  into the eCRF, this can be done in 
either of the following ways:
Investigator and study site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generate d by [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , periodic monitoring visits by [CONTACT_456], and uploading 
data transfers from external service providers into the sponsor’s database . Written instructions 
will be provided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRFs for accuracy  and completeness during on-
site monitoring visits and after transmission to the sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_170514]. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstanc e shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
166
Status: Approved , Date: 4 April 2017If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospi[INVESTIGATOR_40961] (source 
documents) ; a sample may be reviewed .The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the eCRF are known to 
the sponsor and study -site personnel and are accessible for verification by [CONTACT_43786] -site 
contact. If electronic records are maintained at the study site, the method of verification must be 
discussed with the study -site personnel . 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data r ecorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel . 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
In addition to on-site monitoring visits, the monitor may contact [CONTACT_170515]. It is expected that study -site personnel will be available to provide an 
update on the progress of the study  at the site.
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject 
participating in the study . The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
167
Status: Approved , Date: 4 April 2017Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor' s procedures, or GCP guidelines.
Inadequate recruitment of subjects b y the investigator .
Discontinuation of further study  drug development .
Study  is terminated by  [CONTACT_170516]
17.10. On-Site A udits
Representatives of the sponsor 's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediate ly notify  the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding or the sponsor 's operations 
(eg, patent application, formulas, manufacturing processes, basic scientific data, prior clinical 
data, formulation information) supplied by [CONTACT_170517] y 
published, and any data, including pharmacogenomic or exploratory  biomarker research data, 
generated as a result of this study , areconsidered confidential and remain the sole propert y of the 
sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study , and will not use it for other purposes without the 
sponsor 's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_154988] , and thus may  be disc losed 
as required to other clinical investigators or regulatory  agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study .
The results of the study will be reported in a Clinical Study  Report generated by [CONTACT_170518]’s database . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
168
Status: Approved , Date: [ADDRESS_199594] identifiers will not be used in publication o f results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999]) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publi cation Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicen ter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graph s), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
169
Status: Approved , Date: 4 April 2017REFERENCES
1. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated -dose intravenous ketamine for 
treatment -resistant depression. Biol Psychiatry. 2010;67:139 -145.
2. American Psychiatric Association. Highlights of Changes from DSM -IV-TR to DSM -5. 
www.dsm5.org/Documents/changes%20from%20dsm -iv-tr%20to%20dsm -5.pdf. C opyright 2013. Accessed 
24October 2014.
3. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent 
relapse of major depression. J Clin Psychopharmacol. 2015;35:75 -76.
4. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:[ADDRESS_199595] -Revised: normative data 
and analysis of inter -form and test -retest reliability. Clin Neuropsychol. 1998;12:43 -55.
6. Bitter C. Transmucosal nasal drug delivery: pharmacokinetics and pharmacodynamics of nasally applied 
esketamine [dissertation for PhD]. University of Basel, 2011.
7. Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamin e for 
depression. Biol Psychiatry. 2012;72:e11 -e12. 
8. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician -
Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11:125 -136.
9. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI -581) in normal human subjects. Clin Res. 1970;18:597
10. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea. Anesthesiology. 2008;108:812 -821.
11. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in 
humans. J Pharm Sci. 1982;71:539 -542.
12. Clinical Protocol ESKETINTRD2003. A double -blind, doubly -random ized, placebo -controlled study of 
intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment -resistant 
depression (SYNAPSE). Janssen Research & Developm ent (28 Apr 2014). Document 
No.EDMS -ERI-71950055:5.0.
13. Clinical Study Report ES KETINTRD1001. A single -dose study to assess the pharmacokinetics, safety, and 
tolerability of intranasally administered esketamine in healthy subjects. Janssen Research & Development 
(22Oct 2013). Document No. EDMS -ERI-72357339:1.0.
14. Clinical Study Report ESKETINTRD1002. An open -label, single -dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy Japanese and Caucasian subjects. 
Janssen Research & Development ( 21Aug 2014). Document No. EDMS -ERI-74234860:1.0.
15. Clinical Study Report ESKETINTRD1003. An open -label, single -dose study to assess the pharmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy elderly and adult subjects. Janssen 
Research & Development (30 Dec 2014) . Document No. EDMS -ERI-81854053:1.0 .
16. Clinical Study Report ESKETIVTRD2001. A double -blind, double -randomization, placebo -controlled study of 
the efficacy of intravenous esketamine in adult subjects w ith treatment -resistant depression. Janssen R esearch 
& Development (1 May 2014). Document No. EDMS -ERI-63623355:1.0.
17. Clinical Study Report KETIVTRD2002. A double -blind, randomized, placebo -controlled, parallel group, dose 
frequency study of ketamine in subjects w ith treatment -resistant depression. Janssen Research & Development 
(5 Sep 2014). Document No. EDMS -ERI-63976766:1.0.
18. ClinicalTrials.gov Registry Entry [STUDY_ID_REMOVED]. Estimate the efficiency of the association of an injection of 
ketamine and the venlafaxine in the severe major depressive disorder for six w eeks (KETADEP). Sponsor: 
University Hospi[INVESTIGATOR_307], Grenoble. http://clinicaltrials.gov/ct2/show /[STUDY_ID_REMOVED]. Last updated 16 Mar 2012. 
Accessed 16 Dec 2014.
19. ClinicalTrials.gov Registry Entry [STUDY_ID_REMOVED]. Ketamine plus lithium in treatment- resistant depression. 
Sponsor: Mount Sinai School of Medicine. https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. Last updated 
6Dec2014. Accessed 16 Dec 2014.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
170
Status: Approved , Date: 4 April 201720. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 2006;101:1212 -1213.
21. Criteria Committee of the [LOCATION_001] Heart Association. Functional capacity and objective assessment. In: 
Dolgin M, ed. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. 
[LOCATION_011], MA: Little, Brow n & Co; 1994, 253 -255.
22. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95:575 -590.
23. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long -term maintenance with intramuscula r ketamine for 
treatment -resistant bipolar II depression. Am J Psychiatry. 2012;169:868 -869.
24. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Res. 
1993;10:[ADDRESS_199596] antidepressant trials: a clinician 's guide 
to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011;72:1152 -1154.
26. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for tre atment-
resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 ;1345:[ADDRESS_199597]. Chem Senses .1985 ;10:[ADDRESS_199598]: a 
standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32:489 -502.
29. Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol. 2007;21:460 -473.
30. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate 
AMP A receptor membrane localization: relationship to clinical effects in mood disorders. 
Neuropsychopharmacology. 2007;32:793 -802.
31. Duloxetine (Cymbalta®): Summary of Product Characteristics. Eli Lilly Nederland, Houten, The Netherlands; 
Aug 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Info rmation/human/000572/WC500036781.pdf (accessed 6 Mar 2015).
32. Duloxetine (Cymbalta®): US Prescribing Information. Lilly [LOCATION_003], LLC, Indianapolis, Indiana, [LOCATION_003]; Jun2015. 
http://pi.lilly.com/us/cymbalta -pi.pdf (accessed 30Nov 2015 ).
33. Duman RS, Aghajanian GK. Sy naptic dysfunction in depression: potential therapeutic targets. Science. 
2012 ;338:[ADDRESS_199599] changes indicate 
ketamine -induced plasticity in major depressive disorder. Int J Neuro psychopharmacol. 2013;16:[ADDRESS_199600]. Eur J Pharmacol. 1997;333:99- 104.
36. Escitalopram (Cipralex®): US Prescribing Information. Lundbeck Canada Inc., Quebec, Canada; 12 Nov 2014. 
http://www.lundbeck.com/upload/ca/en/files/pdf/product_pi/Cipralex_November_2013/Cipralex.pdf (accessed 
9 Feb 2015).
37. Escitalopram: Summary of Product C haracteristics. Actavis Group PTC ehf., Iceland; Jul 2014. 
http://www.medicines.org.uk/emc/medicine/[ZIP_CODE] (accessed 6 Mar 2015).
38. Effexor XR [[LOCATION_002] Prescribing Information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc subsidiary 
of [COMPANY_007] Inc; 2014.
39. Endou M, Hattori Y, Nakaya H, Gotoh Y, Kanno M. Electrophysiologic mechanisms responsible for inotropic 
responses to ketamine in guinea pig and rat myocardium. Anesthesiology. 1992;76:409 -418.
40. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of 
depression. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/
WC500143770.pdf. Dated [ADDRESS_199601] 2014.
41. EuroQol Group. About EQ -5D. http://www.euroqol.org/about -eq-5d.html (accessed 18 Jun 2014).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
171
Status: Approved , Date: 4 April 201742. EuroQol Group. EQ -5D-5L User Guide: basic information on how to use the EQ -5D-5L inst rument. 
Version 2.0; Oct 2013. 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ- 5D-
5L_v2.0_October_2013.pdf (accessed 6 Aug 2014).
43. Falleti MG, Maruff P, Collie A, Darby [CONTACT_24226], McStephen M. Qualitative similarities in cognitive impairment 
associated with 24 h of sustained w akefulness and a blood alcohol concentration of 0.05%. J Sleep Res. 
2003;12:265 -74.
44. Fava M. D iagnosis and definition of treatment -resistant depression. Biol Psychiatry. 2003;53:649 -659.
45. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to 
patients with treatment -resistant depression? A systematic review of medium to long term outcome studies. 
JAffect Disord. 2009;116:4 -11.
46. Fleisher LA. Evidence -Based Practice of Anesthesiology, 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009.
47. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorder s: a systematic review and 
meta -analysis. Psychopharmacology (Berl). 2014;231:3663 -3676.
48. Freeman MP, Walker R, Laughren TP, Miller KK, Fava M. Female reproductive life cycle and hormones: 
methodology to improve clinical trials. J Clin Psychiatry. 2013;74:1 018-1021. 
49. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J 
Anaesth. 1993;70:666 -671.
50. Guy W. CGI: Clinical Glo bal Im pressions. In: ECDEU Assessment Manual for Psychopharmacology. 
Rockville, MD: US Department of Health and Human Services; printed 1976 (reprinted 1991):217 -222.
51. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulat ory anesthesia. 
Anesth Prog. 1992;39:61 -68.
52. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:625 -629.
53. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -level version of 
EQ-5D (EQ -5D-5L). Qual Life Res. 2011;20:1727 -1736. 
54. Holtman JR, Crooks PA, Johnson -Hardy  JK, Hojomat M, Kleven M, Wala EP. Effects of norketamine 
enantiomers in rodent models of persistent pain. Pharm acol Biochem Behav. 2008;90:676 -685.
55. Humphrey L, Arbuckle R, Moldw in R, et al. The bladder pain/interstitial cystitis symptom score: development, 
validation, and identification of a cut score. Eur Urol. 2012;61:271 -279.
56. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151:779.
57. Ibrahim L, Diazgranados N, Franco -Chaves J, et al. Course of improvement in depressive symptoms to a single 
intravenous infusion of ketamine vs add -on riluzole: results from a 4 -week, double -blind, placebo -controlled 
study. Neuropsychopharmacology. 2012;37:1526 -1533.
58. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. ICH harmonised tripartite guideline: general considerations for cli nical trials, E8. 
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf. 
Dated [ADDRESS_199602] 2014.
59. Inventory of Depressive Symptomatology (IDS) & Quick Inventory of Depressive Symptomatology (QIDS).
www.ids -qids.org/idsqids.pdf. October 2005. Accessed [ADDRESS_199603] 2014.
60. Investigator 's Brochure: JNJ -54135419 -AAC (esketamine hydrochloride) . Document No EDMS -ERI-
49489196 .
61. Jansen KL. Ketamine -can chronic use impair memory? Int J Addict. 1990;25:133 -139.
62. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major 
depression: a meta -analysis. Neuropsychopharmacology. 2013;38:2467 -2474.
63. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs p harmacotherapy for 
relapse prevention in major depression: a multisite study from the Consortium for Research in 
Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63:1337 -1344.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
172
Status: Approved , Date: 4 April 201764. Ketalar 10 mg/mL solution for injection/infusion: Summary of Product Characteristics; Aug 2014. [COMPANY_007] 
Healthcare Ireland, Dublin, Ireland. 
http://www.medicines.ie/medicine/5913/SPC/Ketalar+10mg+ml+Injection+Infusion/ (accessed 25 Feb 2015).
65. Ketamine HCl Injection: US Prescribing Information; Mar 2012. JHP Pharmaceuticals, LLC. [COMPANY_002]ster, 
Minnesota, [LOCATION_003]. http://www.drugs.com/pro/ketalar.html (accessed 25 Feb 2015).
66. Ketanest -S [Summary of Product Characteristics]. Ankeveen, Netherlands: Eurocept BV; 2011.
67. Khan A, Warner HA, Brown WA, Symptom reduction and suicide risk in pati ents treated with placebo in 
antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 
2000;57:311 -317.
68. Khin NA. Update on FDA Exploratory Analyses of Aggregated Efficacy Data from Depression Trials. Sli de 
presentation at NCDEU; May 28 -31, 2013; Hollyw ood, [LOCATION_012].
69. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:[ADDRESS_199604], 
ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen 
Psychiatry. 1994;51:199 -214.
71. Lapi[INVESTIGATOR_58065], Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major 
depressive disorder. Biol Psychiatry. 2014;76:970 -976.
72. Laughren TP. The scientific and ethical basis for placebo -controlled trials in depression and schizophrenia: an 
FDA perspective. Eur Psychiatry. 2001;16:[ADDRESS_199605] -treated 
patients with major depression: a comparison with imipramine and placebo in medium -term continuation 
therapy. Acta Psychiatr Scand. 1996;94:241 -251.
74. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing p sychiatric impairment in primary care with 
the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93 -105.
75. Lexapro [[LOCATION_002] Prescribing Information]. St Louis, MO: Forest Laboratories, Inc; 2014.
76. Lim DK. Ketamine associated psychedelic effects an d dependence. Singapore Med J. 2003;44:[ADDRESS_199606] -electroconvulsive therapy care: 
pi[INVESTIGATOR_170451] -Titrated, Algorithm -Based Longitudinal ECT (STABLE) intervention. J ECT. 
2008;24:179 -182.
78. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests 
and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia 
complex. Arch Clin Neuropsychol. 200 9;24:165 -178.
79. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention 
following intravenous ketamine in treatment -resistant depression: a pi[INVESTIGATOR_47669], placebo -controlled 
continuation trial. Int J Neurop sychopharmacol. 2010;13:[ADDRESS_199607], Lam RW. A systematic review and meta -analysis of 
randomized, double- blind, placebo -controlled trials of ketamine in the rapid treatment of major depressive 
epi[INVESTIGATOR_1841]. Psychol Med. 2015;45:693 -704.
81. Medical Outcome Systems. The M.I.N.I. www.medical -outcom es.com /index/mini. Accessed [ADDRESS_199608] 2014.
82. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical 
practice. Curr Opin Neurobiol. 2015; 30:139 -143.
83. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:382 -389.
84. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40:356 -359.
85. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison 
of frequent, infrequent and ex -users with polydrug and non -using controls. Addiction. 2009;104:77 -87.
86. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 
2012;107:27 -38.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
173
Status: Approved , Date: 4 April 201787. Morgan CJA, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188:[ADDRESS_199609] ration upon 
neurocognitive function and psychological wellbeing: a 1 -year longitudinal study. Addiction. 
2010;105:121 -133.
89. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
phenomenological aspects of ketamine u se. Drug Alcohol Depend. 2008;95:219 -229.
90. Murrough JW, Perez AM, Pi[INVESTIGATOR_61628] S, et al. Rapid and longer -term antidepressant effects of repeated ketamine 
infusions in treatment -resistant major depression. Biol Psychiatry. 2013;74:250 -256.
91. Murrough JW. Ketamine as a novel antidepressant: from synapse to beha vior. Clin Pharmacol Ther. 
2012 ;91:[ADDRESS_199610] obstructive sleep apnea? The Rational Clinical 
Examination systematic review. JAMA. 2013;310:731 -741.
93. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005;162:2352 -2359.
94. Nordenskjöld A, von Knorring L, Ljung T, Carlborg A, Brus O, Engström I. Continuation electroconv ulsive 
therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a 
randomized controlled trial. J ECT. 2013;29:86 -92.
95. Opler LA, Opler MG, Arnsten AF. Ameliorating treatment -refractory depression with intranasal keta mine: 
potential NMDA receptor actions in the pain circuitry representing menta l anguish. CNS Spectr. 2015 :1-11
(ePublication ahead of print).
96. Ostad Haji E, Tadic A, Dragicevic A, Müller MJ, Hiemke C. CGI Rating to predict antidepressant treatment 
under nat uralistic conditions. Eur Psychiatry. 2012;27(Suppl 1):1.
97. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment 
and scaling. Psychopharmacol Bull. 1988;24:[ADDRESS_199611]. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799 -812.
99. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002;30:382 -384.
100. Pam bianco DJ, Vargo JJ, Pruitt RE, Hardi R, Martin JF. Computer -assisted personalized sedation for upper 
endoscopy an d colonoscopy: a comparative, multicenter randomized study. Gastrointest Endosc. 
2011;73:765 -772.
101. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol. 2010;23:455 -460.
102. Pfennig A, Kunzel HE, Kern N, et al. Hypothalamus -pi[INVESTIGATOR_2117] -adrenal system regulation and suicidal behavior 
in depression. Biol Psychiatry. 2005;57:336 -342.
103. Pharm acokinetic Report KET -PK-007. A randomized, open label, single center, single -dose, cross -over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI-150 (intranasal ketamine) 
in healthy adult volunteers. Javelin Pharmaceuticals, Inc. Document No. EDMS -ERI-44757121 ([ADDRESS_199612] 2008).
104. Pi[INVESTIGATOR_41279], Maruff P, Mayes LC, Roman SA, Sosa JA, Snyder PJ. An examination of the construct validity 
and factor struct ure of the Groton Maze Learning Test, a new measure of spatial working memory, learning 
efficiency, and error monitoring. Arch Clin Neuropsychol. 2008;23:433 -445.
105. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capi[INVESTIGATOR_170452] P450 enzymes which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942 -7948.
106. Posner K, Brow n GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: initial validity and 
internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 
2011;168:1266 -1277.
107. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low -dose ketamine for major 
depress ion. J Psychopharmacol. 2013;27:444 -450.
108. Reich DL, Silvay G. Ketamine: an update on the first twenty -five years of clinical experience. Can J Anaesth. 
1989;36:186 -197.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
174
Status: Approved , Date: [ADDRESS_199613] (PWC -20).J Clin 
Psychopharmacol. 2008;28:447 -451.
110. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:[ADDRESS_199614] psychotic epi[INVESTIGATOR_1865]. Int. J. Environ. Res. Public Health. 2012;9:2283 -2292.
112. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology 
(IDS): psychometric properties. Psychol Med. 1996;26:477 -486.
113. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcom es in depressed outpatients 
requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905 -1917.
114. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacot herapy in the prevention of relapse 
following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:[ADDRESS_199615] of medication resistance and 
continuation pharmacoth erapy on relapse following response to electroconvulsive therapy in major depression. 
J Clin Psychopharmacol. 1990;10:96 -104.
116. Safety Report (Interim) ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of 
intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment -resistant 
depression (SYNAPSE). Document No. EDMS -ERI-97270375 (6 Feb 2015).
117. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:[ADDRESS_199616] Optimized Treatment in 
Depression (iSPOT -D): Outcomes from the acute phase of antidepressant t reatment. J Psy chiatr Res. 
2015 ;61:1 -12.
119. Sertraline (Zoloft®): US Prescribing Information. [COMPANY_007], Inc., New  York, [LOCATION_001], [LOCATION_003]; Aug 2014. 
http://labeling.pfizer.com/ShowLabeling.aspx?id=517 (accessed 9 Feb 2015).
120. Sertraline: Summary of Product Characteristics. Sandoz Limited, Surrey, [LOCATION_008]; Sep 2012. 
http://www.medicines.org.uk/emc/medicine/[ZIP_CODE]/SPC (accessed 6 Mar 2015).
121. Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 
1996;11(Suppl 3):[ADDRESS_199617]. 2014;155:123 -129.
123. Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human ab use potential studies. 
Drug Alcohol Depend. 2011;114:185 -193. 
124. Singh J, Zarate CA Jr, Krystal AD. Case report: successful riluzole augmentation therapy in treatment -resistant 
bipolar depression following the development of rash with lamotrigine. Psychophar macology (Berl). 
2004;173:227 -228.
125. Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics: Handbook of 
Experimental Pharmacology. Berlin: Springer -Verlag; 2008;182:313 -333.
126. Snyder PJ, Werth J, Giordani B, Caveney AF, Feltner D, Maruff P. A method for determining the magnitude of 
change across different cognitive functions in clinical trials: the effects of acute administration of two different 
doses alprazolam. Hum Psychopharmacol Clin Exp. 2005;20:263 -273.
127. Spi[INVESTIGATOR_4280], Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the 
GAD -7. Arch Intern Med. 2006;166:1092 -1097.
128. Spi[INVESTIGATOR_4280], Kroenke K, Williams JB. Validation and utility of a self -report version of PRIME -MD: the PHQ 
primary care study. JAMA. 1999;282:1737 -1744.
129. STOP -Bang Questionnaire. www.stopbang.ca/pdf/StopbangQ.pdf. Dated 8 Sep 2014. Accessed 11 Nov 2014.
130. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS 
Neurosci Ther. 2008;14:2 -9.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
175
Status: Approved , Date: 4 April 2017131. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating 
(IDS -C) and Self -Report (IDS -SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating 
(QIDS -C) and Self -Report (QIDS -SR) in public sector p atients with mood disorders: a psychometric 
evaluation. Psychol Med. 2004;34:73 -82.
132. Venlafaxine Extended -release: US Prescribing Information. [COMPANY_007], Inc., New  York, [LOCATION_001], [LOCATION_003]; 
Aug 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=612 (accessed 9 F eb 2015).
133. Venlafaxine: Summary of Product Characteristics. Actavis Group PTC ehf, Iceland; May 2012. 
http://www.medicines.org.uk/emc/medicine/[ZIP_CODE] (accessed 6 Mar 2015).
134. Vos T, Flaxman AD, Naghavi M, et al. Years lived w ith disability (YLDs) for 1160 sequ elae of 289 diseases 
and injuries 1990 -2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012;380:2163 -2196.
135. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a 
systematic review and meta -analysis. JAMA Psychiatry. 2015 ;72:334 -341.
136. Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment -resistant 
depression. J Clin Psychiatry. 2015;76:[ADDRESS_199618]. 
1975;24:260 -263.
138. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery -
Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192:52 -58.
139. Woolf TF, Adams JD. Biotransformation of ketamine, (Z) -6-hydroxyketamine, and (E) -6-hydroxyketamine by 
[INVESTIGATOR_20325], rabbit, and human liver microsomal preparations. Xenobiotica. 1987;17:839 -847.
140. World Health Organization. Depression (fact sheet). October 2012. 
http://www. who.int/mediacentre/factsheets/fs369/en/ (accessed 5 February 2015).
141. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N -demethylation of ketamine in human 
liver microsomes. Drug Metab Dispos. 2001;29:887 -890.
142. Yang P. Recent Advances in Design and Methodology in Psychiatric Clinical Trials. Slide presentation at Joint 
Statistical Meetings; August 3 -8, 2013; Montréal, QC Canada.
143. Yildiz A, Mantar A, Simsek S, Onur E, Gökmen N, Fidaner H. Combination of pharmacotherapy with 
electroconvuls ive therapy in prevention of depressive relapse: a pi[INVESTIGATOR_170453]. J ECT. 2010;26:104 -110.
144. Zarate CA Jr, Payne JL, Quiroz J, et al. An open- label trial of riluzole in patients with treatment -resistant major 
depression. Am J Psychiatry. 2004;161:171 -174.
145. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open -label trial of the glutamate -modulating agent riluzole in 
combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:[ADDRESS_199619] in 
treatment -resistant major depression. Arch Gen Psychiatry. 2006;63:856 -864.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
176
Status: Approved , Date: 4 April 2017ATTACHMENTS
Attachment 1: Prohibited Concomitant Medications With Intranasal Study Medication 
(Esketamine or Placebo)
This list of medications is not all-inclusive ; if necessary, please contact [CONTACT_154990] a medication(s).
Please refer to the local prescribing information of the subject’s oral antidepressant treatment for 
information regarding prohibited concomitant medications. 
Except where specifically noted, the prohibited medications listed in the following table are prohibited 
from 1 week (or 5 half-lives, whichever is longer) prior to the first dose of intranasal study medication 
until after the last dose of intranasal study medication. Note: If a medication is part of the antidepressant 
treatment regimen being taken at the time of signing the ICF (ie, start of screening/prospective 
observational phase), per protocol, the medication is continued until the end of Week 4 of the 
screening/prospective observational phase, therefore this requirement is not applicable. In such cases the 
investigato r may choose to taper the relevant medication during the up to 3-week taper period based on 
their clinical judgment.
Note In the following table: N, Prohibited; Y,permitted, with restrictions (please refer to the column 
labeled “Comments” for additional g uidance).
Drug ClassEpi[INVESTIGATOR_154895] ( As 
Needed)Continuous 
Use CommentsReason for 
Prohibition
ADHD medications (eg, 
atom oxetine, guanfacine)N Y Can be continued but must not be taken 
within 12 hours prior to the intranasal 
treatment session or for 2 hours after 
the intranasal treatment session.Safety
Amantadine N N PD interaction
Anorexiants 
(eg, phentermine, 
phendimetrazine )N N Safety
Anticholinesterase inhibitors N N Subject 
population is 
excluded
Anticonvulsants N N Subjects with seizures are excluded. 
Use as adjunctive treatment for major 
depressive disorder (MDD) is 
prohibited.
-Note: Anticonvulsants used for 
indications other than seizures may 
be allow ed (eg, valproate for 
migraine ; pregabalin ).Safety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
177
Status: Approved , Date: 4 April 2017Drug ClassEpi[INVESTIGATOR_154895] ( As 
Needed)Continuous 
Use CommentsReason for 
Prohibition
Antidepressants 
(other than the specific 
antidepressant started in the 
induction phase of the study )N N -Only [ADDRESS_199620] is taking a monoamine 
oxidase inhibitor (MAOI) during the 
screening/prospective observational 
phase, there must be a minimum 
washout interval of [ADDRESS_199621] dose of intranasal study 
medication.
-Even if used for indications other 
than MDD (eg, trazodone for sleep ), 
the use of any medication listed on 
the ATRQ is not perm itted during 
study phase s that include intranasal 
treatment .Safety and PD 
interaction
Antipsychotics N N PD interaction
Benzodiazepi[INVESTIGATOR_1651] (at dosages 
equal to or less than the 
equivalent of 6 mg/day 
lorazepam) and non-
benzodiazepi[INVESTIGATOR_154819] (including: 
zolpi[INVESTIGATOR_6730], zaleplon, 
eszopi[INVESTIGATOR_11123], and ramelteon)Y Y P rohibited w ithin 12 hours prior to the 
start of each intranasal treatment 
session or cognition testingSafety and PD 
interaction
Benztropi[INVESTIGATOR_050] Y N Prohibited if use is continuous and 
prohibited w ithin 12 hours prior to the 
start of cognition testingSafety and PD 
interaction . 
Chloral hydrate, melatonin, 
valerianN N Safety and PD 
interaction
Clonidine Y Y Use for blood pressure control is
allow ed
Corticostero ids (system ic) Y N Inhaled, intranasal, topi[INVESTIGATOR_2855], and 
ophthalmic steroids are not prohibited.
Intermittent IM/IV /POcorticosteroids 
are permitted with sponsor approval
(chronic use prohibited) .PD interaction
Cough/cold 
preparations/nasal solutions 
containing vasoconstrictors, 
decongestantsY Y Intranasally -administered 
decongestants (vasoconstrictors) 
should not be used from 1 hour prior to 
each intranasal study medica tion 
administration.
Pseudoeph edrine-containing oral 
products should not be used within 
12hours prior to an intranasal 
treatment session.Safety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
178
Status: Approved , Date: 4 April 2017Drug ClassEpi[INVESTIGATOR_154895] ( As 
Needed)Continuous 
Use CommentsReason for 
Prohibition
CYP3A4 inducers - potent N N Subjects may not take a known potent 
inducer of hepatic CYP3A activity 
within [ADDRESS_199622] intranasal dose of study 
medication.
Examples (not all -inclusive): efavirenz, 
nevirapi[INVESTIGATOR_050], barbiturates, 
carbamazepi[INVESTIGATOR_050], glucocor ticoids, 
modafinil, oxcarbazepi[INVESTIGATOR_050], 
phenobarbital, phenytoin, rifabutin, 
rifampin, and St. John 's wortPK
Dextromethorphan N N PD interaction
Diphenhydramine Y N Prohibited w ithin [ADDRESS_199623] 
oral anticoagulation agents 
(eg, dabigatran, rivaroxaban, 
api[INVESTIGATOR_3822])N N Safety
Opi[INVESTIGATOR_2438] N N Note: With Sponsor approval ,brief 
treatment with opi[INVESTIGATOR_170454].PD interaction
Psychostimulants 
(eg, amphetamines, 
methylphenidate, modafinil , 
armodafinil )N Y Prescribed psychostimulants taken for 
indications other than MDD can be 
continued but must not be taken within 
[ADDRESS_199624]. John’s wort N N PD interaction 
and PK
Thyroid hormone supplement 
for treatment of thyroid 
condition only (not for 
depression)N Y Safety
Thyroxine/ triiodothyronine 
(T3), thyroid hormone 
prescribed for depressionN N PD interaction
Warfarin N N Primary 
condition where 
used is excluded
Abbreviations: N, Prohibited ;PD, pharmacodynamics; PK, pharmacokinetics; Y, perm itted, w ith restrictions (please 
refer to the column labeled “Comments” for additional guidance).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
179
Status: Approved , Date: 4 April 2017Attachment 2: [LOCATION_001] Heart A ssociation Classification of Cardiac Disease
Category Description
Functional Capacity
Class I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable 
at rest. Less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea, or an ginal pain.
Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any 
physical activity is undertaken, discomfort is increased.
Objective Assessment
A No objective evidence of cardiovascular disease.
B Objective evidence of minimal cardiovascular disease.
C Objective evidence of moderately severe cardiovascular disease.
D Objective evidence of severe cardiovascular disease.
Source: Reference 21
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
180
Status: Approved , Date: 4 April 2017Attachment 3: Oral A ntidepressant Titration Schedules for Open -label Induction Phase
Below isthe titration schedule for the 4 oral antidepressants to be used in the current study. Adjustments 
to the titration schedules may be required in some countries in order to conform to local labeling.
Global T itration S chedule:
Oral Antidepressant 
(Active Com parator)Titration Schedule
Week 1
(Starting Day 1)Week 2
(Starting Day 8)Week 3
(Starting Day 15)Week 4
(Starting Day 22)
Duloxetine 60 mga60 mg 60 mg 60 mg
Escitalopram 10 mg 20 mg 20 mg 20 mg
Sertraline 50 mg 100 mg 150 mg 200mg
Venlafaxine XR 75 mg 150 mg 225 mg 225 mg
aSubjects should be initiated with 60 mg/day. Subjects that have in the past shown increased sensitivity towards 
serotonin reuptake inhibitors (SSRI) /norepi[INVESTIGATOR_5608] (SNRI) can ,at the discretion of the treating 
physician ,be started on a 30mgdose and up -titrated to the therapeutic range of 60 mg by [CONTACT_154904]2.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
181
Status: Approved , Date: 4 April 2017Attachment 4: Anticipated Events
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen. For 
the purposes of this study the following events will be considered anticipated events.31,32,36,37,60,119,120,132,133  
For esketamine and major depressive disorder (MDD) (including treatment -resistant depression [TRD];
based on DSM -5):
 Suicidal thinking, ideati on, and behavior
 Sleep changes, difficulty sleepi[INVESTIGATOR_007], reduced sleep, abnormal sleep, abnormal sleep, tiredness, fatigue, 
and reduced energy
 Difficulty in sexual desire, performance or satisfaction
 Reduced appetite and weight changes (loss or increase)
 Activ ation or hypomania/ mania
 Excessive happi[INVESTIGATOR_008]
 Irritability, anger, and impulsive behavior
 Agitation, feeling anxious/anxiety, tension, panic attacks, and phobia
For esketamine, regarding events related to concomitant therapy with oral antidepressants (from the 
product’s reference safety information/US prescribing information):
 Duloxetine
 Most commonly observed adverse reactions from pooled studies of all indications (incidence of 
at least 5% and at least twice the incidence in placebo subjects) were nausea, dry mouth, 
somnolence, fatigue, constipation, decreased appetite, and hyperhidrosis (sweating). Duloxetine 
treatment worsens glycemic control in some subjects with diabetes.
 Increased the risk compared with placebo of suicidal thinking and behavior; serotonin 
syndrome; hepatotoxicity; hepatic failure; orthostatic hypotension, syncope; abnormal bleeding; 
severe skin reactions, including erythema multiforme and Stevens -Johnson Syndrome (SJS); 
activation of man ia or hypomania; hyponatremia.
 Venlafaxine XR
 According to the US prescribing information, adverse events in short -term studies occurring in 
at least 5% of subjects receiving venlafaxine XR and at a rate twice the incidence in placebo 
subjects: abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and 
sweating. Sustained hypertension is noted within Warnings and Precautions section.
 Increased the r isk compared with placebo of suicidal thinking and behavior, treatment -emergent 
insomnia and nervousness, activation of mania/hypomania, hyponatremia, mydriasis, abnormal 
bleeding, sustained hypertension, and serotonin syndrome.
 Escitalopram
 Most commonly observed adverse reactions (incidence of approximately 5% or greater and 
approximately twice the incidence in placebo subjects) were insomnia, ejaculation disorder 
(primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.
 Increase d the risk compared with placebo of suicidal thinking and behavior, serotonin 
syndrome, activation of mania/hypomania, hyponatremia and abnormal bleeding
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
182
Status: Approved , Date: 4 April 2017 Sertraline
 Most common treatment -emergent AEs associated with sertraline (incidence of at least 5% for
sertraline or at least twice the incidence in placebo subjects) were ejaculation failure, dry mouth, 
increased sweating, somnolence, tremor, dizziness, fatigue, pain, malaise, abdominal pain, 
anorexia, constipation, diarrhea/loose stools, dyspepsia, nause a, agitation, insomnia, and 
decreased libido, and serotonin syndrome. 
 Increased the risk compared with placebo of suicidal thinking and behavior, activation/mania; 
bleeding events related to SSRI use (have ranged from ecchymosis, hematomas, epi[INVESTIGATOR_3940], and
petechiae to life-threatening hemorrhages), hyponatremia (appears to be the result of the 
syndrome of inappropriate antidiuretic hormone secretion [SIADH]); serotonin syndrome
Reporting of Anticipated Events
These events will be captured on the eCRF and in the database, and will be reported to the sponsor as 
described in Section 12.3.1 , All Adverse Events. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited reporting as individual single cases to health 
authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug. 
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3003 Amendment 4
183
Status: Approved , Date: 4 April 2017INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]